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Summary 
HIV-1 hijacks cellular trafficking pathways in order to transport newly synthesised 
viral subunits, such as the structural polyprotein Gag, to virion assembly sites. HIV-1 
Gag has been reported to interact with clathrin adaptor proteins (AP) 1-3, which 
function to assist clathrin mediated cargo transport. AP-1 and AP-3 assist viral particle 
release, whereas AP-2 inhibits viral particle release. How these APs facilitate HIV 
protein trafficking and particle assembly, and the consequences of HIV infection on the 
function of these trafficking pathways, has not been elucidated. The interaction of these 
pathways with the closely related virus, HIV-2, has also not been defined.  
Confocal immunofluorescence microscopy revealed HIV-1 and HIV-2 Gag have 
different intracellular localisations; HIV-1 displayed a mainly diffuse cytoplasmic 
location, whereas HIV-2 predominantly localised to intracellular compartments. 
Further investigation through microscopy found that HIV-2, unlike HIV-1, heavily 
colocalised with AP-3, which functions in endosomal cargo trafficking. siRNA 
mediated knockdown of the APs also deduced that HIV-2 is more dependent on AP-3 
than AP-1 to facilitate particle assembly, whereas HIV-1 had similar dependencies on 
both. HIV-2 also strongly colocalised with, and redistributed clathrin.  
Initial investigation of adaptor protein dependent trafficking pathways deduced that 
HIV-2 interrupted the trafficking of Diphtheria toxin, which traffics in an AP-3 
dependent manner through endosomal compartments, to a greater extent than HIV-1. 
Taken together, these results suggested that these viruses adopt different pathways to 
reach assembly sites, and that particle assembly likely occurs at different localisations 
between these viruses; the plasma membrane, via an endosomal intermediate, for HIV-
1, and predominantly intracellular compartments for HIV-2. Furthermore, it was found 
that the matrix domain of Gag, which contains AP binding sites, was not sufficient to 
drive this different Gag localisation in mutant chimeric viruses.  
Finally, the interruption of AP dependent trafficking pathways was investigated in 
astrocytes. HIV-1 displayed a striking perturbation of vesicle endocytosis events, 
indicating a global negative effect on these AP dependent pathways and suggesting a 
putative mechanism for the development of neurological symptoms, in particular short-
term memory loss, during HIV infection.  
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CHAPTER 1: INTRODUCTION 
1.1 The Origin of HIV 
Human immunodeficiency virus (HIV) is a retrovirus belonging to the genus 
Lentivirus, and is the causative agent of the degenerative disease acquired immune 
deficiency syndrome (AIDS). There are 3 main groups of Retrovirus; spumaviruses, 
with human foamy virus as the prototype within the Spumavirus genus (Delelis et al., 
2003); oncoretroviruses, such as the human T-lymphotrophic virus type 1 (HTLV-1) 
(Mahieux and Gessain, 2003) and lentiviruses. Lentiviruses are characterised by long 
incubation periods, causing chronic and persistent infections in mammals (Gifford, 
2012). This is due to their inherent ability to stably integrate their genome into that of 
the host, therefore establishing a latent infection that may be reactivated at a later stage 
to produce new viral particles (Schild and Minor 1990). Lentiviruses have been isolated 
from various animal species such as horses, cats, monkeys and cattle, for example the 
well characterised equine infectious anaemia virus (EIAV) but HIV is the only known 
Lentivirus to infect humans (Coffin et al, 1997; Leroux et al., 2004; Sharp and Hahn, 
2011). There are also numerous other immunodeficiency viruses; the simian 
immunodeficiency viruses (SIV) which infect apes and monkeys, bovine 
immunodeficiency viruses (BIV) that infect cattle, and feline immunodeficiency 
viruses (FIV) which infect cats (Yamamoto et al., 2010; Chahroudi et al., 2012; Bhatia 
et al., 2013).  
There are two types of HIV; HIV-1 and HIV-2. HIV-1 is the dominant virus 
worldwide, whereas HIV-2 is largely confined to West African countries, and those 
with links to West Africa such as France and Portugal. HIV-2 is separated into eight 
groups, A-H, with A the most prevalent worldwide. Until recently, HIV-1 has been 
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organised into 3 groups; M (Main) which is responsible for the majority of infections 
worldwide, N (Non-M, Non-O) and O (Outlier) (Coffin et al., 1997). The M group is 
then further divided into 9 subtypes, or clades, of A-D, F-H, J and K which dominate in 
different geographical areas worldwide (see Figure 1) (Coffin et al., 1997; Tebit and 
Arts, 2011). Clade C, which is prevalent in Africa and Asia, is responsible for over 
50% of new infections worldwide (Geretti et al., 2006). Inter-subtype recombination 
events have also resulted in numerous CRFs (circulating recombinant forms) 
worldwide, with at least 49 recorded so far (Castro-Nallar et al., 2012). A new HIV-1 
variant, closely related to the simian immunodeficiency virus SIVgor, which is found in 
wild-living gorillas, has been found in a Cameroonian woman which is distinct from 
the established 3 HIV-1 groups, and has been designated into a novel group; P (Plantier 
et al., 2009). 
Figure 1: The global distribution of HIV-1. The map below displays the global 
distribution of the 9 HIV-1 clades and the common circulating recombinant forms 
(adapted from http://www.pbs.org/wgbh/pages/frontline/aids/atlas/clade.html 
accessed 01.2012). 
Clade C 
prevalent areas 
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Phylogenetic data has shown that the closest lentiviral relatives of HIV are the 
collectively known simian immunodeficiency viruses (SIVs) which infect non-human 
primates, but unlike HIV they do not usually cause disease in their hosts; however 
some species do exhibit very high infection rates (Sharp et al., 2001). More than 40 
species of African primates have been found to harbour SIVs and geographical 
correlations exist between SIVs in their different primate hosts and HIV. Data such as 
this provided undeniable evidence that HIV arose through cross-species transmission 
from primates in Africa (Sharp et al., 2001; Castro-Nallar et al., 2012).  
HIV-1 and HIV-2 arose from independent transmission events and therefore have 
different lineages (Sharp et al., 1995). Closely related SIVs to HIV-2 have been found 
in sooty mangabeys (Cercocebus atys; SIVsm) and three different macaque species 
(SIVmac). The only macaques found to harbour SIVmac have been in captivity as they 
are not naturally infected; wild sooty mangabeys however have been found to carry 
SIVsm in Western Africa, the only region to which HIV-2 is endemic (Sharp et al., 
2001; Castro-Nallar et al., 2012). Specifically, the eight groups of HIV-2 arose from 
eight independent transmissions from SIVsm infected sooty mangabeys in West Africa 
(Sharp and Hahn, 2011).  
HIV-1 has a slightly more complicated lineage; however, each group arose from a 
single transmission event. Groups M and N have been traced to originate from SIV-
infected chimpanzees of the Pan troglodytes troglodytes species (SIVcpz), whereas the 
closest SIV relatives of O and P are in gorillas (SIVgor) (Tebit and Arts, 2011; Ayouba 
et al., 2013). Most cross-species transmission events of SIVs into humans gave rise to a 
virus with limited replicative ability in humans; the single transmission event of 
SIVcpz which gave rise to group M, however, is largely responsible for the AIDS 
epidemic (Sharp and Hahn, 2011). A diagrammatic representation of transmission 
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events and relationships between HIV and SIVs is shown in Figure 2 (reproduced with 
permission by Elsevier).  
Figure 2: A diagram showing the relationships between the HIV-1 groups, M, N, 
O and P, HIV-2 and the SIVs, and transmission events between primates and 
humans (Tebit and Arts, 2011).  
In order to determine when HIV entered the population by cross-species transmission, 
scientists gathered viral sequence data over time, using this to calibrate a “molecular 
clock” based on the rate of change of nucleotides. This can then be used to infer the 
rate of sequence evolution (Wertheim and Worobey, 2009).  The time of most recent 
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common ancestor (tMRCA) of HIV-1 group M was estimated to be 1908; the highest 
probability distribution was estimated to be between 1884 and 1924 (Worobey et al., 
2008). The tRMCA of group O was estimated at 1920 (1890-1940) (Lemey et al., 
2004). The two epidemic subtypes of HIV-2, A and B, were also investigated, and the 
tRMCAs were found to be approximately 1940 (1924-1956) and 1945 (1931-1959), 
respectively (Lemey et al., 2003). Differences in estimates arise from recombination 
events, which are frequent in HIV (Schierup and Hein, 2000). HIV-1 and HIV-2 in 
their present forms share only 40% nucleotide sequence identity (Dilley et al., 2011). 
But how did these viruses get into the human population? The simplest suggestion is 
via direct exposure to infected blood or mucosal secretions from infected animals 
(Sharp et al., 2001), which is logical because indigenous sooty mangabeys, for 
example, are kept as pets or butchered for food in West Africa, the same geographic 
region to which HIV-2 is most prevalent (Gao et al., 1999; Sharp et al., 1999). The rise 
in logging in Africa also opened up previously inaccessible wildlife habitats, leading to 
an increase in the resulting “bushmeat” being sold (Robinson et al., 1999). The 
consumption of improperly cooked meats or exposure to infected secretions whilst 
butchering the animals seems a plausible pathway of entrance.  
Another popular theory of the origin of HIV is that it has always been present in the 
population, but at such low prevalence that it was unrecognised. Changes to society, for 
example urbanisation and the beginnings of world travel may have introduced the virus 
into previously uninfected countries. An increase in promiscuity, intravenous drug use 
and the liberation of gay people would have encouraged rapid spread of the virus 
through the human population (Coffin et al., 1997). 
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1.1.1 Restriction Factors and Crossing the Species Barrier 
The immune system can be separated into two subsystems; the adaptive and innate 
systems. Innate responses are non-specific and form the first line of defence to an 
incoming pathogen. They rely on features that are common to many pathogens but not 
present in the host, and evoke 2 forms of response; an inflammatory response, which is 
mediated in part by cytokines, and phagocytosis (the engulfment of a particular object) 
by cells such as macrophages. The adaptive immune response is more specific and 
complex, providing long-term protection against pathogens by immunologic memory 
and is split into two responses; humoral (antibody) or cell-mediated. The humoral 
response is mediated by a class of lymphocytes called B cells which produce the 
antibodies; whereas the cell-mediated response is facilitated by T cells, of which there 
are many types including helper T cells which release cytokines, and cytotoxic T cells 
(Janeway et al., 2001; Alberts et al., 2002). Both of these responses are important 
features of HIV infection.  
Primate hosts, including humans, have evolved numerous restriction factors as part of 
the innate immune response as a barrier to various pathogens; the virus in-turn evolves 
mechanisms to counteract these; however, these are often species-specific. Therefore, 
the virus needs to develop new ways in which to counteract these restriction factors 
(Sharp and Hahn, 2011). Three classes of restriction factors are known to exist, which 
provide obstacles to SIV cross-species transmission. These are BST-2 (tetherin), which 
forms protein tethers expressed on the cell surface that prevent virus release (Neil et al., 
2008), APOBEC3G (apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-
like 3G) which inhibits reverse transcription (Mehle et al., 2004), and TRIM5α that 
prevents uncoating (Kajaste-Rudnitski et al., 2010). These classical restriction factors 
have been shown to be up-regulated by the antiviral cytokine interferon-alpha (IFN-α) 
Chapter 1                                                                      Introduction 
 
7 
 
(Sakuma et al., 2007; Wang et al., 2008; Homann et al., 2011. Tetherin has had a large 
effect on the success of the viruses introduced into the human population by cross-
species transmission (Sharp and Hahn, 2011).  
Selection pressures imposed during cross-species transmission have resulted in the 
emergence of different anti-tetherin responses; the majority of SIV strains use Nef to 
counteract tetherin, whereas HIV-1 uses Vpu (see chapter 1.4.7iv  for a description of 
these HIV proteins) (Neil et al., 2008; Jai et al., 2009). However, this also in-turn drives 
host evolution; indeed, the human tetherin has a deletion in the cytoplasmic domain, 
which was sufficient to render the SIVcpz Nef ineffective at counteracting tetherin. 
This meant that SIVcpz needed to develop other mechanisms to counteract tetherin, 
which was not always successful. When HIV-1 groups were investigated, it was found 
that only group M viruses possessed strong anti-tetherin responses, which likely 
provides some explanation for the fact that group M is responsible for the majority of 
the AIDS epidemic (Sauter et al., 2009; Sharp and Hahn, 2011). Indeed, the 2 viruses 
within the newly discovered P group are also unable to antagonise tetherin (Sauter et 
al., 2011).  
TRIM5α is a ubiquitin ligase expressed by all primate species, and restricts HIV 
infection by prematurely destabilising the viral capsid through acting as a pattern 
recognition receptor for the capsid lattice, meaning reverse transcription cannot ensue 
(Stremlau et al., 2004; Pertel et al., 2011). It has also been found to promote innate 
immune signalling through initiating a signal transduction cascade (Stremlau et al., 
2004; Takeuchi et al., 2013). Since chimpanzees are relatively closely related to 
humans, it was likely that HIV-1 did not require significant adaptations to counteract 
TRIM5α; HIV-2 on the other hand originated from sooty mangabeys, which are less 
closely related to humans. It was therefore suggested that one of the reasons that HIV-2 
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is less pathogenic than HIV-1 is through an inability to counteract TRIM5α; indeed, it 
was discovered that the CA domain of HIV-2 is more susceptible to TRIM5α than 
HIV-1 (Takeuchi et al., 2013).  
There are also two other restriction factors of HIV infection; SAMHD1 (SAM domain 
and HD domain-containing protein 1) and the recently described REAF (RNA-
associated Early-stage Anti-viral factor) (Marno et al., 2014). SAMHD1 restricts HIV-1 
infection in primary macrophages, dendritic cells and resting CD4
+
 T cells early in cell 
infection by degrading the pool of dNTPs which are required for reverse transcription. 
HIV-2 and SIV encode an accessory protein called Vpx which counteracts SAMHD1 
restriction by targeting it for degradation (Descours et al., 2012; Lahouassa et al., 
2012). REAF inhibits HIV-1, HIV-2 and SIV infection early in the replication cycle. 
Although a limited amount is known so far, it is thought that it may inhibit reverse 
transcription since it associates with viral nucleic acids (Marno et al., 2014).  
1.2 HIV Pathogenesis 
1.2.1 Epidemiology of HIV 
In 2010, it was estimated that 33.3 million people worldwide are living with HIV; 30.8 
million of these are adults. An astonishing 2.6 million individuals are newly infected 
with HIV per year, and 1.8 million infected people die of AIDS every year (UNAIDS, 
2010). The burden of HIV worldwide differs extensively between geographic regions 
(see Figure 3). 
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Total: 34 million 
 
 
 
 
 
 
 
Figure 3: Adults and children estimated to be living with HIV by geographic area 
in 2009 (adapted from UNAIDS 2010).  
There are numerous reasons for the differences observed across continents. For 
example, in Sub-Saharan Africa, poor education about safe sex and a lack of freely 
available contraception, resulting in a high percentage of STIs (sexually transmitted 
infections) in the population, means that HIV spreads rapidly between the heterosexual 
population, accounting for 80-90% of infections among adults (Stratigos and Tzala, 
2000). In contrast, in more developed nations, access to healthcare and education 
programmes results in an overall lower prevalence of infection. (Quinn, 1996). A lack 
of healthcare provision in Sub- Saharan Africa also means that pre-exposure 
prophylaxis has not always been available to give to mothers pre-birth to prevent 
mother-child transmission. Little/no access to clean water also means that almost all 
children are breastfed, leading to more infections of children (Stratigos and Tzala, 
2000). However, new initiatives to prevent mother-to-child transmission by the 
provision of antiretroviral prophylaxis during pregnancy, childbirth and breastfeeding 
has reduced new infections of children by 43% between 2003 and 2011 (UNAIDS 
2012). 
Chapter 1                                                                      Introduction 
 
10 
 
1.2.2 Transmission 
As discussed, the epidemiology of HIV varies greatly worldwide, and this is in part due 
to the mode of transmission which predominates in that region. There are 3 recognised 
routes of transmission of HIV; sexual, perinatal and parenteral (Quinn, 1996).  
Sexual transmission remains the most common route of infection. HIV is found in 
infected mononuclear cells in semen as well as cell-free virus; it is also found in 
cervical smears and vaginal fluid. It has been estimated that the probability of an 
infected male passing HIV into an uninfected female from vaginal intercourse is 0.2%; 
the probability of infection from a woman to man is even less likely. The likelihood of 
infection from receptive male intercourse is, however, much higher due to associated 
tissue trauma and the fact that only a thin mucosal membrane in the rectum separates 
deposited semen from target cells beneath. HIV has rarely been transmitted through 
oral sex (Coffin et al., 1997).  
The risk of HIV transmission from infected individuals with ulcerative genital lesions 
caused by syphilis or herpes is four fold higher than those without, whereas non-
ulcerative STDs (sexually transmitted diseases) such as chlamydia or gonorrhoea pose 
only a two-three fold greater risk (Laga et al., 1994). This is due to a higher probability 
of virus entering the blood through broken mucosal barriers caused by the lesions and 
the higher number of CD4
+
 cells present due to inflammation (Greenspan and Castro, 
1990; Coffin et al., 1997). The association between HIV and STDs is shown below in 
Table 1; the areas with the greatest numbers of HIV infections, Sub-Saharan Africa and 
South East Asia are also the areas with the highest number of STD infections (Quinn, 
1996). 
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Table 1: Worldwide distribution of curable STDs (gonorrhoea, syphilis, 
chlamydia and trichomoniasis) and HIV among young adults in 1995 (adapted 
from Quinn, 1996). 
Meta-analyses have clearly shown that condom use severely reduces HIV transmission, 
which is therefore an important preventative measure in the control of HIV spread. Yet 
in a survey of 745 African Americans in 1999, only 40% knew that condoms were 
effective in preventing HIV transmission, meaning education is half the battle (Weller, 
1993; Rodgers-Farmer, 1999). 
Parenteral transmission, which includes blood transfusions, exchange of blood through 
needles by IDUs (injecting drug users) and infection of healthcare workers through 
inadequately sterilised medical equipment (Quinn, 1996). In Bangkok, as many as 50% 
of known IDUs have been found to be HIV positive (Des Jarlais et al., 1992). Before 
HIV was established as the causative agent of AIDS, one of the main routes of 
transmission was contaminated blood products and a large number of haemophiliacs 
became infected due to inadequate screening (Lowe, 1987). Infection from blood 
transfusions has decreased significantly since the introduction of HIV screening in the 
late 1980s and prevention of high-risk individuals from donating blood, and now rarely 
occurs (Coffin et al., 1997).  
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Perinatal transmission can occur in utero when the maternal blood enters the foetal 
circulation, although this is rare, during delivery via mucosal exposure to virus, or 
postnatally from breastfeeding. A number of factors are associated with an increased 
risk of perinatal transmission, including chorioamnionitis, the presence of other 
sexually transmitted diseases, viral load and low titres of antibody to the HIV-1 
envelope (Peckham and Gibb, 1995; Quinn, 1996).  
Breastfeeding adds an additional 14% risk over the risk of infection pre/during delivery 
(Dunn et al., 1992). Infected mothers are advised to bottle feed their babies in order to 
reduce the risk of transmission, however this is often not possible in developing 
countries where there is poor sanitation and little/no access to clean water (Quinn, 
1996). Specific antipartum and intrapartum regimens of 5’azidothymidine (AZT) or 
zidovudine have been found to reduce the risk of perinatal HIV transmission by about 
two thirds (Peckham and Gibb, 1995; Coffin et al., 1997).  
1.2.3 Host Cellular Targets 
Although HIV has been found to infect numerous different cell types in vitro, including 
eosinophils, cervical cells, columnar epithelial cells, astrocytes and B cells, the main 
cells that are consistently infected in vivo are CD4
+
 effector memory T lymphocytes 
and macrophage-lineage cells. This is because the primary receptor used by HIV for 
cell entry is CD4, which is present on both of the above cell types and various other 
cells. The presence of CD4 is necessary but not sufficient for HIV infection, which 
suggested the necessity for another cofactor for virus entry (Coffin et al., 1997).  
HIV also primarily uses one of two co-receptors for entry; the chemokine co-receptor 
CCR5 or CXCR4 (Veazey et al., 2001; Grossman et al., 2006). CCR5 is the initial 
choice of target in the majority of cases (Douek et al., 2003). This choice of co-receptor 
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is not accidental, since there is a large reservoir of CCR5
+
 CD4
+ 
T
 
cells within and 
immediately below the genital epithelial cell layers, where sexual transmission occurs. 
This population of cells is continually maintained by the proliferation or differentiation 
of CCR5
-
 cells, making this a highly available and abundant target cell population 
(Picker, 2006). Mucosal tissue layers are also rife with inflammatory cytokines, which 
can propagate the activation of resting CD4
+
 T cells and therefore facilitate HIV 
infection of these cells (Douek et al., 2003).  
It has also been demonstrated that HIV can use the fragment crystallisable receptor 
(FcR) to infect cells of the macrophage/monocyte lineage. Infection of CD4
-
 lineages is 
also observed which is mediated by a variety of factors, such as galactosyl ceramide on 
colonic epithelium. HIV replication in CD4
-
 cell lines is, however, limited in 
comparison to CD4
+
 cells (Coffin et al., 1997).  
1.2.4 Cellular Tropism Determinants 
Two phenotypes of HIV-1 have been distinguished, based on the cell types they are 
able to replicate within in vitro. T-tropic viruses are those which can replicate in T-cell 
lines, but not macrophages or monocytes, whereas M-tropic viruses have reverse 
specificity (Coffin et al., 1997). This tropism is influenced by the co-receptor which 
HIV-1 Env binds to and utilises for entry (Sterjovski at al., 2010). T-tropic viruses 
preferentially use CXCR4 (X4) co-receptors for entry into cells, for example 
thymocytes, whereas M-tropic viruses use CCR5 (R5) co-receptors (Berkowitz et al., 
1998). Viruses are often referred to by their preferred co-receptor; X4 and R5 viruses. 
Some variants are also able to use both co-receptors (R5X4 viruses), and are further 
classified according to the efficiency of receptor usage; Dual-R (more efficient usage of 
R5) and Dual-X4 (vice versa) (Bunnik et al., 2011). R5 viruses often predominate early 
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in HIV infection; however a phenotypic switch occurs in most individuals late in 
infection to X4 viruses, possibly because of an increased turnover of naïve T cells 
which X4 viruses preferentially utilise (Ribeiro et al., 2006). The replicative capacity of 
these viruses is, however, not specifically defined by their tropism; some R5 viruses 
cannot infect macrophages, and some X4 viruses can (Duncan and Sattentau, 2011). 
Therefore, the underlying determinants for HIV-1 tropism cannot solely be due to co-
receptor specificity (Sterjovski et al., 2010).  
1.2.5 The Course of HIV Infection 
Although there is often considerable variation of disease presentation between HIV 
infected individuals, a common pattern of disease progression has been shown in 
almost all cases (see Figure 4).  During the early stages of infection, the host is unable 
to mount significant adaptive responses such as the production of neutralising 
antibodies, therefore the adaptive immune system is relied on. Here, toll-like receptors 
(TLR), which are proteins expressed on the surface of macrophages and dendritic cells, 
are activated. This results in the production of numerous cytokines in an acute-phase 
cytokine storm, such as TNF-α and IL-10, which are potent suppressors of viral 
infection (Borrow et al., 2010; Perera and Saksena, 2012). Interestingly, HIV is able to 
down-regulate the TLR pathway which results in a decrease in the production of 
cytokines, which is associated with disease progression (Nicol et al., 2008). Natural 
killer cells, which also form part of the innate immune response, increase dramatically 
in number during this acute phase and assist in the control of HIV replication (Chang 
and Altfield, 2010).  
After the acute response, significant humoral and cellular responses ensue, followed by 
a prolonged period of asymptomatic clinical latency (normally approximately ten 
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years). During this phase, CD4
+
 T cell numbers begin to increase after an initial drop. 
These cells play numerous roles during HIV infection, including homeostasis of CD8
+
 
cells, which initiate cytolytic killing of infected cells, and antibody producing B cells. 
CD4
+ 
cells are thus one of the most important cells in dealing with HIV infection 
(Perera and Saksena, 2012). The humoral response also kicks in during this phase, 
resulting in the production of neutralising antibodies, for example to the viral Envelope, 
which exert significant pressure on HIV. Thus, escape variants with mutations in the 
areas to which antibodies bind in Envelope eventually arise (Haigwood and Stamatatos, 
2003).  
After this chronic phase, alongside severe immune depletion including loss of CD4
+
 
cells, various syndromes will appear as the disease becomes clinically apparent, and 
death usually occurs within 2 years without treatment (Pantaleo et al., 1993).  
 
 
 
 
 
 
 
 
Figure 4: HIV disease progression depicting changes in mucosal and blood CD4
+
 
numbers and viraemia levels. During the acute phase, as viraemia (green) rapidly 
increases, mucosal CD4
+
 cell levels drop dramatically. CD4
+
 cells within the blood 
initially experience a decline, then stabilise at a subnormal level. The immune 
system becomes highly activated (red). During the chronic phase, CD4
+
 cells 
steadily decline as virus levels continue to escalate. At the onset of AIDS, CD4
+
 
cells are virtually abolished and virus levels continue to rise until death (adapted 
from Grossman et al., 2006).  
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1.2.5i Acute Phase 
After initial infection, tissue dendritic cells most likely facilitate the spread of infection 
around the body. Efficient replication of the small viral inoculum at the site of exposure 
dramatically increases viral load, and around 6 days post infection a huge systemic 
infection of target T cells ensues. Any pre-existing inflammation at the site of exposure, 
for example from sexually transmitted diseases, amplifies the efficiency of systemic 
infection (Picker, 2006). Mucosal CD4
+
 T cells, particularly those within the gut, are 
the primary target for HIV proliferation due to the high expression of CCR5 and their 
activated state, and are consequently the largest site of T cell depletion during the acute 
phase. At the peak of infection, around 10 days post exposure, 30-60% of memory 
CD4
+
 T cells are found to be infected, and most of these are destroyed within 4 days 
(Mattapallil et al., 2005). This, combined with apoptosis of cells which have interacted 
with the virus in a receptor/ co-receptor dependent manner, accounts for the massive 
loss in CD4
+
 cells (Picker, 2006).  
In the majority of infections, an acute mononucleosis-like syndrome appears 
approximately 1-3 weeks after initial infection, associated with the high levels of virus 
(Pantaleo et al., 1993). Symptoms may include headache, muscle aches, low/high grade 
fever, malaise and swollen lymph nodes. Although these symptoms only last a few 
weeks, lethargy and lymphadenopathy may persist for many months (Levy, 1993). 
During this high period of viral replication, up to 10
7 
virions per ml in cell-free plasma 
can be detected, although only a small percentage of these are infectious (Coffin et al., 
1997). 
Around 3-6 weeks post infection antiviral immune responses can be detected, 
combined with a significant decrease in viremia and simultaneous appearance of strong 
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antibodies to the viral proteins Env and Gag, resolution of the clinical syndrome and a 
temporary stabilisation of CD4
+
 cell level. This is probably due to a combination of 
responses from both the innate and adaptive systems and the exhaustion of susceptible 
target cells (Clark et al., 1991; Coffin et al., 1997).  
1.2.5ii Clinical Latency 
Following the immune response observed during the acute phase, a prolonged period of 
“clinical latency” ensues (see Figure 5 overleaf), which usually lasts some years 
(Coffin et al., 1997). The term “latency” can be misleading, as the immune status of the 
majority of patients continually gradually declines due to the gradual, progressive 
attrition of CD4
+
 cells (Fauci, 1998; Pantaleo et al., 1993). This decline is not seen in a 
minority of infected individuals, who are termed “long term non-progressors” (Coffin 
et al., 1997) 
 
 
 
 
 
 
 
Figure 5: A schematic of the progression from HIV infection to the development of 
clinical disease (Adapted from Pantaleo et al., 1993).  
Adaptive immune response 
Innate immune response 
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During this stage, the majority of cells that die are bystander cells by apoptosis; most of 
the apoptotic T cells in the lymph nodes and peripheral blood of HIV positive 
individuals are uninfected (Kynsz et al., 2010). This is caused by a combination of 
activation-induced cell death of mature T cells following chronic activation, and by 
direct effects of HIV viral proteins. Some studies have indicated that both in vivo and in 
vitro, only 0.0001 to 0.01% of HIV virions produced are actually infectious, therefore 
non-infectious virions contribute largely to the CD4
+
 decline via the induction of 
bystander apoptosis (Dimitrov et al., 1993; Holm and Gabuzda, 2005).  
1.2.5iii Clinical stage (AIDS) 
The inevitable outcome for the majority of HIV infected patients is clinically apparent 
disease (Panteleo et al., 1993). When the CD4
+
 T cell count drops below the normal 
range (from 600-1200/μl blood) to around 500, and the first disease symptoms start to 
become apparent (see Table 2 on page 16).  
There has been speculation over the years as to how to define the onset of AIDS, and 
now the generally accepted definition is a patient whose CD4
+
 cell count is at or below 
200 cells per microlitre of blood. Prior to using actual T cell counts, the “gold standard” 
of AIDS diagnosis was seropositivity in conjunction with one or more AIDS defining 
illnesses, such as Kaposi’s sarcoma (see Figure 6A) or Pneumocystis jirovecii 
pneumonia (see Figure 6B) (Kerdel and Pennys, 1989).  
At this stage, the patient is susceptible to a number of AIDS-defining opportunistic 
infections and neoplasms. Many patients within this advanced stage will also 
experience a range of neurocognitive problems due to infection of cells within the 
central nervous system (CNS), such as microglia and astrocytes, coined HIV associated 
neurocognitive disorders (HAND). Studies have shown similar features between the 
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development of HAND and other neurodegenerative diseases such as Alzheimer’s, 
including the appearance of amyloid plaques (Kaul, 2009) 
This stage will continue until the T cells are virtually absent in the body, and the patient 
will eventually die from one of a number of conditions as shown in Table 2 (Coffin et 
al., 1997).  
 
 
 
 
 
Figure 6: A- An example of a typical cutaneous lesion seen in Kaposi’s sarcoma. 
Patients present discrete, non-pruritic and non-tender pink/purple papules which 
are often asymmetrical. B- Pneumocystis jirovecii pneumonia chest X-ray 
demonstrating bilateral mid and lower zone infiltrates (Lewthwaite and Wilkins, 
2009). 
Primary 
Infection 
 
Mononucleosis-like syndrome;  
Fever,   malaise, pharyngitis, lymphadenopathy, arthralgias, 
maculopapular rash 
Clinical Latency Fatigue, mild weight loss, thrush, generalised lympadenopathy 
Clinical Disease 
(200-500 CD4
+
T 
cells/μl) 
Oral lesions (thrush, hairy leukoplakia) shingles, 
thrombocytopenia, reactivation of latent M. tuberculosis 
Clinical Disease 
(<200 CD4
+
T 
cells/μl) 
Protozoal infections; Pneumocystis jirovecii, Toxoplasma 
gondii, Isospora belli  
Bacterial infections; Treponema pallidum.  
Fungal infections; Candida albicans, Cryptococcus 
neoformans.  
Viral infections and malignancies; cytomegalovirus, 
lymphoma (Epstein-Barr virus), Kaposi’s sarcoma (human 
herpes virus 8), non-Hodgkin’s lymphoma, invasive cervical 
cancer. 
Neurological symptoms; aseptic meningitis, myopathy, HAD 
A B 
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 Table 2: Pathologic conditions associated with HIV infection/ AIDS (Coffin et al., 
1997, Bower et al., 2006) 
Since up to 90% of HIV infections occur in the developing world, and tuberculosis is 
prevalent in 30-50% in the AIDS clinical series of many of these countries, tuberculosis 
became one of the most common AIDS defining illnesses. The HIV epidemic caused 
more than a 2-fold increase in tuberculosis cases across Sub-Saharan Africa and Asia. 
The presentation of tuberculosis in AIDS patients is, however, different from those 
without HIV infection; it occurs in younger aged individuals, there are a higher 
proportion of smear-negative pulmonary disease and extrapulmonary tuberculosis, and 
a considerably higher 12 month mortality rate exists (Dore and Cooper, 2001).  
Cancer risk is increased with various types of immune deficiencies, including 
immunosuppression following organ transplants and congenital disorders. HIV patients 
have an alarmingly high risk of developing an unusual array of cancers (Goedert et al., 
2012). Although late stage HIV infection can cause numerous cancers, several “AIDS-
defining” cancers exist; Kaposi’s sarcoma, non-Hodgkin’s lymphoma and cervical 
cancer. Kaposi’s sarcoma is the most common AIDS related malignancy, and is caused 
by human herpes virus 8 (Lewthwaite and Wilkins, 2009). Other cancers that HIV 
patients are at a higher risk of developing include Hodgkin’s disease, anal cancer, lip 
cancer, leukaemia and multiple myeloma. It is, however, important to note that since 
HIV patients will be undergoing increased medical surveillance, that some cancers may 
have been diagnosed when they would have otherwise not been apparent, therefore it 
can be difficult to judge whether there is an actual increased risk of particular cancers. 
Medical immunosuppression has been shown to cause similar cancers to those observed 
in HIV patients that are usually caused by viral infections (Grulich et al., 1999).  
(HIV associated dementia), sensory ataxia, and peripheral 
neuropathies. 
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1.3 HIV Treatment 
Prior to 1996, few treatment options were available to HIV+ patients. Standard regimes 
included prophylaxis against opportunistic infections and management of AIDS related 
illnesses, i.e. treating symptoms not the cause. HIV treatment was revolutionised in the 
1990’s by the introduction of inhibitors of two of HIV’s key enzymes; protease and 
reverse transcriptase (RT). The first antiretroviral (ARV) drugs developed were 
administered as monotherapy, but since this was found to be ineffective due to the rapid 
emergence of resistant strains, treatment regimens evolved to the administration of a 
cocktail of 3 or more drugs targeting different stages of the HIV life cycle (Arts and 
Hazuda, 2012). This combination therapy, still used today, was named HAART (highly 
active antiretroviral therapy) and has been critical to reducing HIV associated mortality 
and morbidity (Collier et al., 1996). 
Although HIV drugs have become more advanced and sophisticated since their 
introduction in the mid 1990’s, no drugs can actually yet “cure” patients of HIV, i.e. 
abolish all viral particles and prevent the onset of the disease stage. They are, however, 
effective at reducing viral load and prolonging life. Five major classes of antiretroviral 
drugs exist, targeting different stages of the HIV life cycle: 
 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 Protease Inhibitors 
 Entry Inhibitors 
 Integrase Inhibitors 
More recently, inhibitors of viral assembly and production have been added to the list 
HIV infection is characterised by continuous, high rate viral replication. RTs lack of 
proof-reading during the synthesis of viral DNA, married with HIVs capacity for 
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genetic recombination, is the reasoning behind HIVs high mutability. This also allows 
immune evasion resulting in the emergence and selection of drug resistant variants 
(Pauwels, 2004).  
1.3.1 Highly Active Antiretroviral Therapy (HAART) 
The advent of combination therapy, or HAART, revolutionised HIV treatment, 
reducing both morbidity and mortality associated with HIV infection, allowing patients 
to resume a near-normal quality of life. Typically, 3 ARVs are administered, targeting 
at least two different molecular targets; this is essential in delaying the onset of drug 
resistance. HAART dramatically suppresses viral replication, reducing viral load to 
almost undetectable levels in plasma, allowing the immune system to rebuild (Arts and 
Hazuda, 2012).  
HAART has transformed HIV infection, turning it into a chronic manageable condition 
in many as opposed to an inevitably fatal disease. Despite its success, however, there 
still remains a large proportion of individuals who do not respond to their first line of 
treatment. This means that the patients are at a high risk of virologic rebound, and may 
be less responsive to further treatment options (Vella and Palmisano, 2000).  
1.4 The HIV-1 Life Cycle 
1.4.1 The HIV-1 Genome and Virion 
The HIV-1 genome, as with all other lentiviruses, is complex. All retroviruses have 
RNA genomes and contain 3 benchmark genes; gag, pol and env. HIV-1 contains an 
additional 6 genes, making up a 9.8 kb genome containing 9 open reading frames 
(ORFs), flanked by long terminal repeats (LTRs). These genes can be organised into 3 
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distinct groups; tat and rev are regulatory; gag, pol and env are structural and/or 
enzymatic; nef, vif, vpu and vpr are accessory. These genes encode 15 viral proteins.  
A summary of the HIV-1 genome and viral proteins produced shown in Figure 7.  
 
 Figure 7: The HIV-1 genome and the proteins encoded by these genes. MA 
(matrix), CA (capsid), NC (nucleocapsid), PR (protease), RT (reverse 
transcriptase, IN (integrase), SU (surface), TM (transmembrane) (adapted from 
Suzuki and Suzuki, 2001).   
Mature, infectious HIV particles possess a characteristic conical core encasing the viral 
RNA and replication proteins, which is the most distinctive feature of the mature virion 
(Briggs et al., 2003; Sundquist and Kräusslich, 2012). The mature virion is composed 
of “shell” like layers of Gag; matrix (MA) lies beneath the lipid membrane and 
composes the outer shell. The transmembrane (TM) portion of Env passes through the 
membrane and contacts MA in a non-specific manner, whereas the outer portion 
contacts the surface (SU) domain. Numerous host proteins are also incorporated into 
the lipid membrane, such as the MHC proteins. Inside the virion, the capsid (CA) 
portion of Gag forms the outer core, the capsid domain. The location of p6 (located on 
the carboxy terminus of Gag) is assumed to lie just outside the core. Within the centre 
of the core lies the viral RNA, bound to the nucleocapsid (NC), which are associated 
MA    CA   NC p6 
gp160 
gp120 gp41 
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with some RT and IN molecules (Coffin et al., 1997). A diagram of a mature particle is 
shown in Figure 8.  
 
 
 
 
 
 
Figure 8: The mature HIV-1 virion, showing structure and protein organisation.  
CA (capsid), MA (matrix), NC (nucleocapsid), RT (reverse transcriptase), PR 
(protease), IN (integrase), Env (envelope), SU (surface), TM (transmembrane). 
(adapted from Coffin et al., 1997).  
1.4.2 Stages of the HIV Life Cycle 
The HIV-1 life cycle represents a complex, multi-step process, involving a 
collaboration of events from both the host and the virus (Adamson and Freed, 2010). A 
brief summary of the life cycle is represented overleaf in Figure 9.  
 
 
 
 
 
 
Trimer of gp120 (SU)  
and gp41 (TM) form an  
Env spike 
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Figure 9: A schematic of the main events occurring during the HIV-1 life cycle 
(adapted from Adamson and Freed, 2010). 
The life cycle begins with viral entry where the virus binds, mediated by gp120 of the 
Env spike, to the CD4 receptor and the appropriate co-receptor (CCR5 or CXCR4); a 
conformational change in gp41 of Env results in fusion of the envelope to the cellular 
membrane, releasing the viral core (composed of the capsid, nucleocapsid and the 
single stranded, dimeric RNA genome) into the cytoplasm. After uncoating, the viral 
reverse transcriptase (RT) produces double stranded DNA from the RNA genome, 
which migrates into the nucleus and stably integrates into the host genome, mediated 
by viral integrase (IN). Proviral DNA is transcribed by cellular RNA polymerase II into 
full-length progeny RNA and numerous spliced mRNA transcripts which are exported 
by viral Tat and Rev. Translation, mediated by cellular polysomes, results in the 
synthesis of viral subunits which, together with full-length genomic RNA, are 
transported to assembly sites. After virion assembly, budding occurs, releasing 
immature non-infectious particles which are then proteolytically processed by viral 
Env 
spike 
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protease to produce mature, infectious particles (Sierra et al., 2005; Adamson and 
Freed, 2010). These events will be described in detail in following sections. 
1.4.3 Viral Entry and Uncoating 
The entry of HIV-1 is the first step in the infection process, and involves series of 
tightly controlled steps that ultimately result in the fusion of the viral and cellular 
membranes and the release of the viral genome into the cytoplasm of the infected cell 
(Gomez and Hope, 2005). As mentioned in chapter 1.2.3, HIV-1 utilises host CD4 
receptors (a member of the immunoglobulin super family) expressed on monocytes, 
macrophages, dendritic cells and subsets of T cells, and chemokine receptors CCR5 
and CXCR4 to enter cells  (Tilton and Doms, 2010).  
The entry process is facilitated by viral Env; the env gene encodes a glycoprotein, 
gp160, which is post-translationally cleaved by a cellular protease (furin) to produce 
gp120 (SU, surface subunit) and gp41 (TM, transmembrane portion) which are non-
covalently joined into a trimeric structure (Lu et al., 1995; Gomez and Hope, 2005). 
The first stage of entry involves Env gp120 engaging CD4, upon which various 
important conformational changes in gp120 occur; the V1/V2 and V3 loops become 
exposed, two sets of separated β-sheets come together to form a bridging sheet and the 
orientation is changed in such a way that the bridging sheet and V3 face the cellular 
membrane, thereby allowing stabilising interactions with the co-receptor (CCR5 or 
CXCR4). Following co-receptor binding, further Env conformational changes result in 
the exposure of the hydrophobic fusion peptide of gp41, which is subsequently inserted 
into the host membrane. After this, the heptad regions of gp41 rearrange into a six helix 
bundle, forcing the TM region toward the fusion peptide, and this is subsequently also 
inserted into the host membrane, forming a fusion pore (Esté and Telenti, 2007; Chan 
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et al., 1997; Sackett and Shai, 2002; Tilton and Doms, 2010). The entry process is 
summarised below in Figure 10. 
 
 
 
 
Figure 10: The multi-step process of HIV-1 entry. CD4 and co-receptors are found 
on the host (bottom) membrane, whilst gp120 and gp41 are associated with the 
viral membrane (top) (adapted from Tilton and Doms, 2010).  
The viral capsid enters the host cytoplasm through the fusion pore. The process of 
uncoating involves both cellular factors and viral proteins; MA, Nef and Vif (Sierra et 
al., 2005). Uncoating is defined as the dissociation of the viral Capsid core from the 
ribonucleoprotein complex (Forshey et al., 2002).  
Recently, it was discovered that phosphorylation of CA within the virion acted as a 
“molecular switch” to trigger uncoating, although the kinase is currently unknown. 
Once phosphorylation of a specific serine/threonine residue followed by a proline has 
taken place, a cellular protein Pin1 (a peptidyl-prolyl isomerase involved in 
transcriptional regulation) is able to assist uncoating and binds to this phosphorylated 
region of CA and isomerises the proline (Musumi et al., 2010). Cyclophilin A (CypA), 
another cellular peptidyl-prolyl isomerase, which may be incorporated into virions, is 
also thought to aid uncoating (Li et al., 2009) by destabilising core formation through 
an interaction with specific CA residues G89 and P90 (Friedrich et al., 2011), and also 
contributes to virion infectivity.  
 
  Env                              CD4                            Co-receptor                             Membrane 
Trimer                        Binding                      (CCR5/CXCR4)                                Fusion 
Binding 
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1.4.4 Reverse Transcription and Nuclear Import 
The HIV life cycle, as with that of all retroviruses, requires integration of a DNA copy 
of its genome into a host chromosome, in order to instigate stable replication. Since the 
HIV genome is positive single stranded RNA, it must therefore generate a DNA copy 
before integration can occur (Sleiman et al., 2012). The process involved is reverse 
transcription (RTN), and is shared by retroviruses, retrotransposons and hepadnaviruses 
(Abbink and Berkhout, 2008).  
RTN requires both packaged cellular and viral factors; minimally, the HIV RT and a 
cellular tRNA
Lys3 
primer which is packaged into virions by Pr55
Gag
 and Pr160
Pol 
(Harrich and Hooker, 2002). The HIV-1 RT is encoded by the pol gene with its 
embedded RNaseH (ribonuclease H) activity, alongside integrase and protease. It is an 
asymmetrical heterodimer composed of 2 subunits; p66 and p51. The RNaseH is 
located on the carboxy terminus of the p66 subunit, and is not present on the C-
terminally truncated p51 subunit (see below for further detail of RNaseH activity) 
(Sarafianos et al., 2009).   
RTN occurs in the cytoplasm of the host cell; specifically, within a nucleoprotein 
complex which is only permeable to small molecules such as dNTPs, preventing the 
loss of RT or other essential factors (Sleiman et al., 2012). A specific RTN initiation 
complex (RTNIC) is formed by base pairing between tRNA
Lys3 
and the viral RNA, 
which is postulated to prevent RTN until after infection (Harrich and Hooker, 2002). 
Specifically, the 3’-terminal 18 nucleotides (nts) of tRNALys3 base pair with a 
complementary region of viral genomic RNA called the primer binding site (PBS), 
which is located at the 5’ end of the viral RNA. The 3’-OH of the tRNA primes 
template-dependent DNA synthesis (Abbink and Berkhout, 2008).  
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DNA synthesis begins at the 5’ end of the viral genome, alongside the extension of the 
3’ end of the tRNA. The first DNA product is minus (-) sense, and termed the “minus 
strand strong stop DNA”; a short length of DNA resulting from copying from the 
primer to the 5’-end of the viral RNA (see Figure 11 part A). This short piece of DNA 
then translocates to a site near the 3’-end, via a homologous repeat (minus strand 
transfer); this is required to complete the minus strand synthesis (Figure 11 part B) 
(Goff, 1990). A second transfer is also required to produce the plus (+) strand. RNaseH 
is required for strand transfer as degradation of the RNA template strand from the 
extending DNA strand frees a single stranded region that is capable of annealing to the 
second site (Figure 11 part C) (Basu et al., 2008). (-) strand transfer originates from a 
region at the 5’-end called R region, to an equivalent region at the 3’-end. This region 
consists of a TAR hairpin and a poly(A) hairpin.  
As elongation of the (-) strand continues, RNaseH degrades RNA from the RNA:DNA 
hybrid, which dissociates from the nascent DNA, except for 2 fragments which are 
resistant due to their possession of a polypurine tract (PPT). These RNA oligomers; 3’-
PPT and central PPT (cPPT) act as primers for the synthesis of the (+) strand. (+) 
strand synthesis begins at the 3’-PPT and continues to the 5’-end, using the PBS as a 
template, to produce (+) strand strong stop DNA (Figure 11 part D). This strand must 
then transfer to the 3’-end of the (-) strand to complete the process (Figure 11 parts E 
and F) (Goff, 1990; Charneau et al., 1994; Basu et al., 2008). 
This double stranded DNA, which is longer than HIV RNA due to extended LTRs 
which are critical for integration and transcription, must then be imported into the 
nucleus for integration into the host genome, and subsequent DNA replication. A 
summary of reverse transcription is shown overleaf in Figure 11. 
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Figure 11: A summary of the process of reverse transcription of HIV-1 (adapted 
from Sarafianos et al., 2001).  
Following reverse transcription, the newly synthesised viral DNA must travel to the 
nucleus for integration and DNA replication ensue. At this stage, the DNA is present in 
the cytoplasm in a high molecular weight nucleoprotein complex termed the pre-
integration complex (PIC). This complex contains various viral and cellular 
constituents. MA but not CA are present (Farnet and Haseltine, 1991), alongside IN, 
RT, NC and Vpr (viral protein R) (Dismuke and Aiken, 2006). Cellular proteins 
include LEDGF/p75 (lens epithelium-derived growth factor) and Barrier to 
autointegration (BAF) (Llano et al., 2004; Vandegraaff et al., 2006).  
While oncoretroviruses require nuclear envelope disintegration, which occurs during 
mitosis, in order to integrate their viral DNA, lentiviral PICs are able to access the 
nucleus through the nuclear pore complex. Small proteins may passively enter the 
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nucleus, however, larger proteins (>40kDa) require specific nuclear localisation signals 
(NLSs) for active transport (Friedrich et al., 2011). HIV has developed an active 
mechanism to import its viral DNA into the nucleus. Vpr is one of the main viral 
constituents involved in enhancing nuclear import and has evolved specific strategies 
that promote interactions with cellular machinery that regulate nucleo-cytoplasmic 
shuttling (Le Rouzic and Benichou, 2005). For example, Vpr associates with 
karyopherin alpha, a NLS receptor, which increases the affinity of this receptor for 
NLSs, including those found on HIV MA (Popov et al., 1998).  
In order to traffic to the nucleus, the HIV-1 PIC travels down cellular microtubules 
using cytoplasmic dynein motors. Once at the nucleus, the PIC has the formidable 
challenge of crossing the nuclear envelope. The nuclear envelope is composed of inner 
and outer membranes, studded with embedded nuclear pore complexes, the lamina and 
associated proteins (Li and Craigie, 2006). Various proteins are known to mediate PIC 
entry. Soluble Karyopherin (importin) α/β heterodimers are involved in the import of 
proteins containing basic NLSs; the α subunit binds to the NLS of MA and the β 
subunit enhances affinity of this interaction and mediates the docking of this 
NLS/karyopherin complex to the nucleoporins (proteins constituting nuclear pore 
complex proteins) (Popov et al., 1998), allowing the NLS containing protein and the 
associated soluble import receptor to be translocated into the nucleus. The karyopherin 
α/β heterodimer also aids nuclear import through interactions with HIV-1 integrase in a 
Ran GTP dependent ATP independent manner (Hearps and Jans, 2006). Nuclear import 
is summarised in Figure 12. 
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Figure 12: Viral factors within the HIV-1 PIC (central polypurine tract [cPPT], 
MA, IN and Vpr) involved in nuclear import. Adapted from Suzuki and Craigie, 
2007. 
1.4.5 Integration  
Following nuclear import, integration is the next step. This is defined as the insertion of 
the HIV-1 cDNA into the host chromosome. If this does not occur, the cDNA 
circularises upon itself and forms a 2-LTR circle; a dead end for the virus as it is unable 
to produce any progeny (Friedrich et al., 2010). Once integrated, so called proviral 
DNA is replicated alongside cellular DNA during the normal cell cycle. This provirus 
serves as a template for the production of viral RNA; some of which is translated into 
viral proteins, other proviruses serving as genomic RNA to be packaged into new 
virions. Integration occurs precisely at the termini of the viral DNA, but many locations 
along the host DNA may serve as acceptor sites. Some retroviruses have preferred 
regions for integration, which seem to involve chromatin-associated factors that interact 
with IN, or kinked/distorted DNA (Frankel and Young, 1998; Craigie and Bushman, 
2012). 
 
 
 
 
 
HIV-1 
DNA 
 
 
 
 
MA 
IN 
Vpr 
cPPT 
HIV-1    
PIC 
Karyopherin        
α/β 
 
   Nuclear 
Envelope NPC 
Cytoplasm 
 
 
 
 
 
Nucleoporins 
IN 
Chapter 1                                                                      Introduction 
 
33 
 
The first stages of integration involve directing the viral DNA to host chromatin. BAF, 
alongside preventing autointegration of the cDNA (a suicide pathway using itself as the 
target) prior to integration, binds to MA and orients the PIC toward chromatin (Chen 
and Engelman, 1998), with assistance from lamina-associated polypeptide 2-alpha 
(LAP2alpha). The initial contact with chromatin is mediated by cellular emerin, which 
is a prerequisite to tethering. LEDGF/p75 has been demonstrated to be essential for 
tethering the viral DNA to chromatin (Friedrich et al., 2011).  
The integration reaction is highly coordinated; 2 viral linear DNA ends, separated by 
around 7-10 kb, must be juxtaposed to the host target DNA in a pairwise manner (Katz 
and Skalka, 1994). After alignment of the DNA, the first stage is 3’ end processing, 
whereby 2 nucleotides (nts) are removed from each 3’ end of the blunt linear viral 
DNA, leaving overhanging conserved CAOH ends. In the second step, strand transfer, 
the 3’ ends attack a pair of phosphodiester bonds, separated by 5 nts, localised on the 
major groove of the opposite host DNA. This forms an integration intermediate where 
the 3’ ends of the viral DNA become joined to the 5’ ends of the host DNA. Finally, 
unpaired nucleotides at the 5’ ends are removed, and the ends become joined to the 
target site 3’ ends (Frankel and Young, 1998; Craigie and Bushman, 2012).  
A summary of this process is shown overleaf in Figure 13. 
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Figure 13: DNA breaking and joining reactions during Integration. A- Viral DNA 
is shown in yellow/green, host in red/blue. B- 3’ end processing and the removal of 
2 nucleotides from the 3’ viral DNA.  C- 3’ ends attack a phosphodiester bond in 
target DNA. The 3’ ends of the viral DNA are joined to the 5’ ends of host DNA; 5’ 
viral ends are not joined. D- Removal of unpaired bases at the 5’ end of the viral 
DNA is required before the 5’ ends are ligated to host DNA. E- The fully 
integrated provirus (adapted from Craigie and Bushman, 2012). 
1.4.6 Transcription and Splicing 
After integration, HIV-1 may either initiate transcription via cellular transcription 
machinery to produce progeny RNA, or alternatively enter a latency phase (Friedrich et 
al., 2011). Latency is defined as cells containing integrated HIV DNA that are 
transcriptionally silent; however, upon activation they are capable of producing 
infectious virions. This constitutes a latent reservoir, which creates a barrier to 
successful treatment. It is simple to assume that a latently infected cell would not 
produce viral RNA, however, it has been demonstrated that these cells do produce low 
levels of viral RNA (Pace et al., 2011).  
The first stages of viral transcription are initiated by cellular RNA polymerase II 
binding to the viral 5’LTR, which contains binding sites for many transcription factors 
A B C 
D E 
2 nts 2 nts 
Viral 
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including NF-κB, and results in low levels of full-length viral RNA. The full-length 
RNA may then be spliced to generate over 30 different transcripts. These RNAs can be 
divided into 3 groups; multiply spliced RNAs encoding Tat, Nef and Rev; singly 
spliced RNAs encoding Vpu, Vpr, Vif and Env; and unspliced full-length mRNA 
encoding Gag and Gag-Pol polyproteins (Wu, 2004). The multiply spliced RNAs are 
exported into the cytoplasm where Tat, Rev and Nef proteins are translated. Tat (a viral 
transcription activator) shuttles into the nucleus, where it acts to increase transcription 
of viral RNA by binding to the U-rich bulge of the TAR (trans-activation response) 
element, found at nucleotides +1 to +60 of the viral RNA (Lloyd et al., 2000; Sierra et 
al., 2005). This increase in transcriptional levels is due to a stimulation of a specific 
protein kinase called TAK (Tat-associated kinase), which also binds to TAR. TAK is 
composed of a kinase CDK9 and a cyclin, cyclin T1. During the initiation of 
transcription, the kinase CDK7 of initiation factor TFIIH phosphorylates the carboxy 
terminal domain (CTD) of RNA polymerase II. Tat then stimulates additional 
phosphorylation via TAK; CDK9 hyperphosphorylates CTD of RNA polymerase II, 
greatly enhancing its processivity (Karn, 1999; Wu, 2004). A summary of this process 
is shown overleaf in Figure 14. 
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Figure 14: Activation of RNA polymerase II by Tat and cellular cofactors. A- 
RNA Pol II is recruited to the viral LTR. CDK7 of TFIIH phosphorylates the 
CTD of RNA Pol II, clearing the promoter region and transcription of TAR 
ensues. B-The nascent RNA transcript corresponding to TAR folds into its 
characteristic stem-loop structure and binds to the RNA Pol. C- Tat is recruited to 
the complex and binds to the bulge of TAR. TAK kinase phosphorylates the CTD 
and TAR is displaced. D- The activated complex is able to transcribe the rest of 
the genome. (Adapted from Karn, 1999).  
The second stage of HIV-1 gene expression depends on the nuclear export of intron-
containing transcripts. The multiply spliced viral RNAs use the cellular mRNA export 
pathway to reach the cytoplasm, but singly-spliced and unspliced viral RNAs are 
prevented from exiting the nucleus by this pathway, instead utilising the viral Rev 
protein. Once a sufficient level of Rev is translated, it shuttles into the nucleus and 
binds to a specific RNA structure found only on singly and non-spliced transcripts, 
called the RRE (Rev responsive element). Rev multimerises upon binding and 
stabilises the formation of a complex between Rev and cellular exportin-1 (CRM-1), 
targeting the mRNA to the nuclear pore complex for export. The mRNA is then 
RNA Pol II 
RNA Pol II 
RNA Pol II RNA Pol II 
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directed to polysomes for translation, preventing them for being spliced (Wu, 2004; 
Sierra et al., 2005).  
1.4.7 Viral Translation and Viral Proteins 
1.4.7i Gag and Gag-Pol 
The full-length transcript of the integrated provirus serves as the mRNA for the 
generation of Gag and Gag-Pol polyproteins. Gag and Pol proteins are synthesised on 
cytosolic polysomes, using overlapping open reading frames (ORFs). The first codon of 
gag is the first AUG of the RNA, although this is not the case for many other 
retroviruses. Large numbers of Gag molecules are required to serve as the precursors 
for the structural proteins of new virions; during particle maturation (see section 1.4.9) 
Gag is cleaved by the viral Protease into MA, CA, NC and p6 proteins (see Figure 15). 
However, the enzymes encoded by pol (RT, IN, PR) are needed in smaller quantities; 
this is also essential for viral morphogenesis. HIV has developed a mechanism which 
allows high expression of Gag relative to the protein sequences encoded by pol. This is 
due to the usage of the same initiation codon in the same mRNA to express both gag 
and pol. The ratio of Gag to Gag-Pol is around 20:1; this is conserved among 
retroviruses (Coffin et al., 1997; Shehu-Xhilaga et al., 2001).  
The domains of the Gag polypeptide each play different roles. MA is predominantly 
involved in membrane targeting and triggers particle assembly to occur at the correct 
time. The CA protein assembles into a fullerene cone which encases the viral genome, 
and NC binds to viral RNA, which drives genomic RNA packaging. p6 is responsible 
for recruiting cellular machinery involved in viral budding. The spacer peptide SP1 
stabilises Gag-Gag lattice interactions which are critical for immature particle 
formation, whereas spacer peptide SP2 itself is indispensable, but processing of the 
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NC-p6 region is essential for particle morphogenesis and virion infectivity (Ganser-
Pornillos et al., 2008; de Marco et al., 2012). 
 
 
 
 
Figure 15: The HIV-1 Gag polyprotein domain structure (A) and a structural 
model of the extended Gag polypeptide (B). Arrowheads indicate PR cleavage 
sites. CA is composed of two highly helical domains; the N-terminal domain 
(CANTD) and the C-terminal domain (CACTD) (adapted from Ganser-Pornillos et 
al., 2008).  
The gag gene is located at the 5’ end of the genome, upstream to that of pol. Gag-Pol is 
generated using a strategy whereby the 3’ termination codon of the gag ORF is 
bypassed, allowing translation to continue into the adjacent pro gene. This is achieved 
by a mechanism known as ribosomal frameshifting. The site of frameshifting is a 
heptanucleotide AU-rich sequence, also known as a “slippery sequence” found at the 3’ 
end of the NC domain of gag. A stem-loop RNA structure is present 6 nt after this 
sequence, allowing the ribosome to stall as it scans, slipping back 1 nucleotide (-1 
slippage). After this, the last codon read in the original reading frame becomes the first 
position nucleotide of the first codon in the new reading frame (Coffin et al., 1997; 
Dinman et al., 1998; Jacks et al., 1998; Shehu-Xhilaga et al., 2001; Brierley and Dos 
Ramos, 2006). Gag is also able to produce virus-like particles in the absence of any 
other viral proteins (Delchambre et al., 1989).  
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1.4.7ii Env 
The HIV-1 Env glycoproteins play an essential role in the viral life cycle, mediating the 
fusion between viral and target cellular membranes during the entry process. Like other 
proteins destined for the plasma membrane, gp160 is synthesised on the rough 
endoplasmic reticulum (RER) as a polyprotein precursor, derived from a singly spliced, 
bicistronic vpu/env mRNA. gp120 contains an ER signal sequence at its N-terminus, 
targeting it to the RER. This signal sequence is then cotranslationally removed in the 
ER by signal peptidases. During gp120 translation, it is simultaneously glycosylated 
with N- and O-linked oligosaccharide side chains (Freed and Martin, 1995; Checkley et 
al., 2001).  
After synthesis in the ER, gp120 oligomerises into trimers, facilitating its trafficking to 
the Golgi complex. Once here, it is cleaved at a highly conserved K/R-X-K/R-R motif 
by cellular furin into gp41 and gp120. These remain covalently attached and form a 
heterotrimeric spike with gp41 comprising the transmembrane domain and gp120 being 
fully exposed extra-cellularly. Once at the PM, this spike is rapidly endocytosed by AP-
2 (see 1.5.2ii for further detail of AP-2 function) through a tyrosine YxxL motif located 
on the carboxy terminus of gp41. This internalisation is responsible for the relatively 
low levels of incorporation of Env into newly synthesised particles (Checkley et al., 
2001). This also ensures that Env is retrieved unless the Gag protein is present in the 
same microdomains (Egan et al., 1996). This has led to the proposal that internalisation 
of Env can protect against immune recognition (Marsh and Pelchen-Matthews, 2000). 
1.4.7iii Regulatory Proteins 
HIV-1 encodes two regulatory proteins; Tat and Rev, whose primary functions in HIV 
gene expression have already been discussed. Tat also plays many nontranscriptional 
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roles within the viral life cycle. For example, Tat can influence HIV-1 RNA splicing, 
capping and reverse transcription, and can also modulate the expression of numerous 
cellular genes (Das et al., 2011). This modulation includes the upregulation of the 
chemokine co-receptor CCR5, used for viral entry, and the downregulation of MHC 
class I. Tat can also promote apoptosis by altering microtubule dynamics, and inhibit 
apoptosis by upregulating the anti-apoptotic protein B-cell lymphoma 2 (BCL-2); the 
latter is thought to be crucial to the establishment of latency (Romani et al., 2009).  
In addition to nuclear export, Rev functions to enhance viral translation and facilitates 
the packaging of HIV-1 genomic RNA through interactions with the RRE, contributing 
to the selection of full-length RNAs destined for encapsidation (Groom et al., 2009).  
1.4.7iv Accessory Proteins 
There are 4 accessory proteins produced by HIV-1; Nef, Vif, Vpr and Vpu. These 
proteins function to modify the cellular environment within infected cells in order to 
ensure efficient viral persistence, replication, dissemination and transmission (Malim 
and Emerman, 2008).  
Vpu (viral protein U) is an 81AA (amino acid) integral membrane phosphoprotein 
which mediates the degradation of CD4 within the ER. The Vpu cytosolic domain acts 
as an adaptor to link CD4 to an E3 ubiquitin ligase (TrCP) to facilitate CD4 ER-
associated degradation. This receptor downregulation is employed by many 
retroviruses, including HIV, to avoid superinfection (Margottin et al., 1998; Andrew 
and Strebel, 2010; Strebel, 2013). Vpu, through its TM domain, also counteracts 
tetherin (BST-2), a cellular protein known to prevent viral release (Malim and 
Emerman, 2008). In these distinct ways, Vpu prevents premature CD4-Env association 
within the ER and enhances virion release.  
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The 23 kDa HIV-1 Vif (virion infectivity factor) has long been established in its role of 
inhibiting cellular defences which have the ability of preventing viral replication. In 
particular, the cellular protein APOBEC3G is fully sufficient to prevent productive 
infection, and in the absence of Vif is packaged into virions and consequently carried 
into newly infected cells, where it deaminates C residues in nascent minus strand 
reverse transcripts, resulting in a gross loss of genetic integrity and therefore prevents 
viral spread. Vif is able to antagonise this effect by recruiting a ubiquitin ligase, thereby 
initiating the polyubiquitination of APOBEC3G and targeting it for degradation within 
proteasomes (Mehle et al., 2004; Malim and Emerman, 2008).  
The 14 kDa Vpr (viral protein R) has two main roles in addition to regulating the 
nuclear import of the PIC; arresting the infected cell cycle in G2, and facilitation of 
macrophage infection (Malim and Emerman, 2008). The significance of the G2 arrest is 
not fully understood, however, it is believed that the LTR seems to be more active in 
this phase, conferring a more favourable environment for efficient HIV-1 replication. 
Vpr is able to inactivate the cyclin dependent kinases p34/cdc2, which associate with 
cyclin-B during G2 during the transition from G2 to M phase (Le Rouzic and 
Benichou, 2005).  
Nef is a 27 (HIV-1) or 34 (HIV-2) kDa myristoylated protein encoded by the 3’ end of 
the HIV genome, and early studies suggested that it functions to attenuate viral 
replication, hence the name NEgative Factor. Further investigation, however, actually 
discovered the positive role Nef has on both replication and viral pathogenesis 
(Laguette et al., 2010). Nef is localised both across the cytosol and in association with 
cellular membranes (Sha et al., 2009). It was soon discovered that Nef plays a pivotal 
role in the development of AIDS following HIV infection, dramatically increasing viral 
particle production and therefore viral load. Long term survivors of HIV infection show 
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a lack of disease progression, which is commonly associated with infection of nef 
deleted strains (Peter, 1998; Fackler and Baur, 2002) 
One function of Nef which has been extensively investigated is its role in avoiding 
super-infection by down-regulating CD4 from the plasma membrane. To do this, Nef 
increases the rate of CD4 internalisation through interactions with a di-leucine based 
motif located on the cytoplasmic tail of CD4, and subsequently targets CD4 towards 
lysosomal compartments for degradation (Peter, 1998; Laguette et al., 2010). Alongside 
interacting with the di-leucine motif, Nef also binds to the clathrin adaptor complex 
AP-2, coupling the Nef-CD4 complex to clathrin coated pits and facilitating 
endocytosis (see Figure 16 overleaf) (Oldridge and Marsh, 1998).  Removal of CD4 
from the surface also facilitates viral budding, as CD4 can bind to Env during budding, 
leading to the retention of newly formed viral particles (Horenkamp et al., 2011). 
Alongside CD4 receptor down-regulation, HIV Nef can also down-regulate CCR5, and 
to a lesser extent CXCR4, which also prevents super infection (Laguette et al., 2010). 
 
 
 
 
 
 
Figure 16: Model for Nef-induced endocytosis of the CD4 receptor. Nef binds CD4 
through specific regions within the cytoplasmic tail; a di-leucine motif, and also 
glutamic acid (E), arginine (R), methionine (M) and isoleucine (I) residues at 
positions 405, 406, 407 and 410, respectively. Nef also binds to the clathrin adaptor 
AP-2 through a tyrosine motif (YXXФ). This couples the complex into clathrin 
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coated pits (represented by the clathrin triskelion) (adapted from Oldridge and 
Marsh, 1998).  
Nef is also able to modulate signal transduction machinery in order to augment the 
expression of its own genome and cellular genes, alongside down-modulation of 
various genes which could be detrimental to the HIV life cycle. Nef is able to induce 
transcription factors such as NFκB and c-fos, which transactivate the HIV-1 LTR 
promoter, and also induces the expression of cytokines and chemokines IL-2/4 and 
TGFβ which may assist viral replication. Nef can also down-regulate genes that are 
associated with antigen presentation (Arhel and Kirchoff, 2009). For example, MHC-I 
is downregulated by Nef by promoting binding of this protein to the clathrin adaptor 
protein AP-2, which directs it to endosomes and lysosomes for degradation (Roeth et 
al., 2004; Lubben et al., 2007).  
1.4.8 Viral Protein Trafficking, Assembly and Packaging 
Assembly of HIV particles is dependent on the viral Gag protein. It is well established 
that HIV-1 Gag budding and assembly occurs predominantly within cholesterol-
enriched microdomains (detergent resistant membranes or lipid rafts) at the plasma 
membrane of T-cells (Ono and Freed, 2001). However, it was recently discovered that 
in macrophages and dendritic cells, a multivesicular late-endosome derived 
compartment is the site of particle assembly, prior to release from the PM (Pelchen-
Matthews, 2003; Ono and Freed, 2004). These MVB-like sites of assembly in 
macrophages are also described as VCCs (virion containing compartmentd), which are 
non-acidic and linked to the PM by very narrow channels (Gaudin et al., 2013).  
Live imaging of Gag by confocal microscopy and electron microscopy studies in HeLa 
and HEK 293 cells found the multivesicular body (MVB) was used for particle 
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assembly within these cell lines as well (Sherer et al., 2003). To support this, the use of 
a biarsenic-based imaging technique demonstrated that nascent Gag can travel through 
the MVB and perinuclear compartments as an intermediate, prior to arriving at the PM 
in HeLa cells (Perlman and Resh, 2006). This was suggestive of an involvement with 
endosomal pathways as trafficking routes for Gag in non-macrophage cells as well as 
macrophages. It has been demonstrated that Gag may form particles inside the 
endosomal lumen, which are then later released via fusion of the endosome-like 
structure with the PM by exploiting the pre-existing exosome release pathway, which 
was named the “Trojan exosome hypothesis” (Nguyen et al., 2003).  
Consistent with this, a number of proteins involved in endosomal trafficking and 
recycling were found to interact with Gag. Specifically, the MA of Gag was found to 
interact with the clathrin adaptor proteins AP-1, AP-2 and AP-3 (see chapters 1.5.2i-iii, 
3.1 and 5.1 for more detail). AP-1 and AP-3 were found to facilitate particle release, 
whereas AP-2 inhibits particle release (Batonick et al., 2005; Dong et al., 2005; Camus 
et al., 2007; Liu et al., 2012). The MA region of Gag has been found to be critical for 
Gag trafficking and localisation. More detail on the interaction of Gag with the adaptor 
protein pathways will be discussed in chapters 3 and 5.   
The involvement of endosomes in the trafficking of Gag in T cells is, however, 
complicated by the fact that Gag present in these compartments may be derived from 
assembling particles which have been internalised from the PM. For example, TIRF 
(total internal reflection fluorescence) microscopy demonstrated that the Gag 
population which associated with late endosomal markers was indeed as a result of PM 
internalised Gag (Ivanchenko et al., 2009). Studies using a Gag-GFP construct also 
discovered that Gag reaches the PM prior to being found within intracellular 
compartments in HEK 293T cells (Jouvenet et al., 2006). Therefore, there still remains 
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some discrepancy over the route newly synthesised Gag adopts prior to assembly in T 
cells.  
After trafficking to sites of assembly, Gag and Gag-Pol polyproteins sort into lipid rafts 
(Ono and Freed, 2001), which are rich in cholesterol and sphingolipids, with which the 
HIV-1 particle membrane is highly enriched (Ono, 2009). HIV-1 Gag does not 
extensively polymerise prior to reaching assembly sites; instead molecules are thought 
to arrive as soluble, monomeric proteins, folded into compact arrangements which 
subsequently undergo conformational changes which allow MA-membrane, NC-RNA 
and Gag-Gag interactions. Gag molecules arriving at assembly sites are most likely 
monomers/dimers, which extensively polymerise onto nucleation sites (Sundquist and 
Kräusslich, 2012).  
Targeting of Gag to membranes requires a combination of factors; myristoylation (Gag 
is cotranslationally modified with the 14 carbon fatty acid myristate) (Resh, 2005), and 
the interaction of MA and PI(4,5)P2, which is found on lipid rafts on the inner leaflet of 
the PM, where Gag is  concentrated (Ono et al., 2004; Gousset et al., 2008; Ghanam et 
al., 2012). Upon MA binding to membranes, the myristoyl group becomes exposed 
during an event called the “myristoyl switch”; this anchors Gag to the inner leaflet of 
the membrane (see Figure 17). The inositol head group and unsaturated 2’-fatty acid of 
PI(4,5)P2 bind to MA, allosterically inducing extrusion of the myristoyl group 
(Sundquist and Kräusslich, 2012). Once Gag has reached assembly sites, it dimerises. 
This process is principally driven by the C-terminus of the CA region of Gag. This, 
together with the N-terminus of spacer peptide p2, forms a continuous α-helix, which is 
critical for particle assembly (Gӧttlinger, 2001). 
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As described earlier, Env trimers travel independently of Gag to the PM. The long 
intracellular tail of gp41 (TM) is used to sort the Env spikes into raft-like domains and 
also assists specific interactions with the MA of Gag (Sundquist and Kräusslich, 2012). 
 
 
 
 
 
 
 
 
Figure 17: Myristoyl switch mechanism. MA is shown in yellow with the myristoyl 
(brown), sequestered within the soluble protein (left) and with the myristoyl group 
embedded into the membrane when bound to PI(4,5)P2 (red) (right) (adapted 
from Sundquist and Kräusslich, 2012).  
HIV-1, like all retroviruses, packages two copies of genomic (gRNA) RNA into each 
virion as a dimer, joined by non-covalent linkages at the 5’ UTR. The gRNA is coated 
by NC at a density of roughly 1 NC molecule per 5-8 RNA bases (Johnson and 
Telesnitsky, 2010). Dimerisation initiates through formation of a “kissing loop” 
structure mediated by Watson-Crick base pairing of the self-complementary sequences 
found within the dimer initiation site (DIS). Efficient packaging is dependent on a 
packaging site (Ψ) located at the 5’ end of the genome, which spans the splice donor 
(SD) site and the Gag initiation codon. These are part of 4 stable stem loop structures 
within the highly structured 5’ UTR (see Figure 18 overleaf) (Sundquist and 
Kräusslich, 2012). 
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group 
Soluble MA 
Membrane-
bound MA 
Myristoyl 
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Figure 18: The 5’ UTR of HIV-1 and its interactions with NC. The 4 stem loops 
critical to packaging are highlighted. 3 different NC/RNA complexes are shown; 
NC protein is shown in red, whilst viral RNA is shown in blue. TAR (Trans-
activation response), PBS (primer binding site), DIS (dimer initiation site), SD 
(splice donor) are indicated (adapted from Sundquist and Kräusslich, 2012). 
1.4.9 Particle Budding and Maturation 
Assembling Gag molecules are derived from the cytoplasmic pool; they increase 
exponentially until a plateau is reached, and budding ensues. Initially, an immature 
lattice is formed, where Gag molecules are oriented radially with the amino terminus of 
MA still bound to the inner leaflet of the membrane, and the opposite carboxy-terminus 
facing the middle of the forming particle (Ivanchenko et al., 2009; Sundquist and 
Kräusslich, 2012). Budding of virus particles requires the host ESCRT (endosomal 
sorting complexes required for transport) pathway to terminate Gag polymerisation and 
initiate particle release, and which is recruited by the p6 domain of Gag. p6 contains a 
YXPL (Tyr-X[variable residue]-Pro-Leu) domain which binds the ESCRT III binding 
partner ALIX, and a second motif (PTAP) which binds the ESCRT-1 subunit TSG101 
(Fujii et al., 2009). This interaction results in the further recruitment of ESCRT-III-like 
5’ UTR of viral RNA 
NC protein 
complexes 
Gag initiation 
stem loop 
containing start 
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proteins (CHMPs 2A and 4A), which polymerise into an inward spiral, forming a 
“dome” like structure, which closes the neck of the forming bud. The CHMPs also 
recruit VPS4 ATPases, which plays an active role in membrane fission, remodelling 
CHMP2A subunits which leads to constriction and abscission of the particle (Sundquist 
and Kräusslich, 2012). This process is summarised below in Figure 19. 
 
 
 
 
 
 
 
 
Figure 19: A summary of the ESCRT pathway utilised in HIV-1 budding. p6 
interacts with ALIX (blue) and TSG101 of the ESCRT-1 heterotetramer (red), 
leading to the recruitment of CHMP proteins (green), which polymerise into a 
dome like structure, closing the neck of the bud. Recruited VPS4 ATPases  
(purple) complete membrane fission, releasing the ESCRT-III (adapted from 
Sundquist and Kräusslich, 2012). 
After budding, HIV-1 viral particles are released as immature, non-infectious particles, 
which are proteolytically processed by viral protease to form mature, infectious 
particles. Viral protease is first activated by dimerization of PR in the Gag-Pol 
polyprotein, which is autocleaved. After this, Gag processing occurs in a stepwise 
fashion. First, the SP1-NC junction is cleaved, followed by cleavage of the SP2-p6 and 
MA-CA junctions, releasing MA and p6 together with p25 (CA-SP1) and NC-SP2 
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intermediates. The spacer peptides are separated from the Gag constituents to form 
mature p24 CA and mature NC. The cleavage of structural proteins is coupled with a 
morphological transition, whereby an electron dense ring of Gag is converted into a 
characteristic conical core, consisting of a lattice of 250 CA hexamers (Briant et al., 
2011). This is shown below in Figure 20. 
Figure 20: Morphological changes during HIV-1 maturation, demonstrated by 
electron microscopy (Briant et al., 2011) 
1.5 Cellular Trafficking- an Overview 
Within cells, the majority of proteins translated are required for use in distant locations 
to their site of production, such as membrane proteins or those localised to specific 
compartments, and are trafficked in an anterograde direction to these locations. Many 
extracellular proteins are also internalised, such as ligands bound to their receptors, and 
are trafficked in a retrograde direction to sites of modification, recycling, or destruction 
within the cell. All of these processes require a complex trafficking system, involving 
numerous pathways, molecules and chaperones. One such molecule heavily involved in 
the assistance of cargo trafficking is clathrin, which will be discussed in detail in the 
next section.  
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1.5.1 Clathrin 
Three major classes of coat protein have now been purified which assist in cargo 
trafficking; clathrin, COP [coat protein complex] I and COP II. The vesicle-transport 
hypothesis of protein trafficking was suggested from early electron microscopy studies, 
whereby vesicular transport intermediates initially bud from a donor membrane, and 
are then transported to an acceptor organelle, where membranes fuse and cargo is 
deposited (McMahon and Mills, 2004).  
Coated pits and vesicles used for cargo trafficking, demonstrated by these electron 
microscopy studies, showed membrane invaginations and vesicles with bristle-like 
projections in some areas of the cell, and without them in others. It was later discovered 
that these projections are composed of multiple molecules of a protein called clathrin, 
which forms around vesicles during their trafficking pathways. Clathrin is composed of 
a heavy chain of 180 kDa, and two light chains of 33 and 36 kDa. The heavy chain is 
ubiquitously expressed within cells and different species share high degrees of 
sequence homology between their heavy chains, whereas the light chains seem to be 
more polymorphic (Hirst and Robinson, 1998).   
Clathrin self-polymerises into a supportive lattice, or cage-like structure which forms, 
when membrane bound, into a scaffold required for the deformation of these 
membranes into budding vesicles containing. Clathrin has limited ability to induce 
curvature of membranes around forming vesicles, but it gives directionality to budding 
since the rigid triskelions preserve inward curvature induced by other components 
cargo (Hirst and Robinson, 1998; Young, 2007). The structure of the clathrin unit was 
deduced to be a three-legged triskelion, whereby the three heavy chain legs loosely 
associate at the centre of the molecule, and are in close contact with three light chains 
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(see Figure 21A) (Kirchhausen and Harrison, 1981). The scaffold assembles by each 
triskelion leg extending across two neighbouring edges, resulting in each edge 
consisting of two proximal and two distal triskelion legs (see Figure 21B) (Crowther 
and Pearse, 1981; Hirst and Robinson, 1998).  
Clathrin-coated vesicles are uncoated after abscission from the membrane and vesicles 
may then be trafficked to intracellular sites such as early endosomes, late endosomes, 
lysosomes and the PM by microtubules; the directionality of which is determined by 
the presence or absence of the motor molecule kinesin (Wacker et al., 1997; Liu et al., 
2011).  
 
 
Figure 21: A- Structure of an individual clathrin triskelion molecule. B- Clathrin 
triskelion lattice organisation (adapted from Hirst and Robinson, 1998).  
1.5.2 Clathrin Adaptor Proteins 
Clathrin is a vesicle stabiliser; it is the clathrin adaptors that select cargo, which bud 
from 3 main areas of the cell: the plasma membrane (PM), trans-Golgi network (TGN) 
and endosomes (Mills, 2007). These so called adaptor proteins (APs) function within 
the secretory and late endocytic pathways, assisting the linkage of clathrin to the 
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membrane, coat formation, cargo selection, and also binding of accessory proteins that 
regulate clathrin assembly and disassembly, such as epsins (Robinson, 2004; Mills, 
2007). Seven APs exist, AP-1 -5, with 2 isoforms of AP-1 and 3 (A and B). They are 
cytosolic heterotetrameric complexes, composed of two large subunits; a β subunit and 
one of α, γ, δ, ε or ζ, a medium subunit (µ) and a small (σ) subunit. They form a similar 
“Mickey Mouse” like structure, with a core ‘head’ composed of the amino terminals of 
the large subunits, the medium and small subunits, flanked by two ‘ears’ consisting of 
the carboxy terminal domains of the large subunits, bridged by flexible hinge domains 
(see Figure 22). The different subunits were deduced to play distinct roles within the 
cell. The β subunits are responsible for clathrin binding, and the α, β and presumably γ 
ears recruit accessory proteins where they partake in vesicle scission and uncoating 
(Robinson, 1994; Robinson and Bonifacino, 2001).  
 
 
 
 
Figure 22: Structure of an AP complex, demonstrating the positions of the large, 
medium and small subunits comprising the adaptor (adapted from Hirst et al., 
2011).  
The recruitment of the APs to cellular membranes is a complicated story that has not 
been completely unravelled, but phosphoinositides have been shown to play a role in 
some circumstances. Phosphoinositide interactions were demonstrated to be crucial in 
the recruitment of AP-2; phosphatidylinositol(4,5)-bisphosphate (PIP2), which is 
produced in the inner leaflets of the PM and where AP-2 primarily functions during 
endocytosis, is essential for AP-2 recruitment (Beck and Keen, 1991). AP-2 contains 
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PIP2 binding sites in its µ and α subunits. AP-1 was also found to bind PtdIns(4)P 
which is primarily located on the TGN, where AP-1 functions. Many other adaptors 
have been shown to bind phosphoinositides, but this alone cannot be used to explain 
adaptor recruitment since their localisation is not as restricted as that of the APs 
(Robinson, 2004; Ohno, 2006).  
Central to clathrin-mediated endocytosis is a dynamic network of AP-2 interactions 
with nucleation proteins, cargo and clathrin. The µ and σ subunits bind transmembrane 
proteins, but cargo may also be bound to the adaptor ears indirectly via accessory 
adaptor proteins such as β-arrestin, which recruits G-protein coupled receptors to AP-2 
and clathrin (McMahon and Boucrot, 2011) 
As mentioned, the APs are involved in clathrin coated cargo selection. The APs are 
able to recognise three distinct motifs, or sorting signals, found within specific cargos, 
for example in the cytoplasmic tails of certain receptors, such as the LDL (low-density 
lipoprotein) receptor. These motifs promote endocytosis, influence intracellular 
trafficking and determine steady state distributions of proteins; tyrosine based YXXØ 
motifs (where Ø constitutes a bulky hydrophobic residue, either leucine, isoleucine, 
phenylalanine, methionine or valine), dileucine motifs such as [D/E]XXXL[L/I], and 
the FXNPXY motifs are those currently described (Hirst and Robinson, 1998; 
Robinson and Bonifacino, 2001).  
The µ and β subunits are involved in cargo selection; the µ subunit recognises YXXØ 
motifs, and this interaction is the best characterised; AAK1 (adaptor-associated kinase) 
can phosphorylate a specific residue, Thr156, in µ2 which induces conformational 
changes that unblocks the cargo binding site and ensures high affinity binding of 
YXXØ cargo (Ohno et al., 1998; Olusanya et al., 2001; Ricotta et al., 2002; Smythe 
and Ayscough, 2003). Cyclin-G-associated kinase (GAK) is also able to phosphorylate 
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µ2, but also µ1. The β subunit recruits clathrin through the so-called clathrin-box, a 
linear sequence of 5 amino acids (LØxØ[DE]) which lies within the hinge region 
(Owen et al., 2004).  All of the AP µ subunits have been demonstrated to bind to 
YXXØ motifs, however, their preferences for the X and Ø residues differ; this, together 
with the distinct localisations of the APs, helps explain the differences in steady state 
distributions of proteins containing this motif (Ohno et al., 1998; Robinson, 2004). 
It was originally assumed that adaptors were recruited to membranes simply by binding 
to proteins destined to become cargo. It was discovered, however, that ARF1, a 
GTPase, is critical for recruitment of AP-1, -3 and -4, which acts as a coat protein 
docking site. Members of the Arf family are also able to stimulate production of 
phosphoinositides, particularly PtdIns(4)P, and PIP2; PIP2 was later found to be critical 
for AP-2 recruitment (Robinson, 2004).  
The APs have distinct localisations within the cell, and thus operate in distinct 
trafficking pathways. This will be described for each of the 5 APs in the sections 
below. The known distributions and trafficking pathways of the APs is summarised in 
Figure 23. 
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Figure 23: A summary of coat proteins and cellular trafficking pathways. AP-1 
traffics between endosomes and the TGN, AP-2 assists clathrin mediated 
endocytosis from the PM, AP-3 is involved in endosomal trafficking, AP-4 is 
involved in sorting from the Golgi complex, and AP-5 is involved in endosomal 
sorting from late endosomes. The GGAs facilitate trafficking from the TGN to 
endosomes. COPI is involved in retrograde transport from the cis-Golgi to the ER, 
whereas COPII functions in the reverse (adapted from Hirst et al., 2011).   
1.5.2i AP-1 
As mentioned, there are 2 isoforms of AP-1; AP-1A and AP-1B, differing only in their 
µ subunits (µ1A and µ1B, respectively). Both forms do not differ in their localisation to 
the TGN and endosomes; however, they serve different roles. AP-1A is ubiquitously 
expressed and involved in TGN to endosome transport; presumably this is 
bidirectional, however some controversy still surrounds this. AP-1B is only expressed 
in epithelia and primarily functions to mediate polarised targeting of membrane 
proteins to the basolateral surface. Membrane sorting at the TGN and within the 
endocytic pathway is determined by the critical tyrosine/dileucine residues within the 
cytoplasmic domain of proteins, as described above (Fölsch et al., 2003). AP-1 is 
ER 
COPII 
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thought to work in concert with, or shortly after, another class of cargo-binding 
adaptors; the GGAs (Golgi-localised, γ-ear-containing, Arf-binding proteins), which 
also function in TGN to endosome transport. AP-1 has been demonstrated to sort the 
46kDa mannose-6-phosphate receptor (MPR46) to the TGN, amongst numerous other 
receptors (Chapuy et al., 2008).  
1.5.2ii AP-2 
Unlike AP-1, AP-2 is found and functions exclusively at the plasma membrane (PM), 
within clathrin-coated pits. AP-2 is critical for clathrin-mediated endocytosis; 
endocytosis is the process by which cells internalise extracellular contents and cell-
surface proteins such as receptors (Lau and Chou, 2008). AP-2 holds a central role 
within the endocytic pathway since all proteins functioning within this pathway can, in 
principle, interact with it. It was found that knockdown of AP-2 µ2 or α2 by siRNA in 
HeLa cells results in an elimination of ~90% of endocytic clathrin-coated structures, 
and the disruption of functional AP-2 is lethal in mice, worms and insects (Ungewickell 
and Hinrichsen, 2007).  
The current model proposes that endocytosis begins by the formation of a nucleation 
module containing FCH domain only (FCHo) proteins, EPS15, intersectins and PIP2 at 
a patch of membrane (Henne et al., 2010). This region mechanically invaginates. AP-2 
is then able to bind to PIP2 and cargo directly via the µ and σ subunits, and indirectly 
through other adaptors, with ratcheting from the formation of the developing clathrin 
lattice and various accessory/regulatory proteins (Collins et al., 2002; Kelly et al., 
2008). Proteins are sorted into the pit, and the mature vesicle is eventually “pinched 
off” in a process mediated by the GTPase dynamin which in turn is recruited by BAR-
containing proteins, such as amphiphysin, that prefer the curvature of the vesicle neck 
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and likely assist neck formation (Wigge et al., 1997; Ferguson et al., 2009). After 
release from the PM, auxilin binds the terminal “leg” domains and “ankles” of clathrin, 
which in turn recruits the ATPase heat shock cognate 70 (HSC70) to initiate the 
uncoating of clathrin back to triskelia through the ATPase activity of this protein 
(Kirsch and Beevers, 1993; Ungewickell et al., 1995; Fotin et al., 2004; Taylor et al., 
2011). AP-2 is extensively involved not only in assisting coat formation around the 
assembling vesicle, but also in the recruitment of the numerous accessory proteins 
pivotal to this process, including epsin, CALM/AP180 and dynamin (Owen and Luzio, 
2000; Sorkin, 2004).  
Endocytosed vesicles form part of the endosome system; at its simplest, this involves a 
recycling pathway, for example for membrane receptors; a degradative pathway for the 
degradation of certain molecules, and a connecting feeder pathway which links these 
two former pathways (Huotari and Helenius, 2011). Endocytic cargo is first delivered 
to the early endosome (EE) by fusion of the two compartments; how EEs arise is, 
however, unclear. EEs exchange vesicles with the TGN in a bidirectional manner. EEs 
have tubular and vacuolar domains; late endosomes (LEs) are derived from the 
vacuolar domain, and the tubular domain is lost upon formation of the LE, however 
again it is unclear exactly how this happens, but it is known that Rab7 recruitment to 
the EE precedes LE formation (Vonderheit and Helenius, 2005; Huotari and Helenius, 
2011). From here, LEs undergo a number of changes, or maturation, which ultimately 
results in the fusion of this compartment with the lysosome. Endosomal maturation 
involves a Rab switch, whereby Rab5 converted to Rab7 (Rink et al., 2005), and 
acidification, amongst other changes (Huotari and Helenius, 2011). The pH drop is 
achieved by a group of vacuolar (V)-ATPases, which are proton pumps (Forgac, 2007). 
Acidification is critical for a number of reasons, including the sorting and routing of 
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cargo, and also allows the specific timed activation of various bacterial toxins, such as 
Diphtheria toxin (Lemichez et al., 1997; Huotari and Helenius, 2011).  
1.5.2iii AP-3 
AP-3 is localised generally to endosomes, but also the TGN. There is some discrepancy 
over whether AP-3 delivers its cargo to either late endosomes or lysosomes (Robinson, 
2004). Like AP-1, there are 2 isoforms of AP-3; AP-3A and AP-3B, which also differ 
in their localisation. AP-3A is ubiquitously expressed, whereas AP-3B is localised to 
neurons only (Ohno, 2006). AP-3A generally functions en route to lysosomes and other 
related structures such as melanosomes and platelet-dense granules. AP-3B is solely 
involved in neuron-specific cargo sorting and vesiculation. A deficiency in AP-1 or 
AP-2 is embryonic lethal within mice, whereas AP-3 is not (Seong et al., 2004; Chapuy 
et al., 2008). AP-3 is responsible for the sorting of the lysosomal associated membrane 
protein 1 (LAMP1) and tyrosinase into TGN derived vesicles. Mislocalisation of 
tyrosinase in melanocytes is responsible for the disease Hermansky-Pudlak syndrome 
(a rare form of albinism) (Chapuy et al., 2008).  
There was some discrepancy as to whether clathrin is involved in AP-3 containing 
vesicles, and that it may associate with another scaffold protein with similar 
morphology. It was later, however, demonstrated by Dell’Angelica et al., 1998, that 
clathrin does interact with AP-3 in vitro through the β3A subunit, and that AP-3 and 
clathrin colocalise on endosomal membranes (Nakatsu and Ohno, 2003). However, AP-
3 is not found in pure clathrin coated vesicles (Simpson et al., 1996). Furthermore, 
reconstitution of vesicles from PC12 neuroendocrine cells is AP-3 dependent but 
clathrin-independent (Shi et al., 1998), and immunofluorescence studies have found 
both areas in which AP-3 and clathrin colocalise, and areas where AP-3 is present but 
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clathrin is absent (Simpson et al., 1997). It therefore remains uncertain as to whether 
the AP-3 pathway uses clathrin. 
1.5.2iv AP-4 
In contrast to AP-1, -2 and -3, AP-4 has not been extensively studied. One study 
scrutinised the cellular localisation of AP-4, and found that it has a similar localisation 
to that of AP-1. It is predominantly localised with clathrin coat machinery to the Golgi 
complex, endosomes and transport vesicles (Barois and Bakke, 2005). This adaptor 
protein was found to be involved in the basolateral sorting of proteins containing a 
tyrosine based motif in their cytoplasmic tail (Aguilar et al., 2001; Simmen et al., 
2002).  
1.5.2v AP-5 
Recently, the existence of a fifth adaptor protein complex, AP-5, has been described. 
AP-5 had been previously described before under a different alias, MUDENG (Mu-2 
related death-inducing gene) (Leet et al., 2008). This AP cycles on and off membranes, 
but is not associated with clathrin coated vesicles, but was found to play a unique role 
in endosome dynamics (Hirst et al., 2013). To date, this is the only AP known to 
localise to and associate with late endosomes and lysosomes, and is speculated to have 
a role in the poorly defined recycling of late endosomal membrane proteins, such as 
lysosomal hydrolase receptors, although this has not yet been established (Hirst et al., 
2011; Hirst et al., 2013).  Interestingly, this protein was also described as a putative 
HIV-1 infection-related protein in the UniProt entry of the mu5 subunit.   
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1.5.3 Vesicle Recycling Within Neuronal Cells 
Vesicle recycling has been extensively studied in neurons. Neurotransmitters are 
contained within vesicles which are rapidly released by exocytosis events upon 
stimulation to transmit a signal to target cells, such as neighbouring astrocytes, which 
form part of the tripartite synapse. Vesicle retrieval after neurotransmitter release 
events is essential to prepare for future rounds of exocytosis. Although several 
mechanisms exist, clathrin-mediated endocytosis is one such pathway. A key player in 
this process is AP-2. shRNA mediated knockdown of AP-2 resulted in an impairment 
of vesicle endocytosis, and further investigation revealed AP-2 to be a crucial sorting 
adaptor at the synapse (Kim and Ryan, 2009). Further investigation revealed that in the 
absence of AP-2, AP-1 may behave as a functional substitute for vesicle recycling 
(Kim and Ryan, 2009).  Furthermore, it was discovered that AP-1 deficient mice have 
impaired synaptic vesicle recycling and severely compromised motor coordination and 
long-term memory, indicating a role for this adaptor in learning and memory (Glyvuk 
et al., 2010). Neuronal AP-3 has also been implicated in regulating exocytosis of 
synaptic vesicles, and vesicle biogenesis from endosomes (Nakatsu et al., 2004; 
Scheuber et al., 2006; Danglot and Galli, 2007).  
1.6 Project Aims 
Although interactions between HIV-1 Gag, Nef and the adaptor proteins have been 
described, the consequences of these interactions on both HIV-1 and adaptor protein 
production and localisation have not been extensively investigated. The effects of these 
interactions on adaptor protein dependent protein trafficking has also only vaguely been 
described. Therefore, this project aims to further the knowledge of the complex 
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interactions between these distinct proteins, and how these interactions may disrupt 
well characterised AP dependent trafficking pathways.  
Much research in this area has focussed on HIV-1, neglecting to examine possible 
interactions with HIV-2. Since these are similar viruses, this project also aims to 
scrutinise whether HIV-2, as well and HIV-1, can interact with the APs, and how these 
interactions may again affect the levels and localisation of HIV-2/ the APs in the 
presence of infection.  
Another neglected field of interest is the effects of HIV-1 on protein trafficking within 
cells of the nervous system. This project will also investigate whether HIV infection 
may disrupt protein trafficking within astrocytes, in particular that of synaptic vesicles, 
in a similar manner to that in non-brain cells, as a possible contribution to HIV 
associated dementia. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Antibodies 
Antibody 1
o
/2
o
 Dilution Source 
Rabbit anti-HIV-1 
p24 
Polyclonal 
Primary 1:5000 (Western blots) 
1:1000 (confocal 
immunofluorescence) 
NIBSC  
Sheep anti-HIV-1 Nef 
Polyclonal 
Primary 1:5000 (Western blots) 
1:2000 (confocal 
immunofluorescence) 
NIBSC 
Sheep anti-SIV p27 
Polyclonal 
Primary 1:5000 (Western blots) 
1:1000 (confocal 
immunofluorescence) 
NIBSC 
Mouse anti-AP-1 γ 
subunit 
Monoclonal 
Primary 1:5000 (Western blots) 
1:1000 (Confocal 
immunofluorescence) 
BD 
Biosciences 
Mouse anti-AP-2 µ 
subunit 
Monoclonal 
Primary 1:500 (Western blots) 
1:500 (confocal 
immunofluorescence) 
BD 
Biosciences 
Mouse anti-AP-3 δ 
subunit 
Monoclonal  
Primary 1:1000 (Western blots) 
1:1000 (confocal 
immunofluorescence) 
BD 
Biosciences 
Rabbit anti-GluA1 
Polyclonal 
Primary 1:1000 
(Western blots only) 
Millipore 
Mouse anti-GluA2 
Monoclonal 
Primary 1:1000 
(Western blots only) 
Zymed 
Mouse anti-clathrin 
heavy chain (X22) 
Monoclonal 
Primary 1:350  
(Confocal immunofluorescence 
only) 
Frances 
Brodsky, 
UCSF 
Goat anti-rabbit HRP 
(horse radish 
peroxidase) 
conjugated 
Secondary 1:5000 
(Western blots only) 
Santa Cruz 
Rabbit anti-sheep 
HRP 
Polyclonal 
Secondary 1:5000 
(Western blots only) 
Santa Cruz 
Goat anti-mouse HRP Secondary 1:5000 
(Western blots only) 
Fisher 
Donkey anti-rabbit 
Alexa Fluor 594 
Secondary 1:1000 
(Confocal immunofluorescence 
only) 
Invitrogen 
Donkey anti-sheep 
Alexa Fluor 594 
Secondary 1:1000 
(Confocal immunofluorescence 
only) 
Invitrogen 
Donkey anti-mouse 
Alexa Fluor 488 
Secondary 1:1000 
(Confocal immunofluorescence 
only) 
Invitrogen 
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Antibodies for Western blots were suspended in 5% Marvel/TBS-T and incubated for 
either 1 hour (when used at >1:2000) or overnight (when used at <1:2000) at 4
o
C on a 
rotating platform to ensure even coverage. Antibodies for confocal 
immunofluorescence microscopy were suspended in 1% bovine serum albumin (BSA) 
and incubated for 1 hour at room temperature.  
2.1.2 Proviruses and Plasmid Constructs 
Construct Description Source 
SVC21ΔBgl (HXB2) Env deleted HIV-1 provirus, contains 
premature stop codon in Nef (missing 
AP binding site) 
(Ratner et al., 1987) 
Andrew Lever, 
University of 
Cambridge 
HXB2N
+ 
HXB2 with mutated premature stop 
codon in Nef (produces full length 
Nef) 
Emma Anderson, 
University of 
Warwick 
HXB2ΔGag HXB2 with mutated start codon in 
Gag 
Made 
(see chapter 2.2.3) 
HXB2N
+ΔGag HXB2N+ with mutated start codon in 
Gag 
Made 
(see chapter 2.2.3) 
HVP ΔEC PuroΔB Control provirus, does not contain full 
length Gag (only part of MA) or Nef, 
but contains regulatory genes (Rev, 
Tat) and puromycin 
(Richardson et al., 1993) 
Emma Anderson  
pGag-EGFP Expression plasmid producing full 
length Gag and GFP. Instability 
sequences have been removed so 
mRNA is not degraded. 
(Hermida-Matsumoto and Resh, 2000) 
NIH AIDS Reagent 
Program 
(cat. no. 11468) 
GFP pcDNA Green Fluorescent Protein (GFP) in a 
pcDNA3 vector 
Emma Anderson 
ts045-VSV-G-EGFP 
(VSV-G) 
Temperature sensitive vesicular 
stomatitis virus glycoprotein, tagged 
with EGFP in a pcDNA3 vector 
(Presley et al., 1997) 
David Stephens 
(initial 
construct[University 
of Bristol]), further 
cloned in the lab 
Renilla Luciferase Renilla Luciferase (RL) in a pcDNA3 Philip Gould, 
Mouse anti γ-tubulin 
Monoclonal 
Primary 1:10000 
(Western blots only) 
Sigma 
Mouse anti-CD81 
Monoclonal 
Primary 1:500 
(Confocal Immunofluorescence 
only) 
Santa Cruz 
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vector Warwick University 
HIV-1 Gag C28/49S Packaging mutant virus. HIV-1 non-
envelope deleted provirus containing 
two amino acid substitutions 
(Cysteine-Serine) within the Zinc 
finger domain of NC 
(Dorfman et al., 1993) 
Andrew Lever 
pSVR Full length non-envelope deleted HIV-
2 provirus 
(McCann and Lever, 1997) 
Andrew Lever 
SVRΔNB HIV-2 Env deleted provirus 
(Griffin et al., 2001) 
Andrew Lever 
SVRΔNB MA1 HIV-2 Env deleted provirus chimera 
with Matrix of HIV-1 
Emma Anderson 
SVC21ΔBgl MA2 HIV-1 Env deleted provirus chimera 
with Matrix of HIV-2 
Emma Anderson 
A4 HIV-1 non-envelope deleted provirus 
with a stem loop from the packaging 
signal removed 
(Miele et al., 1996) 
Emma Anderson 
SVCΔP1 HIV-1 non-envelope deleted provirus 
with packaging signal removed 
(Harrison et al., 1998) 
Andrew Lever 
pNL4-3-ΔE-EGFP 
(HIV-GFP) 
HIV-1 provirus with Env substituted 
for GFP 
(Zhang et al., 2004) 
NIH AIDS Reagent 
Program (cat. no. 
11100) 
Sy-GCaMP-mCh Synaptophysin conjugated to mCherry 
tagged GCaMP  
Nick Hartell, 
University of 
Leicester 
KS1620 1620 bp Bgl II fragment of HIV-1 Gag 
in Bluescript vector 
(Harrison et al., 1998) 
Andrew Lever 
2.1.3 siRNAs 
The following siRNAs, except AP-5, were purchased from Ambion (Applied 
Biosystems). All were stored at -80
o
C at a concentration of 50 µM in nuclease free 
water provided. All were used at a concentration of 10 nM, except for AP-5 which was 
used at 25 nM (Hirst et al., 2011).  
AP-1γ subunit (AP1G). Sequence (5’-3’): GCGCCUGUACAAAGCAAUUtt  
(positions 1694-1713) (Camus et al., 2007). 
AP-2µ subunit (AP2M). Sequence (5’-3’): GUGGAUGCCUUUCGGGUCAtt 
(Motley et al., 2003) 
AP-3δ subunit (AP3D). Sequence (5’-3’): CCCUGUCCUUCAUUGCCAAtt 
(positions 3159-3178) (Camus et al., 2007). 
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AP-5- SMARTpool J-015523-09 ORF (Oligo-9) (Dharmacon) 
Silencer Negative Control #2 (Ambion proprietary sequence).  
Doses of siRNAs were optimised previously (Emma Anderson, personal 
communication) except for AP-5 where 10 nM, 25 nM and 50 nM concentrations were 
trialled, and the optimal dose was found to be 25 nm, as described by Hirst et al. 
(2005). 
2.2 Methods 
2.2.1 Tissue culture 
HeLa/ HEK 293T cells were cultured in T75 flasks (BD Biosciences) in Dulbecco’s 
modified eagle’s medium (DMEM) supplemented with 10% heat inactivated foetal calf 
serum (FCS) (Biosera) at 5% CO2
 
37
o
C. When 100% confluent, cells were passaged 
1:10 using trypsin/EDTA incubation (5 minutes) following a phosphate buffered saline 
(PBS) wash. For transfection, cells were passaged and seeded into 12 or 6 well plates 
(BD Biosciences) and grown overnight.  
U373 MG-Uppsala astrocytoma cells (European Collection of Cell Cultures [ECACC], 
Public Health England) were cultured also in T75 flasks in Eagles minimal essential 
medium (EMEM), supplemented with 10% heat inactivated FCS, 2 mM Glutamine, 1% 
non-essential amino acids and 1 mM Sodium Pyruvate at 5% CO2 37
o
C. Cells were 
passaged 1:4-1:6 depending on confluency, as above, when judged to be approximately 
80% confluent, using only versene to prevent trypsin cleavage of external receptors. 
For transfection, cells were passaged and seeded into 12 or 6 well plates and grown for 
48h. For lysate collection, cells were seeded into 60mm sterile tissue culture dishes 
(BD Biosciences).  
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2.2.2 Transfection 
HeLa/ HEK 293T/U373 MG cells were transfected when they were judged to be >85% 
confluent for increased efficiency. 2.5 µl/µg DNA Lipofectamine 2000 (Invitrogen) 
was used, suspended in 250 µl (12 well) or 500 µl (6 well) OPTIMEM (departmental 
media preparation service) containing 1-2 µg plasmid DNA, and left at room 
temperature for 20 minutes. This was then gently added to cells by spot pipetting, 
following media change. Cells were then incubated for either 24, 40 or 48 hours at 
37
o
C/5% CO2.  
For transfections using TransIT-2020 (Mirus) and METAFECTENE-FluoR 
(Biontex), 1 µg per well of plasmid DNA was transfected per well according to the 
manufacturer’s instructions.   
2.2.3 Site Directed Mutagenesis 
In order to generate mutant proviruses that would not produce Gag, it was necessary to 
mutate the ATG start codon in the Gag ORF. Primers were designed as follows for use 
in site-directed mutagenesis: 
Forward primer 5’-GCTAGAAGGAGAGAGACGGGTGCGAGAGCGTC-3’ 
Reverse primer 5’-GACGCTCTCGCACCCGTCTCTCTCCTTCTAGC-3’ 
Primers (at 20 µM), alongside the dNTP mix provided, were added to HIV-1 
subgenomic template (KS1620), and PCR was carried out under the following 
conditions: 18 cycles of 95
o
C 50 sec, 60
o
C 50 sec, 68
o
C 7 min.  Methylated, non-
mutated template strands were digested using 1 µl DpnI, leaving only plasmids 
containing the mutation. The PCR product was then run on a 1% agarose gel to check 
amplification was successful. After confirmation of mutagenesis by sequencing, 
digestions were carried out on the mutated PCR product and 2 proviruses; HXB2 and 
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HXB2N
+
, using SpeI and BssH II restriction enzymes (NEB) at 37
o
C and 50
o
C, 
respectively. The 2 digested vectors and the digested insert were then extracted from 
the agarose gel using a Qiagen DNA extraction kit. T4 DNA ligase (Fermentas) was 
then used to ligate the insert into the 2 vectors, at a molar ratio of 3:1 insert: vector, at 
16
oC overnight in accordance with manufacturer’s instructions. This produced 2 new 
proviral clones. Controls were also set up without the insert to confirm ligation success.  
2.2.4 Transformation of E.coli and Purification of Bacterial DNA 
Products of ligation reactions, or any other plasmid DNA requiring large-scale 
preparation, were used to transform 50 µl E.coli TG1 competent cells (5 µl ligation 
reaction), or 25 µl One Shot Top 10 F’ chemically competent E.coli (Invitrogen; 1 µl 
plasmid DNA). Reactions were incubated on ice for 15 minutes, prior to heat-shock 
treatment at 42
o
C for 30 seconds, followed by placing on ice for a further 1 minute. 200 
µl SOC (super optimal broth with catabolite repression) broth (ligation) or lysogeny 
broth (LB) (plasmid preparation) was added to the cells, and these were incubated for 
one hour at either 37
o
C (TGI) or 30
o
C (Top 10). 100 µl of bacterial suspension was 
plated onto selective LB plates containing ampicillin at 100µg/ml and incubated 
overnight at the respective temperatures (37
o
C or 30
o
C).  
2.2.5 DNA Miniprep 
Resulting colonies from transformations were grown up overnight in a shaking 
incubator at 37
o
C in 2 ml LB supplemented with 100 µg/ml ampicillin. Cultures were 
then decanted into 1.5 ml sterile eppendorfs and centrifuged at 13,000 RPM for 2 
minutes. The supernatant was removed and the DNA was then extracted using reagents 
from the Plasmid Maxi Kit (Qiagen) as follows; the pellet was resuspended in 100 µl 
buffer P1, 100 µl P2, and 100 µl P3 (on ice) sequentially following inversion at each 
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step. Plasmid DNA was then extracted using phenol/chloroform and purified by ethanol 
precipitation.  
2.2.6 Plasmid Maxiprep 
For large-scale plasmid preparation, transformed colonies were grown in 2 ml LB 
supplemented with 100 µg/ml ampicillin (or kanamycin) for 8 hours at 30
o
C in a 
shaking incubator. This culture was then transferred into 400ml LB supplemented with 
100 µl/ml antibiotic, and grown overnight at 30
o
C in a shaking incubator. Cultures 
were then centrifuged at 5,000 RPM for 10 minutes at 4
o
C using a JA-10 rotor. The 
supernatant was removed and the plasmid DNA was extracted following the Qiagen 
Maxi Kit protocol. Resulting DNA was eluted using 400 µl H2O. 
2.2.7 Subcloning 
Upon transfection, it was discovered that the ts045-VSV-G-EGFP (VSV-G) had 
extremely poor expression; only approximately 5% of cells visibly expressed the 
construct. In order to deduce whether there were any obvious errors in the DNA 
sequence, the entire insert of the plasmid was sequenced using primers which were 
designed as follows: 
CMV Forward Primer: GTT GAC GCA AAT GGG C 
VSV-G/GFP Forward Primer: GAG CGG GGT CTT CCC CAT CTC 
GFP Forward Primer: GCG AGA TAC CCA GAT CAT 
Following sequencing, it was deduced that a C residue was missing at the beginning of 
the sequence (before the AUG start site). This could possibly be a missing 
transcriptional start site, which would explain the poor expression. This missing residue 
was after the CMV promoter, and before the XhoI site; therefore removal of the insert 
from the vector was the simplest way to exclude this missing residue. XhoI and BamHI 
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sites were used to cut the VSV-G insert out of the unidentifiable vector with 
corresponding restriction enzymes (NEB) and buffers. This was then inserted into 
pcDNA3.1
- 
(Invitrogen) using T4 DNA ligase as before. This cloning improved 
transfection efficiency to around 30%, therefore, 2 µg VSV-G DNA was transfected in 
each experiment to further increase the number of cells expressing the construct. 
2.2.8 siRNA Transfection 
In order to significantly reduce the levels of the cellular adaptor proteins, siRNAs 
directed against AP-1, AP-2, AP-3 and AP-5 were used. Negative control siRNA (#2), 
which does not have any known mammalian consensus sequences, was also ordered to 
ensure any effects seen by the above siRNAs are specific and not due to the presence of 
any siRNA.  
siRNAs were transfected into (>85% confluent) seeded HeLa cells in either 6 or 12 
well plates, and one of two methods for transfection was adopted; they were transfected 
24h prior to proviral transfection, or co-transfected alongside 1 µg/well proviral DNA.  
10 nM siRNA (AP-1, -2, -3, -ve) or 25nM (AP-5, -ve) was transfected using 
Lipofectamine 2000. Samples were harvested either 24 or 40 hours after transfection 
with the proviral plasmid (either 24 hours after siRNA transfection, or co-transfection 
with the siRNAs).  
2.2.9 Cell Lysate and Viral Supernatant Collection 
Viral supernatants from transfected cells were collected using a sterile 2 ml syringe. 
This was then passed through a 0.22 µm Minisart hydrophilic syringe filter (Sartorius 
Stedim Biotech) and added to half the volume filter sterilised 30% PEG/0.4 M NaCl 
solution for overnight precipitation at 4
o
C. This was then centrifuged (2000 RPM, 4
o
C, 
30 mins) and the supernatant was removed, leaving a small (~0.5 ml) amount. This was 
Chapter 2                                                       Materials & Methods  
 
70 
 
then re-centrifuged, as before, for five minutes. The remaining supernatant was 
removed and the pellet was re-suspended in 90 µl 1X SDS loading buffer (100 mM 
Tris/HCl pH 6.8, 4% w/v SDS, 20% glycerol, 0.2% w/v bromophenol Blue, 
supplemented with 1:20 ratio β-mercaptoethanol on the day).  
To collect cell lysates of HeLa cells, cells were washed (after removal of supernatant) 
with ice cold PBS, and 200 µl/ well 1X Passive Lysis Buffer (Promega) was added, and 
vigorously shaken for 20 minutes to disturb cells. Lysates were collected and 
centrifuged at 13,000 RPM for two minutes, and the remaining supernatant was 
collected for use.  
Denaturation of these lysates was carried out by adding 12 µl denaturing solution (125 
mM Tris-HCl pH 6.8, 6% SDS, 10% βMe, 20% Glycerol) and boiling at 95oC for 5 
minutes, prior to centrifuging as above.  
To collect U373 MG lysates, cells were lysed using a lysis buffer as follows: 1 mM 
EDTA, 1 M Tris-HCL, 1% Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium 
fluoride, 100 mM sodium pyrophosphate, 0.27M sucrose, 20% sodium azide, 1:500 
protease inhibitor cocktail (Fisher). Media was removed and cells were washed as 
before in ice cold PBS. 150 µl lysis buffer per 60mm was added to cells at 4
o
C for five 
minutes. Cells were scraped from the plate and collected, and then left to incubate at 
4
o
C for one hour on a rotating incubator. Cells were then spun as before.  
2.2.10 Western Blot Analysis 
Unless stated otherwise, all cell samples that were collected were measured for total 
protein content using the BCA protein assay kit (Thermo Scientific) as directed in the 
manufacturer’s protocol.  
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Equal amounts of protein as deduced by this method, containing an equal volume of 1X 
SDS-loading buffer (see above for recipe), were loaded onto a 10% SDS-PAGE gel 
(supernatant samples were not assayed for protein content and therefore equal volumes 
of sample were loaded) and run at 35 mA per gel. Gels were then trimmed and soaked 
in pre-cooled tris/glycine transfer buffer with 20% methanol for 20 minutes. Gels were 
then sandwiched in a wet transfer tank (Geneflow) with Whatman paper and a pre-
soaked Nitrocellulose membrane. A magnetic stirrer was added alongside a gel cool 
pack, and transfer was carried out on a magnetic stirrer for 2 hours at 400 mA at 4
o
C. 
Membranes were then blocked in 5% Marvel/1 X TBS-T for either 1 hour at room 
temperature or overnight at 4
o
C. Antibodies were then added as indicated at the 
beginning of this chapter, suspended in 5% Marvel/TBS-T either overnight at 4
o
C or 
for 1 hour at room temperature. Membranes were then subjected to three 10 minute 
washes using 1X TBS-T, and secondary antibodies were added using the same method, 
and incubated for one hour at room temperature. Membranes were then washed again 
and ECL (enhanced chemiluminescence) Western blotting substrate was used for 
detection of HRP (Pierce). Densitometry analysis using ImageJ software was used as 
required.  
2.2.11 Confocal Immunofluoresence Microscopy 
A Leica SP5 confocal microscope was used with a 60X oil immersion objective. HeLa 
cells were seeded onto 12 mm glass coverslips within 12 well plates. Cells were 
transfected with various constructs, as outlined in results chapters. These were then 
washed with cold PBS and fixed, at 24 hours post transfection (or as indicated in results 
chapters), using 10% formaldehyde in PBS (Fisher) and permeabilised using 0.5% 
NP40 in PBS (Sigma). Cells were then blocked with 1% BSA (bovine serum albumin) 
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for one hour at room temperature. Cells were then labelled with antibodies as indicated 
in results chapters, followed by Alexa Fluor secondary antibodies (Alexa-488 and 
Alexa-594) suspended in 1% BSA. Cover slips were inverted and mounted on slides 
with Vectashield (Vector Laboratories) containing DAPI to stain the nucleus.  
2.2.12 Pulse Chase Assays 
HeLa cells were seeded into 6 well plates and then transfected with constructs as 
indicated in results chapters. Cells were then starved in pre-warmed 1.75 ml DMEM 
minus methionine/cysteine (-met/cys) (Invitrogen) supplemented with 4 mM L-
glutamine for 40 minutes, and then pulsed with 0.25 ml of the same media 
supplemented with 60 µCi/well 
35
S–Methionine EasyTag promix. Pulse only cells were 
harvested after 40 minutes. Chase cells were further incubated after the 40 minute pulse 
with 2 ml fresh complete DMEM for 2 hours after removing the radiolabelled medium.  
To harvest cell lysates, radiolabelled medium was removed and cells were washed with 
ice cold PBS, and harvested using 400 µl/well radio-immunoprecipitation assay (RIPA) 
buffer (50 mM Tris-HCL, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% 
NP40) supplemented with 1 mM protease inhibitor benzamidine (Fluka), rotating at 
high speed for 20 minutes to agitate cells. After harvesting, lysates were collected and 
left on ice for 30 minutes. Supernatants were collected after centrifuging at top speed 
for 10 minutes, and added to sepharose protein A beads (Sigma) overnight for 
immunoprecitation (see below).  
Final samples were boiled at 95
o
C for five minutes and loaded onto a 10% SDS-PAGE 
gel. The gel was then fixed by submerging the gel in a gel fix solution (10% acetic acid, 
30% methanol, 60% dH2O) for 15 minutes. The gel was then dried and protein bands 
were identified using Hypermax MR film (Kodak). 
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2.2.13 Immunoprecipitation 
Sepharose protein A beads (Sigma) were swelled at room temperature in RIPA buffer 
for half an hour, followed by three 5 minute room temperature, rotating washes and 
brief centrifugation at 6,000 RPM for 2 minutes, removal of supernatant and addition of 
0.5 ml fresh RIPA buffer. A 50% slurry was then made using RIPA buffer at a 1:3 
ratio. 50 µl of this slurry was added to 100 µl fresh RIPA buffer and 2 µl primary 
antibody (see results sections for further details on antibodies used), which was rotated 
at 4
o
C for one hour. Beads were then washed twice in fresh RIPA buffer, by briefly 
centrifuging at 6,000 RPM for 2 minutes, removing the supernatant and adding 200 µl 
RIPA and returning to rotation at 4
o
C for five minutes.  
After washing, 100 µl of cleared HeLa lysate was added to the beads (see below), 
which were placed on a rotating stand at 4
o
C overnight. Following incubation, beads 
were washed again as before (2X RIPA washes at 4
o
C) and after the final wash was 
removed, 200 µl of pulse/chase sample was added to the beads and rotated again at 4
o
C 
for 4-6 hours. After incubation, samples were washed 3 times as before and 40 µl 1X 
SDS-loading buffer was added to samples prior to boiling and loading on a 
polyacrylamide gel. 
2.2.13i HeLa Lysate Preparation 
Confluent T75 flasks of HeLa cells were washed with ice cold PBS and incubated in 
trypsin to detach cells. Cells were re-suspended in 7 ml fresh DMEM to a total of 10 ml 
and centrifuged for 5 minutes at 4
o
C 1500 RPM to pellet cells. The pellet was then 
washed twice with ice cold PBS and re-suspended in 2 ml ice cold RIPA buffer 
supplemented with 1 mM protease inhibitor Benzamidine per flask, and incubated on 
Chapter 2                                                       Materials & Methods  
 
74 
 
ice for half an hour. Samples were then centrifuged for 5 minutes at 2500 RPM 4
o
C to 
collect the cleared lysate, which was stored at -80
o
C until use.  
2.2.14 Subcellular Fractionation 
HeLa cells were seeded into 12 well plates and transfected the following day with 
constructs as indicated in results sections. Cellular fractions (cytosol, membranes, 
nucleus and cytoskeleton) were obtained as per instruction in the Qiagen Qproteome 
Cell Compartment protocol. To reduce the likelihood of previous fractions remaining in 
the sample and contaminating the next fraction, each fraction was washed with 0.5 ml 
PBS and rotated at 4
o
C prior to centrifugation as directed in the manual to remove trace 
protein, between each stage. 
Fractions were run on a 10% SDS-PAGE gel and the transferred membranes were 
probed either using anti-p24 or anti-AP antibodies.  
2.2.15 Cytotoxicity Assays 
HeLa cells were transfected into 12 well tissue culture plates with all proviruses 
individually using Lipofectamine 2000. After 24 hours, cells were re-plated using 
trypsin incubation, into 96 well plates with fresh media for 16 hours. Decreasing 2-fold 
dilutions of DTx (diphtheria toxin) or RTx (ricin toxin) (50 ng/µl and 25 ng/µl starting 
concentrations, respectively) were then added to both transfected cells and mock cells 
(containing only transfection reagent) in quadruplicate and left for 4 hours. Two 
untreated lanes (only DMEM) were also included for comparative measures. The media 
was removed, and cells were then washed with PBS once and 5 µCi/well [
35
S]-
Methionine EasyTag promix in PBS was added to cells, and left for 20 minutes at 37
o
C. 
The radiolabelled medium was removed, and un-incorporated [
35
S] was then removed 
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by 5x washes with 1% TCA. 100 µl/well scintillant was then added to cells and a 
scintillation counter was used to measure [
35
S] incorporation into proteins.  
2.2.16 Time Course Assays 
HeLa cells were transfected with HXB2 or mock transfected using Lipofectamine 2000 
and re-plated into a 96 well plate 24 hours post-transfection as before. A fixed 
concentration of RTx or DTx (1 μg/ml) was added to wells every 15 minutes across the 
96 well plate for 3 hours. To ensure the plate was kept at 37
0
C at all times, this was 
carried out on a heat block in between incubations. Cells were then washed with PBS 
and 5 μCi of [35S]-Methionine EasyTag promix per well was added for 20 minutes. 
Cells were washed 5 times with 1% TCA, scintillant was added and readings were 
taken from a scintillation counter as above.  
2.2.17 ts045-VSV-G-EGFP Assay 
HeLa cells were seeded into 12 well plates with 12 mm glass coverslips and grown 
overnight.  Cells were then transfected with either 2 µg VSV-G DNA alone, or co-
transfected with 2 µg VSV-G and 1µg HXB2 HIV-1 or SVRΔNB HIV-2 for 24 hours. 
Cells were initially placed in a 37
o
C incubator for 1 hour to improve transfection 
efficiency, then placed at the restrictive temperature, 39.5
o
C (see chapter 6.1 for more 
details), for the remaining 23 hours. After 24 hours, the first time point (t0) cells were 
fixed using the same protocol as above for confocal immunofluorescence microscopy. 
The media on the remaining plates was replaced with pre-warmed (32
o
C) DMEM 
supplemented with 5 µg/ml cycloheximide to prevent protein synthesis. Plates were 
then placed at the permissive temperature, 32
o
C, until fixing at specified time points 
(30 mins [t30], 60 mins [t60], 120 mins [t120]). Cells were blocked as before and stained 
with anti-Nef/Alexa-594 and viewed using confocal microscopy.  
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2.2.18 Luciferase Assays 
HeLa cells were seeded into 12 well plates and grown overnight prior to transfection. 
The following transfection protocols were adopted; transfection of the AP siRNAs 24h 
prior to transfection with the RL pcDNA construct (1 µg/well); co-transfection of the 
siRNAs and the RL pcDNA construct, or transfection of the RL pcDNA 6 hours before 
transfection with the siRNAs. All samples were harvested 24h after the final 
transfection using the same method as stated before.  
 Luciferase assays were carried out using the dual luciferase reporter assay system 
(Promega) according to the Promega protocol, using equal protein concentrations as 
dictated by the BCA protein assay.  
2.2.19 Lysosome Inhibition 
HeLa cells were plated out into 12 well plates and grown overnight at 37
o
C. When 
confluent, cells were co-transfected with the HIV-1 HXB2N
+
, HIV-2 SVRΔNB, MA2 
or MA1 proviruses, and the AP siRNAs, including the negative control siRNA. The 
lysosome enzyme inhibitor ammonium chloride (NH4Cl) (FSA laboratory supplies) 
was added to the cell media 24h post-transfection, at a concentration of 10 mM, before 
harvesting at 40 hours, using the same protocol for cell and supernatant harvesting as 
stated in chapter 2.2.9. Samples were run on a 10% SDS-PAGE gel and Western 
blotted using an anti-p24/p27 antibody.  
2.2.20 Proteasome Inhibition 
HeLa cells were plated out into 12 well plates and grown overnight at 37
o
C. When 
confluent, cells were co-transfected with the HIV-1 HXB2N
+
 or HIV-2 SVRΔNB, and 
the AP siRNAs, including the negative control siRNA. A DMSO only control was also 
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included. The proteasome inhibitor MG132 (zLLL) (Selleckchem) was added to the 
cell media 38h post-transfection, at a concentration of 10 µM, dissolved in DMSO, 
before harvesting at 40 hours (Ortiz-Lazareno et al., 2008), using the same protocol for 
cell and supernatant harvesting as stated in chapter 2.2.9. MG132 is a peptide aldehyde 
which blocks the activity of the 26S proteasome complex (Han et al., 2009). Samples 
were run on a 10% SDS-PAGE gel and Western blotted using an anti-p24/p27 
antibody. For pulse chase analysis, the same concentration of MG132 as stated above 
was added to the media during the starvation period, and again during the pulse and 
chase period.  
In experiments where the HIV protease inhibitor Saquinavir (NIBSC, Dr N Cammack) 
was used, a stock solution of 1 mM was added to HeLa cells seeded in 12 well plates 
overnight, during co-transfection of the HXB2 provirus and AP/negative control 
siRNAs at a final concentration of 1 µM (dose optimised by Emma Anderson, personal 
communication). Cells were harvested as before and cell lysates were run on an SDS-
PAGE gel and analysed by Western blot using an anti p24 antibody. Saquinavir works 
by binding to and blocking the active site of the viral protease; this was thought to be 
specific, however, it was discovered that the cellular 20S proteasome cleaves the same 
sites; therefore, Saquinavir is also an inhibitor of the cellular proteasome (Pajonck et 
al., 2002).  
2.2.21   Total RNA Extraction 
HeLa cells were seeded into 6 well plates and transfected with 25 nM AP-5 siRNA or 
negative control siRNA when sub-confluent, using Lipofectamine 2000. The media 
was removed, and cells were then washed with ice cold PBS. Qiagen RNeasy mini kit 
was then used; 350 μl buffer RLT supplemented with β-mercaptoethanol as directed 
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was applied directly to cells to harvest cells, and RNA was then extracted according to 
the manufacturers protocol.  
2.2.22 cDNA Production and qPCR 
High Capacity RNA-to-cDNA Kit (Applied Biosystems) was used to produce cDNA 
from RNA. 500 ng RNA was used in a final volume of 9 μl in H2O, plus 10 μl 2X 
Buffer ABI, 1 μl enzyme mix. This was heated to 37oC for 60 minutes, then 95oC for 
five minutes.  
20 µl reactions were set up for qPCR using the Agilent Mx3005P qPCR system kit, 
which contained: 10 µl 2X mastermix, 0.3 µl Rox buffer, 0.2 µl forward primer, 0.2 µl 
reverse primer, 8.3 µl H2O, 1 µl cDNA. An Agilent qPCR machine was used for the 
following conditions: 95
o
C 3 min, 94
o
C for 30 seconds, then 40 cycles of 60
o
C for 30 
seconds followed by 90
o
C for 30 seconds.   
2.2.23 Preparation of Samples for Electron Microscopy 
HeLa/HEK HEK 293T cells were seeded into 60mm tissue culture dishes. 
Subconfluent cells were transfected using 16.25 μl Lipofectamine 2000 with 6.5 μg 
DNA in 1600 μl Optimem per plate. After 40 hours, cells were detached using 400 μl 
trypsin/EDTA per plate, and 5 ml DMEM/FCS was added. Cells were then centrifuged 
at 1500RPM for 5 minutes at 4
o
C. The supernatant was discarded, and the pellet was 
washed twice with PBS, and then re-suspended with 1 ml PBS. Samples were then sent 
for overnight fixation in glutaraldehyde and staining.  
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2.2.24 Astrocytoma Vesicle Recycling Visualisation 
2.2.24i FM1-43 Staining and Destaining 
U373 MG-Uppsala astrocytoma cells (ECACC) were passaged using versene as before, 
and plated onto glass coverslips inside 6 well tissue culture plates and grown for 2 days 
at 5% CO2/37
o
C (see 2.2.1 for further details on tissue culture of this cell line). Initial 
studies involved using only mock transfected cells. In later studies, cells were 
transfected with constructs as indicated in results chapters (Gag-GFP, GFP or pNL4-3-
EGFP) using Lipofectamine 2000, and were left at 37
o
C for 24 hours. 
Cells were equilibrated in pre-warmed 37
o
C PBS for 1 hour, at 37
o
C/5% CO2, to 
remove serum from cells in order to prevent receptor activation, and prepare for 
perfusion.  
In studies using mock transfected or Gag-GFP transfected cells, cells were first pre-
loaded with 2.5 µM FM1-43 (Invitrogen) suspended in PBS for one hour at 37
o
C. 
Coverslips were placed under a Leica 2 photon confocal microscope fitted with a 
perfusion chamber, and excited at 800-900 nm. Cells, or GFP expressing cells, were 
selected for analysis and then chambers were perfused with TFLLR-NH2 (Sigma) for 5-
10 minutes, followed by a wash with a hypotonic solution (130 mM NaCl, 3 mM KCl, 
1 mM MgCl2, 2.5 mM CaCl2, 1 mM NaH2PO4, 22 mM NaHCO3, 15 mM Glucose, pH 
7.4).  
In studies using GFP and pNL4-3-EGFP transfected cells, cells expressing GFP, were 
selected for analysis, and the coverslips were then perfused for 10-20 minutes with 5 
µM FM1-43 and 10 µM UTP (Sigma). Cells were then perfused a second time with the 
5 µM UTP and 10 µM TFLLR-NH2. After each addition of agonists, cells were washed 
with a hypotonic solution for 5-10 minutes.  
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Recordings were analysed using ImageJ, measuring fluorescence intensity versus time 
in multiple selected regions, correcting for background fluorescence.  
2.2.25 Measuring Calcium Waves  
U373 MG Astrocytoma cells were passaged using versene and plated onto glass 
coverslips inside 6 well tissue culture plates and grown for 2 days. Cells were co-
transfected with 1 µg SyPhyGCaMP-mCherry plasmid and a 2 µg of a second construct 
as indicated in results chapters (GFP or pNL4-3-GFP) using Lipofectamine 2000, and 
were left at 37
o
C for 24 hours. A lipofectamine only control was also used.  
Media was removed from cells and cells were equilibrated in pre-warmed PBS at 37
o
C 
for 1 hour prior to use. Slides were placed into the perfusion chamber fitted onto the 2 
photon microscope, and excited at 800-900nm. Cells co-expressing GFP and mCherry 
(pNL4-3-GFP or GFP), or mCherry only (lipofectamine only) were selected for 
analysis. Lipofectamine only slides were first perfused with Anandamide (500 nM) for 
5 minutes, followed by 10 µM TFLLR-NH2 for five minutes, and 5 µM UTP for 10 
minutes. 5-10 minute washes were included between each treatment. GFP or pNL4-3-
GFP transfected slides were first perfused with 10 µM TFLLR-NH2 for 10 minutes, 
followed by 5 µM UTP for 10 minutes, with 5-10 minute washes in between agonist 
addition.  
Recordings were analysed using ImageJ, measuring fluorescence intensity versus time 
in multiple selected regions, correcting for background fluorescence.  
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CHAPTER 3: DOES HIV-1 PROTEIN EXPRESSION 
ALTER THE LEVELS/LOCALISATION OF THE 
ADAPTOR PROTEINS? 
3.1 Introduction 
Previous work has demonstrated that HIV-1 Gag interacts with the adaptor proteins in 
order to mediate its own trafficking. Various studies using mutations of the adaptor 
proteins or siRNA knock-outs have suggested an involvement of these adaptor proteins 
in HIV-1 particle production (Batonick et al., 2005; Dong et al., 2005; Camus et al., 
2007; Liu et al., 2012). Studies investigating the interactions between HIV-1 Gag and 
AP-1 found that reduction in AP-1 expression mediated by an siRNA targeted against 
the μ subunit of this complex was found to significantly reduce HIV-1 budding and 
release, delaying viral propagation; however, its overexpression enhanced HIV-1 Gag 
release. This effect was deduced to be due to a direct interaction with the μ subunit and 
a defined region of amino acids within the MA domain of Gag. It was postulated that 
AP-1 directly promotes Gag release by transporting it to intracellular assembly and 
budding sites that could involve late endosomes (Camus et al., 2007).  
AP-2-Gag interactions were also found to occur, again with the MA domain of Gag; 
Tyr132 of the MA-CA junction was suggested to be part of an YXXФ motif, which 
would explain the interaction here. Val135 was also found to be critical in this 
association. Gag binds specifically to AP-2 μ subunits during late phases of viral 
replication, and not during early phases, and colocalises with this complex. Mutations 
of AP-2μ caused opposing effects to mutant AP-1μ, enhancing virus release, suggesting 
that AP-2 normally has an inhibitory effect on viral particle release (Batonick et al., 
2005). 
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Finally, AP-3 also interacts with Gag. siRNA depletion of AP-3 using siRNAs directed 
against both the µ and δ subunits in cotransfected cells reduced HIV-1 particle release 
by approximately 50%. Furthermore, when the experiment was repeated using only an 
siRNA directed against AP-3δ, and a Gag construct in which MA was deleted, the 
perturbation of Gag release was not observed (Dong et al., 2005).  These results 
suggested that both the δ subunit of AP-3, and MA of Gag, are critical for this 
interaction. AP-3 is known to mediate the trafficking of CD63 through interactions 
between its cytoplasmic tail and the µ subunit of AP-3. CD63 is a component of 
multivesicular bodies (MVBs). Although the budding of HIV-1 occurs predominantly 
at the plasma membrane, research has suggested that it may also occur from these 
intracellular compartments. Following these observations, it was found that Gag 
colocalises with CD63, suggesting a role of AP-3 in directing Gag molecules to these 
intracellular budding sites. Specifically, it was suggested that Gag may co-traffic with 
CD63 to these late endosomal compartments, acquiring essential budding machinery, 
and then transport this to the PM ready for particle release (Dong et al., 2005). 
These studies show that the HIV-1 MA domain is essential for cellular Gag trafficking.  
Nef is a 27 kDa peripheral membrane protein which is known for its effects on 
enhancing viral pathogenicity and also replication. Nef protein also interacts with the 
cellular sorting machinery in order to influence cellular membrane protein trafficking. 
Specifically, Nef contains a 30-residue unstructured loop close to the C-terminus of the 
protein, which contains sequences critical for the interactions with various membrane 
proteins, such as ATPase. Alongside these, Nef was found to specifically interact with 
the µ subunit of adaptor protein complexes AP-1, -2 and -3, and colocalises with them 
extensively. Nef, across all primate lentiviruses, contains a conserved leucine-based 
motif (consensus sequence EXXXLL) found within this C-terminal region, which is 
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critical for the interaction with the adaptor protein complexes (Craig et al., 2000; 
Madrid et al., 2005).  
As briefly mentioned in the introduction, HIV-1 Nef is capable of disrupting the 
trafficking of numerous cellular proteins in order to benefit the virus, such as that of 
MHC molecules. Recently, it was described that Nef is able to disturb the 
early/recycling compartment of the cell, and modulating the recycling of the 
prototypical cell surface receptor the transferrin receptor (TfR) by causing it to 
accumulate in an endosomal compartment and reducing its cell surface expression 
(Madrid et al., 2005).   
The reported interactions between HIV-1 Gag/Nef and the APs prompted us to 
investigate whether HIV-1 infection is able to disrupt the normal functioning of these 
APs, which may have implications in the normal functioning of the cell. This chapter 
described experiments to determine whether HIV-1 alters the intracellular distribution 
and levels of these proteins, and if so, whether such disruptions are attributed solely to 
Gag or Nef, or interplay between both proteins.  
3.2 Results 
3.2.1 Producing Mutant Proviral Plasmids 
In order to investigate whether HIV-1 Gag or Nef affect the levels of the adaptor 
proteins within the cell, we generated proviral plasmids (plasmids encoding proviral 
DNA will hereon be termed proviruses) which when used to transfect cells, make full 
length or truncated Gag or Nef proteins. Our parental HIV-1 proviral strain is the 
commonly used HXB2, which contains a premature stop codon in the 3’ end of the nef 
gene; the truncated Nef produced is missing the AP binding sites. Although this HXB2 
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provirus is useful in deducing whether Gag alone can affect AP function, it was 
necessary to generate a provirus which produces full length Nef for comparative means. 
Therefore, the premature stop codon within nef was mutated to generate a provirus 
capable of producing full length, functional Nef; this was termed HXB2N
+ 
(work 
carried out by Emma Anderson). Western blotting of lysates from HeLa cells 
transfected with HXB2 or HXB2N
+
 was carried out with an anti-HIV-1 Nef antibody, 
which recognises a C-terminal epitope of Nef (see Figure 24A). These results 
demonstrated that HXB2N
+
, but not HXB2, expresses full length Nef.  
Two other proviruses were subsequently generated to investigate the effects of the 
absence of Gag; the gag start codon was mutated in the two aforementioned proviruses, 
preventing production of Gag. These two proviruses were coined HXB2ΔGag and 
HXB2N
+ΔGag. In order to ascertain whether these proviruses were unable to produce 
Gag, HeLa cells were transfected with HXB2 proviruses, the Gag deleted proviruses 
and a control provirus; HVPΔEC PuroΔB lacking Gag and Nef (Richardson et al., 
1993). HeLa cells were selected because HeLa cells were used in original papers 
investigating HIV-1/AP interactions (Dong et al., 2005; Batonick et al., 2005; Camus et 
al., 2007). The use of an antibody directed against the CA (p24) region of Gag allows 
detection of full-length Gag (p55), processing intermediates (p41[MA-CA]/p40[CA, 
NC, p6]) and fully processed CA (p24); incompletely processed CA (p25) is also 
detected, which is why we see two CA bands (see Figure 24B). The weaker band 
present between p55 and p41 is likely the result of initiation from a CUG codon that 
encodes leucine at amino acid 61; initiating at this codon would give a resultant protein 
of 48.5 kDa, which is the same size as the band observed in this blot (Emma Anderson, 
personal communication).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Gag mutant proviruses produce full-length Nef, but not full-length 
Gag. A- HXB2 (top panel) and HXB2N
+
 (middle panel) proviruses were 
transfected into HeLa cells, and lysates were harvested 24 hours post transfection. 
These samples were analysed by western blot following SDS-PAGE, using an anti-
Nef antibody. B- Full-length Gag (HXB2, HXB2N
+
) and Gag deleted (HXB2ΔGag, 
HXB2N+ΔGag, HVPΔEC PuroΔB) proviruses were transfected into HeLa cells, 
and lysates were harvested at 24 and 48 hours post transfection. These were then 
analysed by western blot following SDS-PAGE, using antibodies directed against 
p24 Gag (CA). Left 4 lanes; top band p55, second band likely results from 
initiation at a CUG codon, third band p41 MA-CA, bottom band p24 CA. Right 4 
lanes; top band p40 CA-p6, bottom bands (p25 and) p24 CA. (-) lanes show mock 
(Lipofectamine only) samples. Western blots are representatives of 2 repeats.  
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Western blots of lysates, shown in Figure 24B, demonstrate that the mutants do not 
produce full length p55 Gag, and produce a severely depleted amount of fully 
processed Gag (p24 CA). They do, however, produce p40, which is not found in the 
Gag
+
 strains (Figure 24B, lanes 7-10). This is likely produced from an internal 
initiation codon present within the capsid region of gag, which may be used in the 
absence of the correct initiation codon. This produces a protein containing CA, NC and 
p6, as opposed to the partially processed p41 (MA and CA) seen in Gag
+
 strains. The 
blot also demonstrated an increased amount of p24 when full-length Nef was present in 
the HXB2 proviral strain; this supports the role for Nef in facilitating efficient viral 
replication. Since the AP binding sites were found to be present within MA, this mutant 
was sufficient to be used in subsequent experiments.  
3.2.2 HIV Does Not Affect Total AP Levels, or AP Turnover 
Since the APs play pivotal roles in the HIV life cycle, the effect of HIV on the 
expression and turnover of these proteins was investigated initially in HeLa cells.  
To ascertain whether HIV-1 alters total AP protein levels within the cell, we used 
Western blotting of cell lysates harvested after proviral transfection. HXB2, HXB2N
+
 
and the respective Gag-deleted proviruses were used to transfect HeLa cells for either 
24h or 48h. A Gag-GFP expression construct and pcDNA-GFP were also used. 
Different proviruses were used to give an indication of whether any observed 
differences in steady state levels of the APs could be potentially attributable to the 
presence/absence of a particular viral component, such as Gag or Nef. AP-1, AP-2, AP-
3 and γ-tubulin in the cell lysates were detected with antibodies against AP-1γ, AP-2µ, 
AP-3δ subunits or γ-tubulin. The results from one of three repeat experiments are 
shown in Figure 25A.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: HIV does not affect total AP levels or turnover. A- Western blot of the 
APs using anti AP-1γ, -2µ and -3δ antibodies on cell lysates harvested from 
different HIV-1 provirus transfected HeLa cells. γ-tubulin shows endogenous 
proteins levels. B- Pulse chase of the APs following a 24h transfection of HeLa 
cells with proviral plasmids. Anti AP-1γ, -2µ and -3δ antibodies were used for 
immunoprecipitation.  (-) lanes show mock (Lipofectamine only) samples.  
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Across the three repeat experiments, when compared with γ-tubulin levels, there were 
no consistent changes in AP levels with any of the proviral transfected cells relative to 
mock transfected cells.  
Next, new AP synthesis and any turnover was investigated using metabolic labelling 
and immunoprecipitation in a pulse chase assay. This technique involved radiolabelling 
all proteins synthesised within transfected cells in a 40 minute “pulse” period by 
providing medium containing radiolabelled methionine and cysteine. Cells were then 
washed and provided with complete “cold” medium (without labelled methionine and 
cysteine) for a 2 hour “chase” period. These two stages allowed visualisation of total 
protein produced within the defined pulse period, and the fate of these proteins during 
the chase period.  
Proteins were visualised following immunoprecipitation (IP), in this case with 
antibodies against AP-1γ, AP-2µ or AP-3δ. HXB2 was used in this experiment, 
alongside HVPΔEC PuroΔB as a control, which were used to transfect HeLa cells for 
24 hours prior to pulse chase. A mock (Lipofectamine) only sample was also used as a 
negative control (-). Results of a representative experiment are shown in Figure 25B.  
Many more protein bands (background) were observed in comparison to Western blot 
of the APs, which indicates insufficient blocking during the IP. AP-2 could not be 
detected via immunoprecipitation; therefore this assay was unsuitable for investigating 
AP-2 turnover. AP-3 showed little protein synthesis, making it difficult to interpret any 
turnover in the presence of HXB2, or the control provirus. Although there was a 
substantial decrease in synthesised AP-1 in the presence of HXB2, the same was seen 
for the control provirus which does not contain AP binding sites. It was also clear that 
far more total protein had been synthesised in the mock-transfected cells. It was 
therefore difficult to ascertain whether the slight decrease in newly made AP-1 
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observed in transfected cells was due to an interaction with HIV-1, or merely the result 
of cellular toxicity, which in turn caused less AP-1 to be synthesised in the 40 minute 
pulse following the 24 hour transfection. In an attempt to account for general cellular 
toxicity, densitometry of a background band on the autoradiograph was used to correct 
for differences in protein loading. This revealed that there were no specific differences 
in AP-1 synthesis in the presence of HIV-1 (data not shown). The similarity in the AP-
1 levels between the pulse and chase samples suggested that the presence of HIV-1 did 
not affect AP-1 turnover, at least during the time course of this experiment.  
3.2.3 The APs are not Incorporated into Viral Particles 
Recently, it was discovered that HIV actively incorporated clathrin into viral particles 
(Zhang et al., 2011). This is in contrary to earlier beliefs that it is passively 
incorporated into virions following particle release which takes with it a small portion 
of the plasma membrane. Since the adaptor proteins bind clathrin and Gag, the 
possibility of HIV-1 also incorporating the APs into viral particles alongside clathrin 
was contemplated.  
HeLa cells were transfected with HXB2 provirus, and cell lysates and released virions 
(supernatants) were harvested. Since we were primarily interested in supernatant 
samples, cell lysates were directly loaded onto an SDS-PAGE gel without prior 
equalisation with the BCA protein assay. All samples were analysed by Western blot 
for both Gag and the APs, and the results are shown in Figure 26.  
Here, we can see that Gag was detected in both cell lysates and in released viral 
particles within the supernatant (processed Gag p41 [top band] and p24 [bottom band] 
only), whereas the APs could only be detected in cell lysates. Therefore, it can be 
concluded that the APs are not incorporated into viral particles. Although the APs bind 
  
 
 
 
 
 
 
 
 
 
Figure 26:  The APs are not incorporated into viral particles. Western blots of cell 
lysates and released particles (viral supernatants) harvested from HIV-1 HXB2 
transfected HeLa cells at 48 hours post transfection. Membranes were probed for 
p24 Gag (top panel) and the APs using anti AP-1γ, -2µ and -3δ antibodies (bottom 
3 panels). (-) lanes show mock (Lipofectamine only) samples.  
 
 
 
 
 
 
 
 
Figure 27: Subcellular Fractionation of the adaptor proteins in HIV-1 transfected 
cells. HeLa cells were transfected with HXB2 HIV-1 provirus, and fractions were 
collected using a Qiagen Q Proteome Cell Compartment kit protocol. A negative  
(-) Lipofectamine only control was also used. These were resolved by SDS-PAGE 
and analysed by western blotting for the APs and the cytosolic Unr protein as a 
control for endogenous protein levels.  
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clathrin, this may indicate that they dissociate prior to particle release. Since clathrin is 
actively, not passively, incorporated into virions in order to assist particle formation 
and infectivity, it is therefore likely that the APs have no further role in the HIV life 
cycle post particle egress and therefore are not required for incorporation.  
3.2.4 Does HIV Alter the Intracellular Localisation of the APs? 
3.2.4i Subcellular Fractionation 
During the infection process, newly synthesised viral components will need to be 
trafficked to distant assembly sites, requiring a constant flow of the APs if they are 
involved in this trafficking. It was therefore postulated that HIV protein expression may 
re-localise the APs as a result of this. The first assay to be used was a biochemical 
assay, followed up by confocal immunofluorescence microscopy.  
Subcellular fractionation of HeLa cells transfected with HXB2 was carried out using 
the Qiagen Q Proteome Cell Compartment kit. Cytosolic and membrane-bound 
fractions were analysed by Western blotting using antibodies directed against the APs. 
Results are shown in Figure 27.  
This data showed that no significant differences in the intracellular location of AP-1 or 
AP-3 were observed in HeLa cells transfected with HXB2 compared to mock-
transfected cells (-). No differences in cytosolic AP-2 were found; however, a decrease 
in membrane-associated AP-2 could be seen. AP-2 is known to interact with HIV-1 
Gag and Nef, which may result in less membrane-bound AP-2, although no 
corresponding increase in cytosolic AP-2 was observed. A problem with this assay was 
that the fractions were not compatible with the BCA protein quantification assay. 
Although a control antibody against the cytosolic protein Unr (upstream of N-ras), a 
cytoplasmic RNA binding protein, was used to demonstrate both successful 
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fractionation and equal loading, this protein was not found in the membrane fraction. A 
control membrane protein was not available to test whether the fractionation was clean 
at the level of soluble versus membrane proteins, therefore, the possibility that the 
difference in AP-2 levels in the membrane fraction is merely a result of unequal 
loading cannot be excluded.  
3.2.4ii Confocal Immunofluorescence Microscopy 
Although subcellular fractionation allows investigation of total protein content within 
different compartments of the cell, it is quite a crude experiment in that it does not 
show whether, for example, proteins are being directed from one membrane to another. 
Therefore, this assay is limited in telling the full story. In order to investigate the 
cellular location of the adaptor proteins further, confocal immunofluorescence 
microscopy of transfected HeLa cells was carried out in order to observe any potential 
differences in AP localisation in the presence of HIV-1. This method would also give 
insights as to whether HIV-1 colocalises with the adaptor proteins. Preliminary 
experiments optimised staining of HIV-1 Gag using an anti-p24 antibody, HIV-1 Nef, 
AP-1γ, AP-3δ, but AP-2 could not be detected in immunofluorescence experiments. 
Subsequently, co-staining of cells for HIV-1 Gag or Nef, and AP-1 or AP-3 was carried 
out. The results are shown in Figure 28.  
HIV-1 Gag (p24) was seen throughout the cytoplasm, as was AP-3 (Figure 28C). There 
was a small amount of colocalisation between Gag and AP-3, demonstrated by 
yellowing areas where pixels overlap. In order to quantify this colocalisation, ImageJ 
was used to calculate Pearson’s Correlation Coefficient (Rr), which was found to be an 
average of 0.206 across 3 repeat experiments. Cut off values for this coefficient are 
considered as follows; 0-0.1 no colocalisation, 0.1-0.3 low colocalisation, 0.3-0.5 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: HIV-1 alters the intracellular localisation of AP-1. Confocal 
immunofluorescence microscopy images of HIV-1 transfected HeLa cells co-
stained for p24/Nef and AP-1γ/-3δ. A- Cells transfected with HIV-1 HXB2 
provirus, stained with anti-Gag p24 (red) and anti-AP-1γ (green). White arrows 
indicate changes in AP-1 localisation in HIV Gag expressing cells. B- 
HXB2N
+ΔGag transfected HeLa cells, co-stained with anti-Nef (red) and anti-AP-
1γ (green). Some colocalisation could be seen, as shown by white arrows. C- Cells 
transfected with HXB2 and co-stained with anti-Gag p24 (red) and anti-AP-3δ 
(green). Colocalisation across independent repeat experiments was calculated by 
Pearson’s Correlation Coefficient using ImageJ (Rr=0.206), which was deduced to 
be low.  
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moderate colocalisation, 0.5-1.0 high colocalisation. No obvious re-distribution of AP-
3 in cells expressing HIV-1 Gag could be observed. 
The opposite could be seen for AP-1; HIV-1 Gag did not colocalise with AP-1, but AP-
1 did show a somewhat altered localisation (Figure 28A). In HXB2 transfected cells, 
AP-1 appeared in a tighter juxtanuclear position as compared to untransfected cells in 
the same field shown. In order to investigate whether this effect was mediated by Gag, 
the HXB2N
+ΔGag provirus was used to transfect HeLa cells (Figure 28B) and staining 
of Nef and AP-1 analysed. Although less obvious differences between transfected and 
un-transfected cells in the same field were observed, all cells in this experiment seemed 
to have tight juxtanuclear AP-1 staining, in contrast to the experiment described above 
whereby un-transfected cells displayed a more diffuse juxtanuclear AP-1 staining. 
However, some cells did show colocalisation between Nef and AP-1 in juxtanuclear 
regions, as indicated by the white arrows, which supports the current literature 
described on these protein interactions (Craig et al., 2000; Roeth et al., 2004; Lubben et 
al., 2007).   
3.3 Discussion  
Although the interactions between HIV-1 and the adaptor proteins have been 
researched recently, these studies did not to characterise the effects that HIV has on the 
functioning of the APs; namely, their levels and localisation. This chapter aimed to fill 
in gaps of current research and shed light on the consequences of HIV-1 infection on 
the APs.  
The first aim of this chapter was to investigate whether, as a consequence of HIV-1 
infection, expression or turnover of the APs was altered. It was that diversion of the 
APs from their normal cellular functions by HIV-1 Gag and/or Nef may result in their 
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increased turnover, or possibly increased expression of the APs via homeostatic 
mechanisms. 
Western blot analysis of cell lysates collected in the presence of various HIV-1 
proviruses demonstrated that the total levels of the APs were unaltered under these 
conditions. 
Although no change in total protein levels was found, a simple Western blot cannot 
provide information on what happens to the APs over defined periods of time. This is 
where pulse chase analysis is particularly useful, allowing information to be divulged 
on protein synthesis and turnover. Since HIV will be constantly and rapidly producing 
progeny viral proteins which all require the APs to traffic to assembly sites, it may be 
that a consequence of HIV-1 infection is a transient up or down-regulation of AP 
expression or turnover. Pulse chase analysis, however, failed to demonstrate this for 
AP-1 and -3. AP-2 was unable to be investigated since the antibody was not suitable for 
immunoprecipitation. We can therefore conclude that despite the strains imposed on the 
AP trafficking pathway by HIV protein expression, the host cell does not up-regulate 
AP-1 or -3 expression in order to ensure normal functioning of these pathways.  
It has been demonstrated that HIV-1 actively incorporates clathrin into particles (Zhang 
et al., 2011). Since the APs bind clathrin alongside cargo, it was postulated that the APs 
may also be incorporated into particles. Analysis of viral particles through Western blot 
of collected viral supernatants, however, could not find evidence of any presence of the 
APs. This could be for several reasons. Firstly, since clathrin is actively recruited into 
viral particles to assist virion morphogenesis, it may be that HIV does not require the 
APs post viral egress and therefore has no reason to actively incorporate them into 
assembling virions. Second, it may be that the APs dissociate from clathrin prior to its 
incorporation into virions. It may well also be that very small amounts of the APs are 
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incorporated, for example AP-2 which would be present in the plasma membrane from 
which HIV buds, but that they are in too small quantities to be detected by Western 
blot. More sensitive methods, for example mass spectrometry, may shed more light on 
this.  
Finally, the ability of HIV-1 to alter the cellular location of the APs was investigated 
using two different techniques; a biochemical assay, and immunofluorescence 
microscopy. Although subcellular fractionation is a crude assay, it can divulge 
information on whether proteins are shifted from one total fraction to another, i.e. from 
membranes to the cytosol or vice versa. Subcellular fractionation here, however, could 
not provide any evidence for any change in the localisation of AP-1 or -3. A small 
decrease in membrane associated AP-2 was observed. Since a protein assay was not 
compatible with this kit, equal amounts of protein could not be loaded onto gels for 
investigation. Therefore, the possibility that this is a result of unequal loading cannot be 
excluded. If this is a real effect, it may be a result of HIV-1 Nef recruiting AP-2 for 
internalisation CD4 molecules (Chaudhuri et al., 2007).  
More information was gained from confocal immunofluorescence microscopy with 
regards to AP-1 and -3 localisation in the presence of HIV-1. Although the interactions 
between HIV-1 and these APs have been described, the intracellular localisation of 
these with respect to Gag has not been investigated, although studies have elucidated 
distributions with respect to various endosomal/Golgi markers (Liu et al., 2012). 
Colocalisation between Gag and AP-1 could not be observed, as Gag and AP-1 
appeared to have very separate intracellular locations, which was surprising since AP-1 
facilitates Gag trafficking. AP-1 was observed in a tight juxtanuclear location, whereas 
Gag was diffuse throughout the cytoplasm or at the plasma membrane. What could be 
seen, however, was that in the presence of HIV-1, AP-1 staining appeared more 
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condensed than in un-transfected cells within the same field. When compared with a 
Gag-deleted mutant (Figure 28B), the differences in AP-1 staining between Gag 
expressing and non-Gag expressing cells within the same field were not as obvious, 
which could suggest a Gag mediated effect. It may be that through disrupting the AP-1 
trafficking pathway, the trans-Golgi network becomes compromised, resulting in an 
altered appearance of this compartment. This in turn may have other effects on the cell, 
indirectly affecting the trafficking of host cellular proteins.  
With regards to AP-3, little colocalisation between Gag and AP-3 could be observed. 
Conflicting results have been obtained as to whether HIV-1 Gag can directly bind AP-
3δ. Data collected by Dong et al., (2005) showed a direct interaction, whereas later data 
collected in 2012 by Kyere at al., in a different cell line suggest that there is no direct 
interaction. This may explain why limited colocalisation can be seen. Alternatively, this 
data may also support the fact that we do not see AP-3 in the supernatant samples; 
interactions with AP-3 may be transient.  
3.4 Future Work 
One limitation of this section was that a suitable AP-2 antibody for 
immunoprecipitation and immunofluorescence microscopy was not available. Future 
experiments should consider utilising a more appropriate antibody that can fill in the 
gaps in this chapter. 
Another crucial set of experiments to be considered are further confocal 
immunofluorescence studies. This is because, although results gathered in this chapter 
suggest that AP-1 is relocalised in the presence of HIV-1 Gag, the area which AP-1 is 
relocalised to was not investigated. Therefore, appropriate studies may include the use 
of TGN markers, such as TGN38 (Bos et al., 1993), which could indicate whether more 
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AP-1 is present in the TGN area in the presence of HIV-1 Gag, as compared with cells 
not expressing Gag. 
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CHAPTER 4: DO THE ADAPTOR PROTEINS 
AFFECT HIV-1 GENE EXPRESSION? 
4.1 Introduction 
The clathrin adaptor proteins play pivotal roles in cargo trafficking within the cell. 
They function in various different well characterised pathways, including clathrin 
mediated endocytosis (AP-2), and secretory/endocytic pathways (AP-1/-3). HIV has 
evolved ways to utilise these proteins in order to assist the viral life cycle. The 
interactions of HIV-1 Gag, Nef and Env with these adaptor proteins have recently been 
characterised, indicating roles within the later stages of the life cycle. Specifically, AP-
1 and -3 facilitate particle release (Dong et al., 2005; Camus et al., 2007), whereas AP-
2 inhibits particle release (Batonick et al., 2005). Much still, however, remains 
unknown about their precise involvement within the viral life cycle. 
Previous results gathered in this lab indicated a role for AP-1 in HIV-1 Gag expression; 
siRNA mediated knockdown of AP-1 was found to reduce protein expression from a 
transfected viral plasmid (Gemma Watkins, personal communication). This opened up 
the possibility that a role for the adaptor proteins in protein synthesis or turnover had 
been overlooked, suggesting a potential role for these adaptor proteins in other stages 
of the viral life cycle besides viral egress.  
This chapter describes work carried out to investigate the role of the clathrin adaptor 
proteins -1, -2 and -3 in earlier stages of the viral life cycle through characterising 
effects mediated by siRNA knockdown of these proteins.  
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4.2 Results 
4.2.1 siRNA Knockdown of AP-1 or AP-3 Prior to Proviral 
Transfection Reduces HIV-1 Protein Expression, but not Endogenous 
Protein Expression 
In order to deduce whether our custom designed siRNAs against the gamma subunit of 
AP-1, the mu subunit of AP-3, and the delta subunit of AP-3, achieved a significant and 
specific reduction of the APs, Western blots and confocal microscopy were performed 
on siRNA treated HeLa cells. Figure 29A shows Western blots of 24h HeLa cell lysates 
collected in the presence of the same siRNAs, including AP-2. A negative control 
siRNA was included to ensure specificity of the siRNAs. Samples were compared to 
siRNA untreated cells. As can be seen, these siRNAs cause efficient and specific 
(knockdown not observed in negative control siRNA samples) knockdown of these 
adaptor proteins over 40 hours. Figure 29B shows confocal immunofluorescence 
images of the adaptor proteins with and without siRNA treatment, using antibodies 
directed against the APs.  As can be seen in Figure 29Bi and ii, AP-1 presents a diffuse 
staining throughout the cytoplasm, coupled with strong juxtanuclear Golgi staining, and 
AP-3 presents a combination of diffuse and punctuate cytoplasmic staining. Punctae 
may represent endosomal compartments, but without colocalisation studies it is not 
possible to identify them. Figure 29Biii and iv demonstrate 40h siRNA mediated 
knockdown of AP-1 and AP-3, respectively.  Quantification of the average number of 
cells which did not appear to express these proteins by counting fluorescent cells in 
siRNA treated samples across multiple fields of cells deduced these siRNAs to reduce 
expression in >90% of cells (data not shown). AP-2 was found unsuitable for 
immunofluorescence, as staining appeared highly non-specific due to showing the same 
level of fluorescence in extracellular areas as within cells, therefore true staining could 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: siRNA mediated knockdown of APs. A- Western blot of HeLa cell 
lysates treated with no siRNA (-), an siRNA against AP-1γ, AP-2µ, AP-3δ (AP 
siRNA) or a negative control siRNA (-ve siRNA), using antibodies against AP-1γ, 
AP-2µ or AP-3δ. B- Confocal immunofluorescence microscopy of HeLa cells using 
antibodies against AP-1γ (i and iii) and AP-3δ (ii and iv) in the absence of siRNAs 
(I and ii) or after treatment with siRNAs against AP-1γ (iii) or AP-3δ (iv). Blue 
stain=DAPI (included in overlay of individual channels).  
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not be deduced from background despite attempting numerous concentrations of 
antibody (data not shown). 
In order to investigate the effects of reducing the adaptor proteins on HIV-1 Gag 
expression, siRNAs directed against AP-1, -2 and -3 were transfected into HeLa cells 
24 hours prior to HIV-1 proviral transfection, in order to achieve a significant reduction 
in these proteins. Cells were harvested 24 h and 48 h post proviral transfection, and 
samples analysed by Western blot using antibodies directed against HIV-1 p24 and γ-
tubulin. Figure 30A shows representative blot, revealing a reduction in the level of full 
length Gag protein (p55), the processing intermediate MA-CA (p41), and fully 
processed CA (p24) at both 24h and 48h in the presence of AP-1 and -3 siRNAs, but 
endogenous protein levels remained the same as shown by γ-tubulin levels. AP-2 
siRNA and the negative control siRNA were found to have no effect on Gag levels. 
Densitometry was used to quantify autoradiograph bands corresponding to p55, p41 
and p24 from 3 independent experiments, and the results are shown in Figure 30B. 
Student’s t-test deduced Gag to be significantly lower in the presence of AP-1 and AP-
3 siRNAs, but not AP-2 (p>0.05), as shown by asterisks.  
In order to visualise this effect, HeLa cells plated onto coverslips were again siRNA 
treated 24h prior to HIV-1 proviral transfection, and 24h later were fixed, 
permeabilised and stained for the adaptor proteins and Gag p24. These slides were then 
analysed by confocal immunofluorescence microscopy. Figure 31 demonstrates a 
significant reduction in p24 expressing cells in the presence of AP-1 and AP-3 siRNAs, 
but not the negative control siRNA. In order to quantify this data, five randomly 
selected fields of cells were chosen, and cells expressing p24 were counted. This was 
repeated across three independent experiments. Figure 32 shows these results 
graphically; there was a clear reduction in Gag expressing cells in the presence of AP-1 
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Figure 30: HIV-1 Gag expression in HeLa cells after siRNA treatment. A- 
Western blot analysis of cellular HIV-1 Gag with and without AP/control siRNAs 
at 24 and 48 hours. The same lysates were probed with γ-tubulin antibody to 
ensure loading was equal. Densitometry was carried out across 3 independent 
repeat experiments using ImageJ, with numbers expressed as percentages of no 
siRNA treated samples (B and C). B shows 24 hour Gag expression, C shows 48 
hour Gag expression. Statistically significant (p<0.05) values are indicated with 
asterisks. 
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Figure 31: AP-1 and -3 knockdown appears to reduce HIV-1 Gag expression. 
Confocal immunofluorescence images of HIV-1 Gag following no/AP siRNA 
treatment. Panel A shows AP-3 (green) and Gag p24 (red) with no siRNA 
treatment. B shows AP-1 (green) and Gag p24 (red) in the presence of AP-1 
siRNA, C shows AP-3 and Gag p24 in the presence of AP-3 siRNA and D shows 
AP-3 and Gag p24 in the presence of a negative control siRNA. Blue stain= DAPI.  
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Figure 32: Quantification of HIV-1 Gag expressing cells in siRNA treated and 
untreated HeLa cells, as visualised by confocal immunofluorescence microscopy. 
Average counts of Gag expressing cells from 5 randomly selected fields of cells 
from each of 3 independent experiments were plotted and analysed by Student’s t-
test for significance. Significant results are highlighted by asterisks (p<0.01).  
 
 
 
 
 
 
Figure 33: AP-1 and -3 knockdown reduces the level of HIV-1 Nef. Nef levels (top 
panel) are demonstrated by western blot of 24 and 48h cell lysates harvested from 
HeLa cells transfected with HXB2N
+
 provirus 24 hours after siRNA treatment. 
The same lysates were probed with γ-tubulin antibody to ensure that loading was 
equal (bottom panel).  
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and -3 siRNAs, but not AP-2 or the negative control. These results were deduced to be 
significantly different to siRNA untreated cells (p<0.01).  
To investigate whether this effect was specific to Gag, Western blots were also 
performed on independently collected lysates following the same protocol, using anti-
Nef antibodies. Figure 33 demonstrates that Nef is clearly reduced in the presence of 
AP-1 and AP-3 siRNAs, but not AP-2 or the negative control. Again, endogenous 
proteins were unaffected as shown by constant γ-tubulin levels.  
It has been demonstrated previously (Dong et al., 2005; Camus et al., 2007) and in this 
thesis that knockdown of AP-1 or AP-3 inhibits viral particle release (see chapter 
5.5.2). One explanation of the decreased cellular levels of Gag and Nef when these APs 
are knocked down may be that prevention of viral particle release increases turnover of 
the viral proteins within cells, although there is no evidence in the literature for this.  
4.2.2 Reduction in Exogenous Protein Expression is not specific to 
HIV  
In order to investigate whether reducing AP-1 or AP-3 specifically reduces HIV gene 
expression, expression of two other exogenous proteins were tested; Renilla luciferase 
(RL) and GFP. HeLa cells were transfected with either pcDNA RL or pcDNA GFP, 24 
hours after AP siRNA transfection, and analysed either by quantifying relative 
luminescence, or by confocal immunofluorescence microscopy, respectively.  
Figure 34A shows data collected from Renilla luciferase experiments. The graph 
demonstrates that Renilla luciferase expression is also significantly reduced when AP-1 
and AP-3 siRNAs were transfected prior to the luciferase expression plasmid, but not 
AP-2 or the negative control siRNAs. Analysis of Variance (ANOVA) was performed, 
which deduced AP-1 and AP-3 to be extremely significantly different (p<0.001) from 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: siRNA reduction in AP-1 or -3 reduces expression of other exogenous 
proteins. A demonstrates 24 hour Renilla luciferase (RL) expression using two 
different transfection reagents, in AP/negative control siRNA treated cells. Values 
are relative luminescence, expressed as percentages of siRNA untreated samples 
(RL), from 3 independent repeat experiments. Statistically significant values are 
highlighted by an asterisk (p<0.001). B- Confocal immunofluorescence images of 
GFP expression in untreated/siRNA treated cells. Average percentages of cells 
expressing GFP across independent repeat experiments are shown in the table. 
(Trans-IT 2020 and GFP data collected by Jade Gumbs).  
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siRNA untreated samples. To deduce whether this effect was specific to the 
transfection reagent used (Lipofectamine 2000), a different reagent was tested; 
TransIT-2020. Figure 34 also clearly shows that when AP-1 and AP-3 are reduced 
prior to transfection with this transfection reagent, we see the same result as with 
Lipofectamine 2000; a significant reduction in expression as deduced by ANOVA 
(p<0.001). Again, AP-2 and the negative control siRNAs were seen to have no effect.  
Confocal immunofluorescence microscopy revealed the same pattern of results when 
pcDNA GFP was transfected, with both Lipofectamine 2000 (data not shown) and 
TransIT-2020 (Figure 34B).  
Collectively, these data suggest that reducing the levels of AP-1 or -3 has a non-
specific inhibitory effect on protein expression from transfected plasmid DNA 
introduced into cells by lipofection, which is non-specific. This therefore excludes a 
role for AP-1 and -3 in specifically assisting viral gene expression, but indicates a more 
general role for these adaptor proteins in expression from transfected plasmids.  
4.2.3 Co-Transfection of AP siRNAs with HIV-1 Provirus Does Not 
Affect HIV-1 Protein Expression 
To deduce whether the same reduction in exogenous protein expression could be 
observed when the siRNAs were not transfected prior to proviral transfection, the AP 
siRNAs (10 µM) were co-transfected alongside the HIV-1 provirus. To investigate total 
Gag protein levels, this was carried out in the presence of the HIV-1 Protease inhibitor 
Saquinavir (1 µM). Cell lysates were again collected 24h and 48h post transfection and 
analysed by Western blot using antibodies directed against p24 and Nef. Figure 35A 
shows that both Gag and Nef protein levels now appeared to be unaffected by 
knockdown of AP-1 or AP-3. Densitometry was then carried out on 3 independent 
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Figure 35: HIV expression in proviral plasmid and siRNA co-transfected cells. A- 
Western blots of cell lysates harvested 24 and 48 hours post siRNA/provirus co-
transfection; the top panel shows total Gag (p55) protein in the presence of the 
protease inhibitor Saquinavir, the bottom panel shows total Nef levels. These were 
quantified in ImageJ using densitometry, normalising to siRNA untreated 
samples. B and C show these values for Gag and Nef, respectively. No differences 
were found to be statistically significant (p>0.05).  
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experiments, and the results are shown in Figures 35B and C. Student’s t-test deduced 
none of the results to be significantly different to the siRNA untreated control (p>0.05). 
To ensure that the siRNAs were effective when transfected in this way, Western blots 
were carried out using these lysates, and it was found that they were still able to 
significantly reduce AP expression (Jade Gumbs, personal communication).  
Again, in order to investigate whether this was specific to HIV, the same protocol was 
repeated but using pcDNA RL. This also found that when siRNAs were co-transfected, 
protein expression was unaffected when AP-1 or AP-3 were reduced (p>0.05) (data not 
shown).  
These results suggest that the effects of reducing AP-1 and AP-3 can be bypassed if 
plasmids are transfected alongside the siRNAs. However, since a pool of pre-existing 
APs will exist for some time after the co-transfection, this may reduce any potential 
effects of the AP knockdown.  
4.2.4 Reduction in Exogenous Protein Expression Does not Occur 
when mRNA is Transfected 
Results obtained so far infer a non-specific reduction in gene expression from 
transfected plasmids, only when levels of AP-1 and -3 subunits are reduced prior to 
transfection. In order to investigate the stage of transfection which is affected by 
knocking down AP-1 or -3, mRNAs were used in transfection as opposed to DNA. This 
is because mRNA can be directly translated in the cytoplasm, and does not require 
nuclear entry, as plasmids do for transcription.  
Renilla luciferase (RL) and GFP mRNAs were in vitro transcribed, capped and 
polyadenylated, and used to transfect cells 24 h post-siRNA transfection. Cell lysates or 
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Figure 36: Protein expression from transfected mRNA is not decreased by AP-1/-3 
knockdown. A- Renilla luciferase (RL) expression after RL mRNA transfection 
into AP siRNA treated cells. Relative luminescence units are expressed as 
percentages of siRNA untreated samples. B- Confocal immunofluorescence 
microscopy images of GFP (green) mRNA transfected into AP siRNA treated 
cells. The table shows counts of average percentage of GFP expressing cells from 
repeat experiments. None of the differences were found to be statistically 
significant (p >0.05). Blue stain = DAPI.  
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fixed cells were analysed for relative luminescence or by confocal 
immunofluorescence, respectively.  
Luciferase results from transfected RL mRNA (shown in Figure 36A) showed that 
although differences in protein expression could be observed in the presence of the AP 
siRNAs, Student’s t-test revealed that none of the results were significantly different 
(p>0.05); furthermore, no reduction in RL expression in AP-1 or AP-3 treated cells was 
observed.  
Confocal immunofluorescence microscopy of GFP mRNA-transfected cells also 
showed no differences in the presence of the AP siRNAs (Figure 36B). Together, these 
results infer that AP-1 and AP-3 depletion likely affects DNA trafficking to the 
nucleus, rather than lipoplex entry or escape from endosomes.  
4.3 Discussion 
This chapter aimed to investigate a potential role of the adaptor proteins in facilitating 
viral protein expression. Previous results obtained in this lab suggested a potential role 
of AP-1 in viral Gag expression, therefore this chapter focussed on investigating this 
effect, extending it to include the other adaptor proteins with which HIV-1 is known to 
associate.  
Initial results obtained supported previous results, indicating that AP-1 does indeed 
play a role in facilitating viral protein expression (Figures 30-33). This was found to 
not be specific to AP-1 only, but AP-3 also. AP-2 was deduced to have no effect. 
Investigation of endogenous protein expression levels (γ-tubulin) revealed that this 
effect is specific to exogenous proteins. Since experiments were performed using 
transfected envelope deleted proviral constructs, we know that the effect observed is 
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not via obstruction of viral entry, since this is bypassed in transfection. Progeny 
particles produced by infected cells are also uninfectious since they do not possess Env, 
which is absolutely required for viral entry into cells. Therefore, we can also conclude 
that we were not affecting re-entry into uninfected cells. The fact that AP-1 and -3 
knockdown inhibits viral egress (Dong et al., 2005; Camus et al., 2007; chapter 5.2.2) 
also rules out that the effect on cellular Gag is due to an increase in particle release.  
GFP and RL expression studies revealed that the effect of AP-1/-3 reduction was not in 
fact specific to HIV proteins, but rather a general effect on protein expression from 
transfected plasmids (Figure 34). Co-transfection of plasmids and siRNAs also revealed 
that this effect can be bypassed if the siRNAs are not transfected prior to plasmid 
transfections (Figure 35), which has implications on appropriate methodology for 
future experiments in which AP knockdown is required. This also narrowed down the 
effect we were seeing to exclude the possibility that reducing AP-1/-3 affected protein 
turnover.  
As mentioned earlier, AP-2 was deduced to have no effect on plasmid protein 
expression. It has been suggested that lipoplexes may enter the cell by 2 mechanisms; 
coated pit/ clathrin mediated endocytosis (Friend et al., 1996; Zuhorn et al., 2002), or 
non-coated pit endocytosis (Simões et al., 2000), and that this may be due, at least in 
part, to cell type (Elouahabi and Ruysschaert, 2005). Since AP-2 plays a pivotal role in 
the former process, we can infer that this is not the mechanism by which the plasmids 
are entering the cell, or at least within HeLa cells.  
mRNA studies were critical in narrowing down the stage in the lipoplex trafficking that 
is affected by reducing AP-1/-3 expression. Protein expression from transfected 
mRNAs was unaffected under conditions in which expression from transfected 
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plasmids was reduced (Figure 36). Firstly, this suggested that cell entry of lipoplexes 
was not inhibited by AP-1/-3 depletion (unless mRNA-liposome complexes have very 
different properties to DNA-liposome complexes). Secondly, these results suggested 
that escape of lipoplexes from endosomes is not dependent on the APs, as mRNA 
would need to enter the cytosol for translation. Thirdly, this suggested that trafficking 
of DNA to the nucleus requires AP-1 and AP-3. Since we transfected dividing cells in 
which plasmid nuclear entry can occur during nuclear membrane breakdown, it is more 
likely that AP-1/-3 depletion affected trafficking of DNA to the perinuclear region 
rather than translocation of the nuclear membrane. 
Since a major pathway of lipoplex entry was found to be endocytosis, a subsequent 
stage of endosomal escape is necessary to facilitate cytosolic entry of DNA destined for 
the nucleus (Elouahabi and Ruysschaert, 2005). Whether after this stage DNA enters 
the nucleus still in lipoplex complexes, or dissociated as naked DNA, is disputed.  
Further studies in our laboratory using a fluorescent transfection reagent (Metafectene-
fluoR, data not shown) have found that DNA enters the nucleus in a lipid complex, 
since a strong nuclear signal from the Metafectene-fluoR was observed in cells 
expressing GFP from a plasmid (Jade Gumbs, personal communication). Therefore, the 
APs may facilitate the trafficking of lipid/DNA complexes, rather than naked DNA. 
However, it seems unlikely that the APs can bind lipoplexes directly since they bind 
specific peptide motifs found on cargo. That being said, it is not implausible that their 
ability to bind other molecules has been overlooked. Another interesting discovery 
through the use of Metafectene-fluoR (data not shown) was that, although 6 hours post 
transfection, Metafectene-fluoR fluorescence seemed relatively even in siRNA treated 
and untreated samples, at 24 hours, there was a dramatic reduction in Metafectene-
fluoR fluorescence in cells. Since it is unlikely that rhodamine, the dye used in 
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Metafectene-fluoR, would be degraded as a result of instability, there must be a specific 
reason for the reduction in signal observed at this time point. It is possible that since 
Metafectene-fluoR, and other transfection reagents, are toxic, that if they are unable to 
enter the nucleus as a result of AP-1/-3 knockdown, that they are degraded in 
lysosomes or recycled out of the cell in order to prevent cell death.  
Recent studies have shown that the molecular motor kinesin KIFC1 is involved in the 
intracellular trafficking of naked DNA (Farina et al., 2013). It cannot be ruled out that 
these APs might therefore play a role in the delivery of kinesin KIFC1 to 
DNA/lipoplexes, or vice versa, prior to trafficking along cytoskeletal filaments towards 
the nucleus. Although most kinesins are plus end directed, KIFC1 moves towards the 
minus end (Farina et al., 2013), which would fit in with this theory.  
Together, these results demonstrate a novel and surprising role for adaptor proteins 1 
and 3 in the trafficking of lipoplexes to the nucleus, but not earlier stages of the 
lipoplex trafficking pathway.  
4.4 Future Work 
This chapter has shed some light on the mechanisms underlying lipoplex trafficking. 
The finding that AP-1 and -3 are required for efficient nuclear delivery of lipoplexes 
was surprising, as was the apparent observation that AP-2 is not involved in lipoplex 
entry. Much more work is needed on this topic to divulge the precise action of the APs 
in lipoplex delivery. For example- are the APs the only players in this process? Since 
these APs generally function in concert with other proteins, such as clathrin, one could 
assume that they are likely not the only players. If so- which other molecules work as 
chaperones to collectively deliver lipoplexes to the nucleus? Kinesin KIFC1 is one such 
possibility that could be investigated.  
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Another crucial set of experiments which may shed light on what happens to lipoplexes 
if they are unable to enter the nucleus would be to repeat Metafectene-fluoR 
experiments, but at different time points. For example, 6 hours, 12 hours, 18 hours and 
24 hours post transfection. We may then be able to see where the complexes go, and at 
what time point they disappear.  
It is also necessary to investigate whether it is indeed the APs which directly bind to the 
lipoplexes, or whether they act as a linker molecule between the lipoplex and another 
chaperone/molecule.  
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CHAPTER 5: WHAT IS THE EFFECT OF 
ADAPTOR PROTEIN DEPLETION ON HIV-1 GAG 
TRAFFICKING? 
5.1 Introduction 
Progeny virion formation is a complex multi-step process which is driven by HIV Gag. 
Preceding this stage of the life cycle are trafficking events which bring together both 
the full-length Gag precursor polypeptides and the viral RNA to discrete assembly 
domains within the cell. As mentioned earlier in chapter 1, HIV Env trafficking follows 
a distinct pathway to that of Gag, but ultimately becomes inserted within the cellular 
membranes at the site of viral budding. Gag trafficking has come under scrutiny over 
the past few years due to the presence of an incomplete story; how precisely is Gag 
targeted to assembly sites, and what factors determine these areas as sites of assembly? 
HIV-1 has been observed through electron microscopy (EM) to bud from 2 different 
areas; the plasma membrane (PM) and late endosomes/multivesicular bodies 
(LEs/MVBs), and preferences for these sites differs in two natural host cell types; in T 
cells HIV-1 preferentially buds from the PM, whereas in macrophages budding 
preferentially occurs into MVBs. Gag has also been observed at both sites in certain 
cell lines, suggesting that the endosomal pathway may serve as a route for both the 
trafficking of Gag and assembled particles (Ono, 2009).  
Consistent with the notion of an endosomal trafficking pathway, various cellular factors 
which are involved in endosomal trafficking have been found to associate with HIV-1. 
As mentioned in chapter 3.1, AP-1 and AP-3 are thought to facilitate particle release by 
directing Gag through its MA region to intracellular assembly and budding sites (Dong 
et al., 2005; Camus et al., 2007). In contrast, AP-2 has an inhibitory effect on particle 
release, also through direct binding of the MA region (Batonick et al., 2005).  
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After the discovery of interactions between Gag and various cellular trafficking 
pathway components such as these adaptor protein complexes, we began to postulate 
exactly the route which Gag takes to reach assembly sites via these cellular proteins. A 
summary of some potential pathways is given below in Figure 37.  
 
Figure 37: Possible trafficking pathways of HIV-1 Gag to intracellular assembly 
sites. 1- Gag may be directly targeted to the PM. 2- Gag may be targeted to the 
PM by travelling first through an endosomal intermediate. 3- During trafficking 
through endosomes, Gag may form particles in the endosomal lumen which 
become released extracellularly through endosome/PM fusion. 4- Gag particles 
present in endosomes may alternatively have formed through the internalisation 
of particles at the PM, assisted at least in part by AP-2, which will then be released 
extracellularly (adapted from Ono, 2009).  
As this image suggests, there exists some controversy over the precise route which Gag 
takes in order to bud from cells. It is clear that particles must be released from the PM 
in order for infection to be productive, but also evident that Gag may use an endosomal 
   AP-2 
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route prior to reaching the PM; but whether this is a separate pathway, a detrimental 
consequence or an intermediate step is unknown.  
Despite the fact that differing budding sites have been observed in T cells and 
macrophages, it has been postulated that regardless of cell type, Gag traffics to the PM 
via endosomes, forming particles within the endosomal lumen which will be released 
extracellularly through fusion of the endosomal and plasma membranes (Sherer et al., 
2003; Perlman and Resh, 2006). This theory, however, was complicated by the fact that 
Gag presence in endosomes could be explained by internalised particles which first 
formed at the PM. Long-term monitoring studies of GFP tagged virus concluded that 
the majority of endosomal Gag was indeed derived from internalised particles that had 
initially reached the PM first. However, they did not rule out the idea that Gag could 
indeed traffic via endosomes in a minority of cases (Jouvenet et al., 2006; Ono, 2009).  
The purpose of this chapter, therefore, is to gain some more insight into the trafficking 
of HIV-1 Gag, through its use of the clathrin adaptor proteins. Do AP-1 and AP-3 have 
the same consequences on Gag localisation? Does AP-2 also affect Gag localisation? Is 
it likely that Gag simply diffuses through the cytoplasm without an intermediate step, 
and then arrives at the PM for budding? Are localisation and budding the only effects 
that the APs exert on Gag?  
5.2 Results 
5.2.1 AP-1 and -3 knockdown Affects Gag localisation 
It was recently shown that cells deficient of AP-3 caused an accumulation of HIV-1 
Gag in an intermediate endosomal compartment (Lui et al., 2012). Dong et al. (2005), 
using a different cell line, also found that addition of a dominant negative AP-3 
decreased plasma membrane localisation of Gag, however, it also resulted in an 
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increase in diffusely stained Gag, which is in contrast to the more punctate appearance 
observed by Liu et al., (2012). In order to investigate the effects of AP knockdown on 
Gag localisation, confocal microscopy of transfected HeLa cells was carried out, for 
consistency with the previous chapters. Results are shown in Figure 38.  
Experiments carried out using siRNAs within this chapter were performed using 
siRNA/provirus co-transfection; thus siRNAs were used for the time period stated 
when the time samples were taken (see chapters 2.1.3 and 2.2.8 for a more detailed 
description of the siRNAs and transfection protocol).  
Images shown in A, B and C show the 3 typical Gag localisations observed by p24 
staining in a population of cells. As can be seen, HIV-1 Gag either displays a punctate 
intracellular localisation, a predominantly plasma membrane (PM) localisation, or a 
diffuse cytoplasmic localisation. The relative abundances of these 3 different 
localisations is demonstrated in G, whereby cells expressing Gag were counted across 
repeat experiments and assessed for Gag localisation. As can be seen, HIV-1 Gag 
predominantly displays diffuse cytoplasmic staining when no siRNA is present; PM 
and punctate have roughly similar abundances; this is in contrast to Dong et al. (2005) 
who found HIV-1 Gag to be predominantly punctate. Figures D, E and F demonstrate 
typical Gag staining observed in the presence of AP-1, -2 and -3 siRNAs, respectively 
(see figure 39A for confirmation of siRNA efficacy). As can be seen, when AP-1 is 
knocked down Gag appears very diffuse, more so than in untreated samples. AP-2 
knockdown visually had no effect on Gag localisation, as cells were still a mixture of 
punctate, diffuse and PM localised. AP-3 siRNA resulted in cells appearing more 
punctate, which would support data collected by Liu et al. (2012), as described above, 
but is in contrast to Dong et al. (2005) who found a shift towards a diffusely stained 
cytoplasmic Gag. A likely explanation for the differences observed here is that a more 
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aggressive knockdown of AP-3 was adopted by Dong et al., who transfected the AP-3 
siRNAs twice prior to further co-transfection alongside the provirus. As results 
gathered in the previous chapter demonstrate that knocking down the APs prior to 
plasmid transfection decreases transfection efficiency and therefore protein expression, 
it is possible that differences in Gag levels could contribute to the apparent visual 
differences observed in Gag patterns.  
 To quantify this data, counts of Gag expressing cells across 3 repeat experiments were 
also taken as before. Average Gag localisations in the presence of AP siRNAs are also 
shown in Figure 38G. As can be seen, a significant decrease in PM Gag is observed in 
the presence of AP-1 siRNA. When AP-3 siRNA is used, PM localisation is 
significantly reduced, and punctate staining is significantly increased. AP-2 and –ve 
siRNAs had no significant effect.  
These results suggest that both AP-1 and AP-3 are required for HIV-1 Gag to reach the 
plasma membrane, but that they may function at different points in the pathway. AP-3 
is implicated in directing Gag from endosomal compartments to the plasma membrane, 
in an indirect manner, for example by facilitating delivery from an early 
endosome/intermediate compartment to a late endosome, which may then be recycled 
back to the PM (Dong et al., 2005; Liu et al., 2012), whereas AP-1 may be involved 
prior to this stage of trafficking; likely facilitating trafficking from the TGN to either 
the PM or endosomes, since Gag trafficking has been found to be positively affected by 
the TGN associated ubiquitin ligase hPOSH (Alroy et al., 2005). This would agree with 
published cellular roles of AP-1 in TGN-endosome trafficking, and AP-3 in endosome-
lysosome trafficking.  
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Figure 38: AP-1 and -3 knockdown affects Gag localisation in HeLa cells. A-C- 
Confocal immunofluorescence microscopy images of the 3 typical Gag (p24) 
localisations observed in HIV-1 transfected cells; punctate intracellular, plasma 
membrane (PM), and diffuse cytoplasmic, respectively. D-F- Typical Gag staining 
in the presence of AP-1, -2 and -3 siRNAs, respectively. G- Quantification of Gag 
expressing cells from 3 repeat experiments. Statistically significant results are 
highlighted by asterisks (*=p<0.05, **=p<0.01).  
D E F 
A B C 
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5.2.2 AP-1 and -3 Assist Gag Processing and Viral Particle Release 
Although previous studies have inferred a link between AP-1 and -3 and viral assembly 
(Dong et al., 2005; Camus et al., 2007), this link has only been suggested through the 
observation that particle release is severely retarded in the absence of these proteins. 
We investigated the effects of siRNA mediated knockdown of the APs on both cellular 
Gag and released Gag by Western blot of harvested HIV-1 and AP siRNA co-
transfected HeLa cells. By using an antibody against the capsid region of Gag, we 
could detect full length Gag (p55), processing intermediates (p41) and fully processed 
CA (p24). Gag processing depends on the activity of the HIV-1 Protease, which is only 
activated when GagPol proteins dimerise during the assembly process (see chapter 1). 
Consequently, changes in the ratio of p55, p41 and p24 suggest changes in the ability of 
virus particles to assemble. 
Figure 39A shows a Western blot of AP siRNA treated cells (1 of 3 repeats), 
confirming that when both AP-1 and AP-3 siRNAs were added, significant knockdown 
of both APs occurred. AP-2 appeared to have no effect on any Gag fractions. As shown 
by the γ-tubulin Western of the cell lysates, endogenous protein levels were unaffected 
and differences observed could not be attributed to uneven protein loading.  
Figure 39B shows that in the presence of AP-1 or -3 siRNAs, little change was 
observed at 24 hours, however there was a decrease in the amount of viral p24 
produced in cells at 40 hours post transfection, but p55 remained unchanged. This is in 
contrast to results gathered in chapter 4 (see figure 30A) whereby a significant decrease 
in all Gag fractions were observed at both 24 and 40 hours post-transfection; however, 
the siRNAs were co-transfected in this chapter, as oppose to transfection 24h prior to 
proviral transfection in chapter 4.  
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Figure 39B also demonstrated a modest decrease in p41 could be observed when AP-1 
or -3 siRNAs were used, 40 hours post transfection. When AP-1 and -3 siRNAs were 
transfected together, however, it could be seen that the effect on viral p24 was 
increased at both 24 and 40 hours post transfection; this additive effect of dual 
knockdown suggests that there may be some redundancy between AP-1 and AP-3 
function. Western blot of viral supernatant samples also confirmed that AP-1 and -3 
siRNA co-transfections had an additive effect (middle panel, Figure 39A, 1 of 3 
repeats); inhibiting viral particle release (middle strong band = p41, bottom faint band 
= p24). AP-2 knockdown also confirmed an increase in particle release as per the 
literature (Batonick et al., 2005). 
In order to quantify this data, densitometry using ImageJ was carried out across repeat 
experiments. Results are shown in Figure 40. At 24 hours post transfection (Figure 
40A), no effect was seen on p55, however, p41 was reduced by 18% when AP-1 and -3 
siRNAs were used together, which was found to be significantly lower than when no 
siRNA was present (p<0.001). p24 was also found to be significantly lower at 24 hours 
post transfection when AP-1 and -3 siRNAs were added in combination, reducing this 
fraction by 44%. AP-1 alone was also found to significantly reduce p24 at 24 hours, but 
only by 15%. By 40 hours (Figure 40B), AP-1 and -3 siRNAs alone significantly 
reduced the p24 band by 40 and 38%, respectively. AP-1 and -3 in combination was 
found to significantly reduce all 3 Gag fractions (15, 20 and 64%, respectively).  
With regards to viral release, p41 and p24 levels were investigated. AP-1 and -3 
knockdown in combination reduced p41 release by 94%, and p24 by 75%. AP-1 and -3 
knockdown individually was found to also significantly reduce particle release, as is 
described in current literature (Dong et al., 2005; Camus et al., 2007). Knockdown of 
AP-2 was found to facilitate particle release, also as per the current literature (Batonick 
  
 
 
 
 
 
 
 
 
 
 
Figure 39: AP-1 and -3 knockdown affects HIV-1 Gag processing and particle 
release. A- Western blot of HeLa cell samples harvested 40 hours post-transfection 
with AP or negative control siRNAs, using anti AP-1γ (upper panel) and anti AP-
3δ (middle panel) or anti γ-tubulin (lower panel, control) antibodies.  B- Western 
blots of cell (upper and lower) or supernatant (middle panel) samples collected at 
24 or 40h post co-transfection of HeLa cells with HIV-1 HXB2 proviral plasmid 
and AP or negative control siRNAs. Proteins were detected with an anti-Gag p24 
antibody (upper and middle panel) or anti γ-tubulin control antibody (lower 
panel). 
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Figure 40: Co-transfection of AP-1 and -3 siRNAs has an additive effect on HIV-1 
Gag processing and release.  Densitometry was carried out on cell (A, 24h; B, 40h) 
and supernatant (C) western blots from repeat experiments. Results are expressed 
as percentages of siRNA untreated samples. Statistically significant results are 
highlighted by asterisks (Key: *=p<0.05, **p<0.01, ***p<0.001).  
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et al., 2005). This is likely due to prevention of AP-2/clathrin-mediated endocytosis of 
budding viral particles.  
Another observation to note from this data is that, when AP-1 and -3 were knocked 
down individually, a corresponding increase in unprocessed p55 was not seen to co-
occur with the reduction in processed Gag. AP-1 and -3 siRNAs in combination also 
reduced all 3 Gag fractions by 40 hours. Since there was also less Gag being released 
from cells, this suggested that Gag is disappearing when it cannot be assembled. Three 
hypotheses were made to account for this, and tested below.   
5.2.3 AP-1 and -3 Knockdown does not Increase Gag Translation 
Inhibition 
Anderson and Lever (2006), found that at high levels, Gag modulates its own 
translation. This was found to be through interactions between zinc fingers present in 
Gag NC and the packaging signal present on viral RNA. At high levels, Gag bound to 
this signal, sterically obstructing the ribosome from scanning through the RNA, and 
therefore preventing Gag synthesis. It seemed a plausible idea that, if Gag is unable to 
traffic to intracellular assembly sites in the absence of AP-1 or -3, that Gag may 
accumulate at its site of synthesis and therefore reduce translation by this mechanism. 
We hypothesised that by using mutant viruses in which the interaction between NC and 
the packaging signal is inhibited, Gag translation would be able to continue in the 
absence of AP-1 or AP-3. The first mutant virus, C2849S, contains point mutations of 
the first cysteine residue of each zinc finger (C28 and C49 of NC) to serine, and 
consequently RNA binding is inhibited (Dorfman et al., 1993). The second, SVCΔP1 
has the packaging signal removed (Harrison et al., 1998). The third, A4, has a stem 
loop from the packaging signal removed, but also results in an in-frame AUG codon 
upstream of the Gag start codon. As a consequence, this N-terminally extended Gag is 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: The effect of AP knockdown on Gag processing of packaging mutants. 
Western blots of cell samples 24 and 40h post co-transfection with AP siRNAs and 
C2849S (A), ΔP1 (B) and A4 (C) proviruses detected with anti-Gag p24 antibody. 
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not myristoylated (Miele et al., 1996). These 3 proviruses were co-transfected with the 
siRNAs, and collected cell lysates were analysed by Western blot. The results are 
shown in Figure 41.  
These blots show that in the presence of AP-1 or -3 siRNA, despite still observing a 
decrease in processed p24, we did not see a corresponding increase in unprocessed p55 
when the AP siRNA lanes were compared with the no siRNA lanes in each experiment 
(Figure 41A-C). This would indicate that negative feedback inhibition of Gag synthesis 
is not increased when AP-1 and -3 are absent. These results suggest that the absence of 
AP-1 or AP-3 does not result in increased accumulation of Gag at its site of synthesis. 
This is not attributable to an increase in viral egress since particle release is severely 
impeded/absent in these mutants (Dorfman et al., 1993; Miele et al., 1996; Harrison et 
al., 1998), which was confirmed by Western blot of viral supernatants (data not shown). 
One observation, however, is that when the myristoylation signal is absent in A4, Gag 
levels were very low (detectable only at 40 hours) and the absence of AP-1 or -3 further 
depleted the amount of Gag present within the cell. This would indicate a role of the 
myristoylation domain in Gag stabilisation.  
5.2.4 Knockdown of AP-1 and -3 does not Increase 
Lysosomal/Proteasomal Gag Degradation  
Another possible explanation for the disappearance of Gag in the presence of AP-1 and 
-3 siRNAs is that Gag may be being degraded as a result of a failure to be released. 
This hypothesis was tested using proteasome and lysosome inhibitors MG132 and 
ammonium chloride (NH4Cl), respectively, on siRNA and HIV-1 co-transfected 
samples. The results are shown in Figure 42.  
As this Figure shows, inhibiting either the proteasome (Figure 42A) or lysosomes 
(Figure 42C) did not increase the amount of Gag present when AP-1 or -3 were 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Absence of AP-1 or -3 does not cause an increase of Gag degradation 
by lysosomes or the proteasome. A- Western blot of cellular Gag levels after 2 
hour MG132 treatment 40hours post siRNA and HIV-1 provirus co-transfection. 
B- Western blot of supernatant samples collected under the same conditions as A. 
C- Western blot of cellular Gag levels after 16 hour NH4Cl treatment 40 hours 
post siRNA and HIV-1 provirus co-transfection.  
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Figure 43: Absence of AP-1 or AP-3 does not cause Gag to aggregate in a way that 
cannot be recovered by passive lysis. Western blot of samples collected 24 and 40 
hours post HIV-1 provirus and AP or negative control siRNA co-transfection in 
HeLa cells. Samples were either collected using only a passive lysis buffer (non-
denatured) which excluded cellular debris, or using a passive lysis buffer followed 
by denaturation of the total sample including the cellular debris (denatured). Gag 
proteins were detected using an anti-Gag p24 antibody.   
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knocked down. Although controls were not used to ensure that either inhibitor were 
working, the supernatant samples collected from MG132 treated cells (Figure 42B) 
demonstrate that in the presence of MG132 (lane 1), viral release is decreased, as 
compared with the DMSO only control (lane 2). This would agree with the published 
results that the proteasome is required for viral release, and indicates that the inhibitor 
is exerting an effect and therefore is functioning (Schubert et al., 2000). Lysosomal and 
proteasomal degradation are, however, not the only forms of degradation found in the 
cell, so it still remains a possibility that Gag is degraded when it is unable to be 
released.  
Another hypothesis that could explain the disappearance of Gag is that when AP-1 or -
3 are knocked down, Gag may aggregate in such a way that it is not recovered by the 
method of lysis used, since only centrifuged supernatants are included, which excludes 
cellular debris such as membranes. Therefore, HeLa cells were co-transfected with the 
HIV-1 provirus and the AP siRNAs in duplicate; half of the samples were lysed as 
normal, whereas the other half were lysed followed by denaturation of the whole 
sample, including the cellular debris, using a “denaturing solution” (see chapter 2.2.9 
for more details). The results are shown in Figure 43. As can be seen, no significant 
increase in p55 occurred in the denatured samples when AP-1 and -3 were knocked 
down, as compared with the non-denatured samples. While more total protein was 
harvested in the denatured samples, the pattern of p55, p41 and p24 Gag products in 
siRNA-treated cells was similar between denatured and non-denatured samples. 
5.2.5 AP-5 Does Not Affect HIV-1 Assembly, Release or Localisation 
A fifth adaptor protein complex has recently been discovered (Hirst et al., 2011). 
Intriguingly, the UniProt entry of the mu5 subunit lists “Putative HIV-1 interacting 
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protein” as an alternative name. The only related reference given, however, is a 1998 
nucleotide entry of the partial mRNA sequence under the title “HIV-1 induced gene 
expression”, author Li. F. Although we were unable to find any further published data 
to back this up, we decided to investigate whether AP-5 may play a role in HIV-1 Gag 
trafficking. We used siRNA mediated knockdown of the mu5 subunit of AP-5 as 
recently described (Hirst et al., 2011). Although a commercial antibody was available 
for this protein, it was unable to detect anything in HeLa cells, even at high protein 
concentrations (data not shown). Therefore, to investigate whether the siRNA did 
indeed reduce AP-5 levels, RT-qPCR was carried out of AP-5µ mRNA. Figure 44A 
demonstrates cDNA copies from non-quantitative RT-PCR run on an agarose gel, 
showing that visually AP-5µ mRNA is reduced in the presence of the siRNA. Results 
from qPCR are demonstrated in Figure 44B, which shows that the siRNA significantly 
reduces AP-5µ mRNA levels by 70%.  
To investigate the effect of AP-5 on cellular and released Gag, 25 nM AP-5/-ve siRNA 
was co-transfected with HIV-1 provirus, and harvested cell and supernatant samples 
were analysed by Western blot. These are shown in Figures 45A and B. Visually, AP-5 
had no effect on either Gag assembly or release. Repeat experiments were analysed by 
ImageJ, which revealed AP-5 had no significant effect on cellular or released Gag (data 
not shown).  
Next, the effect of AP-5 knockdown on Gag localisation was investigated by confocal 
immunofluorescence microscopy. Figures 45 C, D and E show HIV-1 Gag in untreated, 
AP-5 treated, and –ve siRNA treated HeLa cells, respectively. Visually, no effect of 
AP-5 on Gag localisation could be observed. To quantify this, counts of Gag expressing 
cells were analysed for Gag localisation across repeat experiments. As Figure 45F 
shows, AP-5 knockdown did not significantly alter the localisation of HIV-1 Gag.  
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Figure 44: AP-5 knockdown by AP-5 siRNA. A shows an agarose gel of RT-PCR 
products. AP-5µ PCR product in the absence (lane 1) or presence (lane 2) of 24 
nM AP-5µ siRNA. GAPDH PCR product in the presence of 25 nm AP-5µ siRNA. 
B- Relative quantity of AP-5µ RNA in HeLa cells transfected with no siRNA, AP-
5µ siRNA, or negative control siRNA, as determined by RT-qPCR.   
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Figure 45: AP-5 does not affect HIV-1 Gag processing, release or localisation. A 
and B- Western blots of Gag from no siRNA, or AP-5/control siRNA and HIV-1 
proviral co-transfections 24 and 40 hours post-transfection; cell (A) and 
supernatant (B) samples, respectively. C, D and E show confocal 
immunofluorescence images of HIV-1 Gag in untreated (C), AP-5 siRNA (D) and 
control siRNA (E) transfected HeLa cells. Gag localisation from 2 repeat 
experiments was quantified, and the data is shown graphically in F.  
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5.3 Discussion 
This chapter aimed to investigate the roles of the APs in HIV-1 Gag trafficking and 
assembly further, and to investigate a potential role for the newly discovered fifth 
adaptor protein complex.  
Evidence reported recently (Liu et al., 2012) and in this chapter support the hypothesis 
that HIV-1 Gag can traffic via endosomes to the PM. This is because when AP-3 is 
knocked down, we see a concomitant decrease in PM Gag staining, and an increase in 
punctate intracellular staining (Figure 38). This is suggestive of Gag becoming stuck in 
endosomal compartments in the absence of AP-3. One could postulate that this is 
because AP-3 is required for Gag to subsequently traffic from these compartments to 
the PM, which could involve directing Gag from early endosomal compartments to late 
endosomal compartments, which would then be recycled to the PM. This would also 
support a decrease in viral assembly/Gag processing (Figure 39), since if Gag is not 
arriving at the correct assembly sites, particles are unlikely to be able to form 
efficiently. It is possible that AP-3 may assist in the trafficking of Gag to the PM in a 
similar manner to how AP-3 was found to assist in the trafficking of VSV-G 
(Nishimura et al., 2002). 
Although there remains some discrepancy over the exact trafficking pathway that AP-3 
facilitates, studies using naturally occurring AP-3 mutants have shown that AP-3 does 
indeed facilitate the trafficking of cargo toward the LE/lysosome, because lysosomes 
and lysosome-related organelles such as melanosomes are affected. It was found that 
the AP-3 pathway begins from EE-associated tubules (Peden et al., 2004). However, 
these studies have also shown that AP-3 is not absolutely required for this pathway to 
function, because AP-3 mutants are not embryonic lethal, and some lysosomal cargo 
Chapter 5                                                                              Results       
 
118 
 
can still reach lysosomes/lysosome-related organelles in the absence of AP-3. What is 
also interesting is that in an absence of AP-3, alongside a fraction of cargo still being 
able to reach melanosomes, there was a concomitant increase in endosomal-associated 
AP-1. This indicates that AP-1 and AP-3 may function in partially redundant pathways 
(Theos et al., 2005). Therefore, it is evident that compensatory pathways may be 
adopted in the absence of AP-3; this could explain why not all Gag becomes punctate 
when AP-3 is knocked down, and why AP-3 knockdown does not entirely abolish Gag 
release. While the results gathered in this chapter with respect to AP-3 in Gag 
trafficking contradict those gathered by Dong et al. (2005), who found that AP-3 
knockdown caused an increase in diffuse (cytosolic) Gag in the same cell line (HeLa), 
our results do make sense in that when AP-3 is knocked down, Gag accumulates 
upstream of AP-3 function, perhaps in early endosomes. This could explain the 
punctate appearance of Gag observed. The harsher knockdown of AP-3 utilised by 
Dong et al. (2005) may explain differences with our results.  
AP-1 knockdown presented an interesting Gag phenotype. Although PM staining was 
decreased significantly, unlike when AP-3 was knocked down, an increase in punctate 
Gag was not observed (Figure 38). This would infer the possibility that AP-1 and -3 
function in different stages of Gag trafficking, which would make sense since they 
function in different cellular pathways, although there is some overlap. We could 
envisage an earlier role for AP-1 in driving newly synthesised Gag into endosomal 
compartments, likely from the TGN, followed by the delivery of Gag from these 
compartments to the PM by AP-3 in an indirect manner. This is because the human 
ubiquitin ligase POSH, which functions at the TGN, was found to positively affect Gag 
release (Alroy et al., 2005); therefore it may be that after Gag ubiquitination at the 
TGN, Gag is directed to endosomes by AP-1. It is also possible, however, that in 
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instances whereby endosomal trafficking is bypassed, AP-1 delivers Gag straight to the 
PM and assists particle assembly here. This would explain the lack of PM staining 
observed, but also the very diffuse phenotype. 
Interestingly, it was discovered that AP-2 has no effect on Gag localisation (Figure 38). 
AP-2 is thought to assist in the clathrin-mediated endocytosis of plasma membrane 
associated particles, and its knockdown results in an increase in viral particle release. 
But our data suggest that AP-2 plays no role in intracellular Gag trafficking or particle 
assembly. 
Data gathered in this chapter from Western blot of cellular protein samples revealed 
that when AP-1 and -3 were reduced, less processed p24 Gag was also present (Figure 
39). This would infer that these APs facilitate particle assembly, since you would not 
expect to see processed Gag until particle assembly begins. This is because GagPol 
multimerisation at assembly sites is a pre requisite for Protease activity. It could be 
assumed that the decrease in p24 is merely a result of a perturbation of Gag trafficking, 
whereby particles do not reach assembly sites and therefore cannot begin to assemble. 
However, if this were the case, we would expect to see a corresponding increase in 
unprocessed p55.   
Three hypotheses were postulated as an explanation for Gag disappearance in the 
absence of AP-1/-3; Gag accumulation results in an increase in Gag translation 
inhibition, Gag is degraded by the proteasome/lysosomes, Gag may aggregate in such a 
way that cannot be recovered by passive lysis.  
To investigate the first hypothesis, 3 mutants were used which are unable to package 
RNA, and therefore are unable to inhibit Gag translation by obstructing ribosomal 
scanning. It was found that in the presence of AP-1/3 siRNAs, unprocessed Gag was 
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not increased, despite still seeing a reduction in processed Gag (Figure 41). Therefore, 
it is apparent that when Gag is unable to traffic to assembly sites in the absence of AP-
1/3, Gag does not likely accumulate at translation sites and therefore switch off its own 
translation. A possible explanation for this is that Gag may initially accumulate when it 
cannot be trafficked, but that it is rapidly degraded by the cell, and therefore does not 
build up around translation sites. Therefore, no effect will be seen.  
The second hypothesis to be tested was that Gag may be being degraded when it cannot 
be assembled and processed into viral particles. This would support previous 
suggestions that clathrin may stabilise Gag processing products (Zhang et al., 2011); in 
the absence of AP-1/3 we could propose that clathrin is unable to be recruited to 
assembly sites and therefore assist in the formation of viral particles. Two potential 
degradation pathways were tested; lysosomes and proteasomes. Some conflicting 
results exist for the role of the proteasome in the viral life cycle; it has been suggested 
that both lysosomes and the proteasome are capable of destroying HIV and therefore 
decrease viral infectivity (Wei et al., 2005), however another group suggest that the 
proteasome is required for processing, release and maturation (Schubert et al., 2000).   
Results gathered in this chapter, although supporting a role for the proteasome in viral 
release, did not suggest that degradation by these pathways is increased when particles 
cannot assemble (Figure 42). This was particularly surprising since this seemed the 
most logical explanation for the disappearance of Gag. It must be pointed out, however, 
that MG132 (and indeed all proteasome inhibitors) is only functional for up to 2 hours, 
before cellular compensatory mechanisms prevent its efficacy. Therefore, it is entirely 
possible that the Gag had already been degraded prior to MG132 addition, meaning we 
saw no effect of the inhibitor.  This is may not be the most appropriate assay to 
investigate proteasomal degradation, and so it remains possible that proteasomal 
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degradation of HIV-1 may indeed increase upon cellular accumulation when viral 
release is prevented by AP knockdown. A pulse chase assay could be considered in 
future experiments, as this is a more effective way of investigating protein stability, 
rather than only looking at steady-state levels.  
To investigate whether the disappearance of Gag could be attributed to Gag aggregates 
that are not recovered by the method of lysis used, cellular debris including membranes 
was included and denatured in samples which were then analysed by Western blot. 
Unfortunately, since no increase in Gag was seen in these samples in the presence of 
AP-1 or -3 siRNAs when compared to non-denatured controls (Figure 43), we can rule 
out the likelihood of this hypothesis.  
Some evidence gathered by other groups which may explain the disappearance of Gag 
relate to the role of clathrin in the HIV life cycle. Zhang et al. (2011) suggested that 
clathrin is responsible for regulating the activity of protease, or alternatively stabilises 
the products of Gag proteolysis during particle morphogenesis. In the absence of AP-
1/-3, we would expect the recruitment of clathrin to be compromised. Therefore, this 
could explain why we see less processed Gag, and why we do not see a corresponding 
increase in p55 when these proteins are knocked down. How precisely Gag is degraded, 
or rendered undetectable, however, remains unsolved.  
A reasonable model that can be drawn from our data and that of others is that the APs 
assist particle assembly, likely by first directing Gag towards appropriate membranes, 
which may involve an endosomal intermediate, and then directly facilitating particle 
assembly. This may be by binding to and facilitating clathrin formation around 
membrane-bound Gag and promoting particle formation via recruitment of further 
proteins required for clathrin scaffold formation and disassembly, such as epsins. 
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AP-5 has been recently characterised as an adaptor protein complex associating with 
late endosomes; however, it does not associate with clathrin. Although AP-5µ had been 
suggested to have role in the HIV-1 life cycle, no evidence for this is published, and we 
found no influence of AP-5 on HIV-1 trafficking (Figure 45). This would suggest that 
HIV-1 does not require late endosomes in its trafficking pathway. Since AP-5 does also 
not associate with clathrin, it makes sense that reducing AP-5 does not affect Gag 
assembly, since we can assume that this will not affect clathrin function.  
5.4 Future Work 
Although the most likely explanation for the disappearance of Gag in the absence of 
AP-1/-3 seems degradation, this could not be ascertained. Limitations imposed by the 
short window of efficacy of MG132 may be the reason that we did not see an increase 
in Gag; therefore a pulse chase assay whereby protein synthesis and turnover in the 
presence/absence of MG132 would be a more appropriate assay for future experiments. 
The use of proteasome inhibitors, however, is not the only method which can be 
applied to inhibit proteasomal degradation. Therefore, an appropriate way to take this 
section further would be to inhibit ubiquitination, for example via the use of ubiquitin 
ligase inhibitors such as SMER 3, which inhibits E3 ubiquitin ligase.  
Another interesting set of experiments which could follow on from this data would be 
to use a clathrin siRNA. Gag phenotypes across AP and clathrin knockdown could be 
compared, which may give further insight into whether it is likely clathrin 
destabilisation which causes both a disappearance of unprocessed and processed Gag. 
However knockdown of clathrin may have a severe effect on cell function.  
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CHAPTER 6: INVESTIGATING HIV-2 
TRAFFICKING AND THE ROLE OF THE MATRIX 
DOMAIN IN HIV-1 AND HIV-2 TRAFFICKING 
6.1 Introduction 
As mentioned in Chapter 1, multiple interspecies introductions from simian species 
gave rise to two genetically distinct HIV viruses; HIV-1 and HIV-2. Genomic analysis 
deduced that HIV-2 is closely related to the simian immunodeficiency virus (SIV) of 
sooty mangabeys (SIVsm), inferring this is the species responsible for the introduction 
of HIV-2 into the human population (Lemey et al., 2003). Although the HIV-1 groups 
are distributed globally, albeit different clades dominate in different geographical 
regions, HIV-2 is almost exclusively found in Western Africa, although infections have 
been described in Europe and America (Campbell-Yesufu and Gandhi, 2011). HIV-2 is 
categorised by either epidemic subtypes (A and B) or non-epidemic subtypes (C-H) 
(Lemey et al., 2003). All HIV-1 subtypes and HIV-2 A and B have established human-
human transmission chains (Wertheim and Worobey, 2009). The non-epidemic 
subtypes have only been isolated from single individuals, and are “dead-end” viruses; 
they are weakly pathogenic, replicate poorly and are not transmissible to other humans. 
They are also exclusively found within the range of the sooty mangabey, for example 
HIV-2 subtype F was found in one individual among over 9,000 living in the same area 
of Sierra Leone, where SIVsm is found naturally within the sooty mangabey population 
(Marx et al., 2001).  
Although these two viruses are closely related, HIV-2 is less pathogenic than HIV-1. 
Heterosexual transmission is less efficient in HIV-2, and vertical transmission rarely 
occurs. HIV-2 infected individuals progress to AIDS at a slower rate than those 
infected with HIV-1; around 95% of HIV-2 infected individuals are classified as long-
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term non-progressors 8 years after infection. It was initially assumed that this may be 
related to proviral levels, which were assumed to be lower in individuals infected with 
HIV-2; interestingly, this was found not to be the case, and proviral levels are in fact 
similar in both HIV-1 and HIV-2 infected individuals. It was discovered, however, that 
the viral load remains relatively stable even years after initial infection, which is 
consistent with a lack of disease progression, and similar to the trends seen in long-term 
nonprogressors (Popper et al., 1999; de Silva et al., 2013). 
Although similar proviral levels have been observed in HIV-1 and HIV-2 infected 
patients, it was discovered that plasma viraemia, or plasma RNA, levels were much 
lower in HIV-2 patients (Simon et al., 1993). Furthermore, in a study carried out on 
HIV-2 infected patients in Portugal, it was found that plasma viral load also correlated 
with CD4
+
 cell levels (Soriano et al., 2000). It was also discovered that plasma viral 
load levels were correlated with disease progression, whether the patient was infected 
with either HIV-1 or HIV-2 (Gottleib et al., 2002). In a study investigating both HIV-1 
and HIV-2 infected AIDS patients in a West African clinic, it was found that HIV-2 
AIDS patients had higher CD4 levels, even at the time of death, suggesting that a loss 
of CD4 cells does not provide a complete story for the immune pathology in infected 
individuals (Martinez-Steele et al., 2007; Nyamweya et al., 2013).  
Therefore, a scenario has emerged whereby there are two distinct groups of HIV-2 
infected individuals; the first is individuals with low plasma viral load, who have 
mortality rates similar to that of the background rate of the population. This is 
highlighted by a cohort study of HIV-2 infected individuals in Caio, Guinea Bissau, 
where low and stable plasma viraemia levels were present in the population, and 37% 
had less than 100 RNA copies per ml, with a concomitant high percentage of CD4
+
 
cells. Infected individuals also had the same mortality rate as the uninfected control 
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group (Berry et al., 2002; Nyamweya et al., 2013). A similar study found that HIV-2 
infected patients with undetectable viral load also had normal survival rate, indicating 
this could be a predictor for survival (Schim van der Loeff et al., 2012). The second 
group contains HIV-2 infected individuals who have a high viral load (>10,000 copies 
per ml), and consequently progress to AIDS at a similar rate to HIV-1 infected 
individuals (Martinez-Steele et al., 2007).  
Several possible explanations have emerged for the lower levels of plasma viraemia in 
HIV-2 patients, including tighter transcriptional control and a weaker ability to evade 
immune responses. For example, a study found that HIV-1 and HIV-2 had similar 
levels of integration, but that HIV-2 produced lower amounts of mRNA, which is 
consistent with lower plasma viraemia levels observed (MacNeil et al., 2007). 
Differences in the LTRs between HIV-1 and HIV-2 have also been observed, which 
could contribute to lower levels of mRNA expression (Guyader et al., 1987; de Silva et 
al., 2008). With regards to the immune system. it has been suggested that HIV-2 may 
be more susceptible to broadly neutralising antibodies than HIV-1, perhaps due to a 
more open V3 domain in the envelope (Shi et al., 2005). It was also discovered that 
HIV-2 is controlled by the restriction factor tripartite motif protein isoform 5 alpha 
(TRIM5α) to a greater extent than HIV-1 (Ylinen et al., 2005).  
Since they are closely related, HIV-1 and HIV-2 have a similar genome composition 
and organisation, although differences can be observed. See Figure 46 overleaf for a 
schematic of the HIV-1 and -2 genomes. 
 
 
 
Chapter 6                                                                              Results       
 
126 
 
 
 
 
 
 
 
 
Figure 46: HIV-1 and HIV-2 genome organisation. Note the presence of vpu in 
HIV-1, and vpx in HIV-2.  
(Source: adapted from http://www.mcld.co.uk/hiv/?q=HIV%20genome, accessed 
June 2013)  
As this figure shows, HIV-2 does not possess vpu, but instead has a vpx gene. The Vpx 
protein encoded by this gene was found to antagonise the restriction factor SAMHD1 
by enhancing its proteasomal degradation. SAMHD1 is expressed in myeloid and 
dendritic cells; HIV-1 is unable to counteract SAMHD1, rendering HIV-1 replication in 
dendritic cells severely impaired (Laguette et al., 2011). SAMHD1 was found to 
deplete the pool of dNTPs to levels lower than those required for DNA synthesis during 
reverse transcription (Laguette et al., 2011).  
Like HIV-1, HIV-2 Gag is synthesised as a polyprotein which is later cleaved during 
maturation. HIV-2 Gag is, however, 57 kDa, as oppose to 55 kDa in HIV-1 (Luo et al., 
1990), but is still cleaved into the same constituent mature structural proteins of MA, 
CA, NC and p6. Despite their similarity, only ~60% amino acid sequence identity has 
been found between HIV-1 and -2 Gag, and only 40% genome nucleotide identity 
(Dilley et al., 2011). It has been established that HIV-2 is more closely related to the 
simian immunodeficiency viruses than HIV-1; gag, pol and env proteins of SIV and 
HIV-2 were found to be antigenically cross reactive, whereas cross reactivity to the 
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corresponding HIV-1 proteins are restricted to only certain antigens (Guyader et al., 
1987).  
As mentioned in the previous chapter; the current theories surrounding HIV Gag 
trafficking are incomplete. More specifically, it is assumed that HIV-1 and -2 Gag 
follow similar trafficking pathways, although this has never been established.  
Early electron microscope images of HIV-1 found that assembly differs in two natural 
host cell types; T cells and macrophages. It was found that in the former, HIV-1 is 
found predominantly budding from the plasma membrane (PM), where Gag recruits 
ESCRT proteins away from multivesicular bodies (MVBs), whereas in the latter, 
abundant ESCRT components at MVBs can permit budding within these intracellular 
compartments, or MVB-like organelles rich in tetraspanins such as CD81 that are 
continuous with the PM (Raposo et al., 2002; Deneka et al., 2007; Welsch et al., 2007). 
Amino acid substitutions in the basic region of MA were found to retarget Gag from 
the PM to MVBs in HeLa cells and COS cells, but did not affect the localisation to 
MVBs in macrophages. These MA mutations were also found to lead to less efficient 
particle release from HeLa cells, but not from macrophages; together these results were 
suggestive of the presence of an alternative pathway whereby Gag was directed to 
MVBs. Further evidence also ruled out the possibility that the presence of Gag in 
MVBs was merely a result of internalisation of released virions (Ono and Freed, 2004).  
The purpose of this chapter is to further investigate the role of the MA domain in Gag 
trafficking and localisation, since it is this region which was found to both contain the 
AP binding sites, and also determine preference for intracellular budding sites of HIV-
2. Does HIV-2 follow the same trafficking pathway as HIV-1? Are the same 
interactions with the APs present in HIV-2 Gag? Does the MA region of Gag determine 
the localisation of both HIV-1 and HIV-2? 
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6.2 Results 
6.2.1 Adaptor Proteins 1 and 3 Affect HIV-2 Particle Assembly and 
Release 
Throughout this chapter, when siRNAs have been used with proviral constructs, they 
have been co-transfected at the same time. To investigate whether HIV-2 interacts with 
the APs in the same manner as HIV-1, HeLa cells were co-transfected with the AP 
siRNAs and a HIV-2 proviral construct (SVRΔNB); this provirus is once again env 
deleted. Cell lysates were harvested at both 24 and 40 hours post transfection, and 
analysed by Western blot with anti-SIV p27 antibody (which recognises HIV-2 CA). 
Viral supernatants were not harvested for this provirus since in the absence of Env, 
HIV-2 particle release is inefficient. Therefore, wild-type (WT) HIV-2 (SVR) was also 
utilised to analyse viral supernatant samples; cellular samples were also taken for 
comparative measures. Results are shown in Figure 47.  
As can be seen, in a similar manner to HIV-1, at 24 hours, little effect was seen on both 
cellular HIV-2 Gag samples, except when AP-1 and -3 siRNAs were used together. At 
40 hours, however, a slight decrease in p57 (full-length unprocessed HIV-2 Gag) and 
p27 (fully processed CA) could be seen in the presence of AP-1 siRNA. When AP-3 
siRNA, or AP-1 and -3 siRNAs together were used, p57 was reduced to a greater extent 
than in the presence of AP-1 siRNA. AP-2 siRNA had no observed effect on HIV-2 
cell samples, as with HIV-1. The third panel demonstrates that the effect was not due to 
a decrease in total protein, or errors in loading, since the endogenous protein γ-tubulin 
remained even.  
Interestingly, viral supernatant samples presented a slightly different story to that of 
HIV-1. As the bottom panel in Figure 47 clearly shows, AP-2 knockdown did not cause 
an increase in HIV-2 particle release. AP-1 siRNA had a slight effect on particle 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: The adaptor proteins affect HIV-2 Gag processing and release. 
Western blots of cell lysate (top and second panel) and viral supernatant (bottom 
panel) samples using an anti-SIV p27 antibody, harvested following 24 and 40 
hour transfection of HeLa cells with HIV-2 provirus and AP or control. env 
deleted HIV-2 (SVRΔNB) was used for the top panel, WT HIV-2 (SVR) was used 
for second panel and viral supernatant (bottom) samples. The third panel shows 
SVRΔNB cell lysate samples detected with an anti-γ-tubulin antibody.  
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release, causing a modest decrease in p27. AP-3 siRNA, or AP-1 and -3 in 
combination, caused a larger decrease in particle release.  
In order to quantify this data, densitometry was carried out using ImageJ on three 
repeat SVRΔNB experiments only, and the results are shown in Figure 48. Figures 48A 
and B show data from 24 and 40 hour cell samples, respectively. Similar to HIV-1, the 
only significant effect seen at 24 hours was when AP-1 and -3 were used together, 
however, it was unprocessed Gag (p57) which was significantly reduced, rather than 
processed Gag (p27), which was the case for HIV-1. At 40 hours, AP-1 siRNA 
significantly reduced both p57 and p27 by 25% (p<0.05). AP-3 siRNA treatment, 
however, had a larger effect than AP-1, and significantly reduced p57 and p27 by 50% 
and 35%, respectively (p<0.005). When AP-1 and -3 siRNAs were used in 
combination, an even bigger effect was seen on p57 and p27; a 68% and 46% 
reduction, respectively (p<0.001). These results would indicate that although both AP-1 
and AP-3 play a role in the HIV-2 life cycle, that AP-3 likely plays a more important 
role, perhaps in facilitating particle assembly. Alternatively, it may mean that AP-1 and 
AP-3 play roles at different stages of the HIV-2 life cycle. 
Figure 48C shows densitometry results from 40 hour viral supernatant samples. 
Although particles could be sometimes observed at 24 hours, bands were inadequate to 
analyse and were therefore excluded. This Figure shows a similar story to that of the 
cell samples; AP-1 had a small but significant impact in facilitating particle release, 
whereas AP-3 plays a larger role. AP-1 siRNA treatment resulted in a modest (25%) 
reduction in p27 release (p<0.05). Although AP-2 siRNA treatment caused a 22% 
reduction in particle release, this was found to not be statistically significant (p>0.05). 
AP-3 siRNA treatment resulted in a much larger reduction in particle release; 77% less 
than when no siRNA was used (p<0.005). Again, when AP-1 and -3 siRNAs were 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: AP-1 and -3 assist HIV-2 particle processing and release. Densitometry 
was performed on bands from western blots using ImageJ, to calculate Gag levels 
obtained from independent repeat experiments. A and B- Gag p57 and p27 levels 
from 24 and 40 hour post-transfection cell lysate samples, respectively. C- p27 
levels from 40 hour post-transfection viral supernatant samples. Results shown 
are percentages of Gag expression with no siRNA treatment. (Key: *=p<0.05, 
**=p<0.005, ***=p<0.001).  
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added together, a larger effect was seen than when the siRNAs were used alone; an 
81% decrease in particle release was observed (p<0.001).  
Together these results suggest that although AP-1 clearly plays a role in the HIV-2 life 
cycle, AP-3 likely plays a more essential role. Since AP-3 functions along the 
endosomal pathway, this may indicate that HIV-2 traffics via endosomes to reach 
intracellular assembly or release sites.  
6.2.2 Absence of AP-1 or -3 does not Increase Lysosomal/Proteasomal 
HIV-2 Degradation 
Since it is evident that knockdown of AP-1, and particularly AP-3, caused a decrease in 
total HIV-2 Gag, one possible explanation for this seemed degradation. Although HIV-
1 was found not to be degraded by lysosomes/proteasomes when AP-1/-3 were absent, 
the effect observed on HIV-1 was less dramatic than with HIV-2. Therefore, the same 
protocol as before was followed whereby the lysomotropic NH4Cl or the proteasome 
inhibitor MG132 were added to AP siRNA/HIV-2 co-transfected HeLa cells for either 
16 or 2 hours, respectively. Cell samples were harvested at 40 hours and were analysed 
by Western blot. The results are shown in Figures 49 A and B. 
As both of these Figures demonstrate, no significant increase in HIV-2 Gag steady state 
levels was observed in the presence of these inhibitors, when AP-1/-3 were knocked 
down. This would again indicate that the reduction in Gag observed is not mediated by 
these degradation pathways. However, no controls were performed to confirm these 
treatments were effective under the conditions used.  
Since MG132 was only used for 2 hours, the experimental design of checking steady 
state levels is flawed. To get around this, a pulse chase immunoprecipitation was 
carried out on AP-1/-3 siRNA and HIV-2 provirus co-transfected HeLa cells. MG132 
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was added to the cells during the methionine starvation period prior to the pulse, during 
a 40 minute pulse with 
35
S-methionine, and again during a 2 hour chase with cold 
methionine. HIV-2 Gag was then immunoprecipitated from the cell lysates, run on 
SDS-PAGE and exposed to a film to visualise the fate of HIV-2 Gag synthesised 
during the pulse period. Figure 49C shows the results of the pulse chase.  
This Figure demonstrated that the proteasome may degrade HIV-2 Gag, as there was 
more HIV-2 Gag present in lanes where MG132 was added, as compared with the 
DMSO control. As is also evident, the proteasome is essential for Gag proteolytic 
processing, as lanes containing MG132 showed much less p27 than the DMSO only 
lanes. This supports the current literature on the roles of the proteasome on the HIV-2 
life cycle (Schubert et al., 2000). When pulse and chase lanes are compared, it is 
evident that the signal in all of the chase lanes is weaker than in the pulse lanes; this 
would infer that the inhibitor only has a weakly stabilising effect. What was also once 
again clear was that in the presence of AP-1/-3 siRNAs, the level of HIV-2 Gag was 
still less than in the untreated or negative control siRNA treated cells. Therefore, it is 
currently not clear as to what happens to Gag when AP-1 and AP-3 levels are reduced. 
A time course with more chase points would likely give more clear-cut results.   
In chapter 5.2.4, it was suggested that in the presence of AP-1 or -3 siRNAs, HIV-1 
Gag may form aggregates that are not recovered by passive lysis, for example because 
they are collected as cellular debris which is excluded from samples used for Western 
blot analysis. To investigate this in HIV-2 transfected cells, the same protocol was 
followed as for HIV-1 but using the HIV-2 provirus, but once again no more Gag was 
recovered in samples which included denatured cellular debris (data not shown).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: HIV-2 Gag processing in the presence of lysosome and proteasome 
inhibitors. Western blots of cellular HIV-2 Gag levels in HeLa cells co-transfected 
with HIV-2 provirus and the AP or negative control siRNAs, after 16 hour 
treatment with a lysosome inhibitor (NH4Cl) (A) or after 2 hour treatment with 
the proteasome inhibitor MG132 (B), harvested at 40 hours, using an anti-SIV p27 
antibody. C- HIV-2 Gag levels during a pulse chase assay in transfected HeLa 
cells, whereby MG132/DMSO control was added during the pulse, and again 
during the chase. IP was carried out using anti-SIV p27.  
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6.2.3 The Effect of AP-1 and -3 on HIV-2 Gag Localisation 
As mentioned in chapter 5, HIV-1 Gag displays 3 typical cellular distributions; diffuse, 
punctate intracellular, and plasma membrane (PM), with diffuse being the most 
abundant. To investigate whether HIV-2 Gag follows the same pattern, envelope 
deleted HIV-2 (SVRΔNB) transfected HeLa cells were stained with anti-SIV p27 
antibody and viewed under the confocal microscope. Figures 50A and B demonstrate 
the 2 typical Gag localisations found in HIV-2 transfected cells. As can be seen, HIV-2 
Gag was either very punctate or localised strongly to the PM. HIV-2 Gag was never 
found to be diffuse, unlike HIV-1. Gag localisation was recorded in cells across 3 
repeat experiments, and the average localisation is shown graphically, shown in Figure 
50C. As can be seen, HIV-2 Gag had a very different localisation to that of HIV-1; 
instead of diffuse being the predominant pattern observed, HIV-2 Gag was mainly 
punctate (74%). HIV-1 and -2 have fairly similar percentages of PM Gag, although 
HIV-2 has a slightly higher percentage (24% vs. 16%).  
This very punctate distribution would support the results previously obtained by 
Western blot, which indicate a role of AP-3 in the HIV-2 life cycle. Since we would 
expect that if Gag was accumulating in endosomes, or endosomal structures, we would 
see aggregates of Gag, therefore explaining the punctate staining.  
To investigate whether AP knockdown affects HIV-2 localisation, siRNA and HIV-2 
provirus co-transfected HeLa cells were investigated by confocal immunofluorescence 
microscopy as before. The results are shown in Figure 51.  
AP-2 siRNA had no visual effect on HIV-2 Gag. This means that the punctate 
appearance of Gag is likely not a result of clathrin-mediated endocytosis budding or 
membrane-linked viral particles, which would be assisted by AP-2. Some PM staining 
010
20
30
40
50
60
70
80
90
HIV-1 HIV2
C
el
ls
 D
is
p
la
y
in
g
 G
a
g
 (
%
) 
Provirus 
PM
Punctate
Diffuse
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: HIV-2 Gag displays a different intracellular localisation to HIV-1. A 
and B- Confocal immunofluorescence images of 24 hour HIV-2 provirus 
transfected HeLa cells, demonstrating the TWO typical staining patterns observed 
by using an anti-SIV p27 antibody (red). These are punctate intracellular (A) and 
plasma membrane (PM) (B). Blue stain = DAPI. C- Average percentages of Gag 
distributions in HIV-1 and HIV-2 provirus transfected HeLa cells taken from cell 
counts from 3 independent experiments.   
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Figure 51: AP-1 and -3 affect HIV-2 Gag localisation. A-C- Confocal 
immunofluorescence images of 24 hour anti-SIV p27 (red) staining in HIV-2 co-
transfected HeLa cells with either AP-1, -2 or -3 siRNAs, respectively. Blue stain= 
DAPI. Experiments were quantified by counting Gag localisation in cells from 3 
independent experiments (D). (Key *=p<0.05, **=p<0.01).  
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could be observed in the presence of AP-1 siRNA, however, when AP-3 siRNA was 
used, PM Gag was almost totally abolished. No diffusely stained Gag appeared in any 
condition. When these results were quantified by counting Gag localisation in cells 
across repeat 3 experiments (shown in 51D), a similar story emerged. AP-1 siRNA had 
a significant effect on reducing PM HIV-2 Gag by approximately 50% (p<0.05), 
whereas AP-3 had a larger effect, reducing PM Gag by around 90% (p<0.005). Since 
diffuse Gag was not observed in HIV-2 transfected cells, a decrease in PM staining 
resulted in a significant increase in punctate intracellular staining also. AP-2 was found 
to have no significant effect, as with HIV-1, indicating that the punctate appearance of 
HIV-2 Gag is not due to clathrin-mediated endocytosis of assembled particles at the 
PM. 
The likely explanation for the increase in punctate HIV-2 Gag in the presence of AP-3 
siRNA is that, if HIV-2 also uses an endosomal trafficking pathway to reach assembly 
sites, it stands to reason that AP-3, like in the case of HIV-1, assists in the transport of 
Gag through endosomal compartments, thereby indirectly facilitating PM trafficking of 
Gag. Therefore, knocking down AP-3 causes an accumulation in endosomal 
compartments upstream of the AP-3 pathway.  
6.2.4 AP-5 Affects HIV-2 Assembly, Release and Localisation 
As mentioned in the introductory chapter, the newly discovered fifth adaptor protein 
complex (AP-5) is the only AP to date known to associate with late 
endosomes/lysosomes, although the precise location and function of AP-5 is currently 
unclear; however it is likely important in late endosome dynamics (Hirst et al., 2011; 
Hirst et al., 2013). Although results gathered in the previous chapter found no role for 
AP-5 in HIV-1 assembly or localisation, since it seems that HIV-2 may adopt a 
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different trafficking route to HIV-1, it seemed plausible that this protein may affect 
HIV-2. This seemed especially likely due to the strong involvement of AP-3 found in 
the HIV-2 life cycle in this chapter.  
The first experiment carried out with AP-5 was to investigate the effects on cellular 
Gag. AP-5 siRNA was co-transfected with the HIV-2 SVRΔNB provirus, and samples 
were harvested at 24 and 40 hours. Equal amounts of protein were run on an SDS-
PAGE gel, and Western blotted using anti-SIV p27 antibody. The results are shown in 
Figure 52.  
As can be seen in Figure 52A, at both 24 and 40 hours, a decrease in p57 and p27 was 
observed. Again, endogenous protein levels were unaffected. To quantify this, 
densitometry was carried out across 3 repeat experiments, and the results are shown in 
Figures 52B and C. As can be seen, a significant decrease (68%) in p57 was observed 
at 24 hours in the presence of AP-5 siRNA (p<0.05), however p27 was not significantly 
reduced. At 40 hours, both p57 and p27 were significantly reduced; 42% and 38%, 
respectively. Although the negative control reduced p57 by 25% at 40 hours, this was 
found not to be significant (p>0.05), suggesting that although a small non-specific 
effect of using 25 nM siRNA may be exerted, the effect seen with AP-5 is specific. 
This would possibly indicate a role for AP-5 in HIV-2 assembly, and further supports 
the hypothesis that HIV-2 traffics at least via endosomes.  
To investigate the role of AP-5 on particle release, WT HIV-2 was used as before, and 
viral supernatant samples were again analysed by Western blot. The results are shown 
in Figure 53. As can be seen in Figure 53A, AP-5 siRNA qualitatively reduced HIV-2 
Gag release, further indicating a role of AP-5 in the HIV-2 life cycle. Cell samples 
obtained from WT HIV-2 also displayed the same pattern to that of env deleted HIV-2. 
Densitometry (Figure 53B) indicated that an absence of AP-5 caused decrease in Gag 
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Figure 52: The effect of AP-5 on HIV-2 Gag processing. A- Western blot of cell 
samples from 24 and 40 hour HIV-2 provirus and AP-5 siRNA co-transfections, 
using an anti-SIV p27 antibody. B and C- Quantification of cellular Gag levels 
from 2 independent experiments using densitometry at 24 (B) and 40 hours (C). 
Values are expressed as percentages of Gag in siRNA untreated samples. (Key: 
*p<0.05, **p<0.01).  
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Figure 53: The effect of AP-5 on HIV-2 release. A- Western blot viral 
supernatants taken from untreated, AP-5 or negative control siRNA treated HeLa 
cells 24 and 40 h post-transfection. B- HIV-2 Gag (p27) release was quantified 
from 3 repeat experiments using ImageJ. (Key: *=p<0.05, **p<0.01).  
 
 
 
 
 
 
 
 
Figure 54: AP-5 knockdown causes a slight reduction in Gag expressing cells. 
HeLa cells were transfected with HIV-2 provirus, with or without the AP-5 or 
negative control siRNA. Confocal immunofluorescence microscopy was used to 
identify Gag expressing cells using an anti-SIV p27 antibody. This was quantified 
from 2 repeat experiments, and represented graphically. Statistically significant 
differences from untreated cells are highlighted by an asterisk (p<0.05).  
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release at both 24 and 40 hours, although it is difficult to ascertain quality data from 
smeared bands.  
Since AP-5 knockdown seemed to be reducing total Gag at both 24 and 40 hours, it 
seemed plausible that the number of HIV-2 Gag expressing cells would also be 
reduced. To investigate this, AP-5 siRNA and HIV-2 provirus co-transfected cells were 
investigated by confocal microscopy. The results are shown graphically in Figure 54. 
As can be seen, the presence of AP-5 siRNA caused a significant (40%), reduction in 
HIV-2 Gag expressing cells (p<0.05). The negative control siRNA also reduced Gag 
expressing cells by 12%, but this was found not to be significant (p>0.05). This again 
indicates that although there is some non-specific effect of using siRNAs at this 
concentration, AP-5 siRNA also exerts a specific effect on HIV-2 Gag.  
The final investigation of the role of AP-5 on the HIV-2 life cycle was to investigate 
whether it affected HIV-2 Gag localisation. The same protocol was followed as before 
for the other siRNAs, and cells were viewed under the confocal microscope. Results are 
shown in Figure 55.  
Figures 55A-C demonstrate typical Gag staining observed with no siRNA, AP-5 
siRNA, and the negative control siRNA, respectively. As can be seen, in the presence 
of AP-5 siRNA, some slightly more diffusely stained cells appeared, as indicated by the 
white arrow, in comparison to the usual appearance of HIV-2 Gag (Figure 55A). To 
quantify whether this was significant, counts of Gag localisation in cells across repeat 
experiments were plotted, and the results are shown in Figure 55D. As can be seen, 
when AP-5 was knocked down, there was an increase in cells displaying a diffuse Gag 
stain from 0% to 7%. This was, however, not found to be significant (p>0.05). What 
was found, however, was that AP-5 siRNA caused a significant decrease the percentage 
of PM localised Gag (from 22% to 7%) (p<0.05), with a concomitant significant 9% 
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Figure 55: The effect of AP-5 on HIV-2 localisation. A-C- Confocal 
immunofluorescence images of HIV-2 Gag in HeLa cells using an anti-SIV p27 
antibody (red), in untreated, AP-5 siRNA treated and negative control siRNA 
treated cells, respectively. A diffusely stained cell is indicated by the white arrow. 
Blue stain= DAPI. Gag localisation was quantified across 2 repeat experiments, 
and the results are shown in D. Statistically significant differences from untreated 
cells are highlighted by an asterisk. (Key *=p<0.05, **p<0.005).  
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increase in the percentage of punctate Gag (p<0.005). This would again suggest a role 
for AP-5 in the trafficking and localisation of HIV-2 Gag, unlike HIV-1 where it was 
found to play no role. 
Together these results, alongside the role found for AP-3, indicate that HIV-2 Gag 
transport likely involves intracellular compartments as a route to release sites. Whether 
this is transient, or Gag actually begins to assemble within these intracellular organelles 
is unclear 
6.2.5 The Effect of the Adaptor Proteins on MA2 Assembly and 
Release 
In order to investigate the role of the matrix (MA) domain on HIV trafficking, 2 
chimeric viruses were used; MA1 and MA2. MA1 has the HIV-2 pSVRΔNB backbone, 
but with HIV-2 MA replaced by HIV-1 MA. MA2 has the HIV-1 pSVC21ΔBgl 
(HxB2) backbone, but with HIV-1 MA replaced with HIV-2 MA (E.C. Anderson and 
M. Marongiu, unpublished results). The MA domain of HIV-1 has been reported to 
contain the AP binding sites (Dong et al., 2005; Batonick et al., 2005; Camus et al., 
2007), although Kyere et al. (2012) have since reported that MA does not interact 
directly with AP-3. Through the use of these chimeric viruses, we should be able to 
deduce whether it is solely MA which is responsible for the trafficking/assembly 
phenotypes of HIV. At present, the AP binding sites of HIV-2 Gag have not been 
identified in the literature.  
To investigate the effects of AP siRNA treatment on MA2 assembly and release, HeLa 
cells were co-transfected with MA2 and the AP siRNAs as before, and cell and 
supernatant samples were analysed via Western blot using an anti-HIV-1 p24 antibody, 
after loading equal amounts of (cell) lysate onto an SDS-PAGE gel. The results are 
shown in Figure 56.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: The effect of the adaptor proteins on MA2 processing and release. The 
top panel shows a western blot of cell lysate samples from MA2 and AP or 
negative control siRNA co-transfected HeLa cells 24 and 40h post-transfection, 
using an anti-HIV-1 p24 antibody. The middle panel shows a western blot of viral 
supernatants collected at the same time points. The same cell samples were probed 
with an anti-γ-tubulin antibody (bottom panel).   
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As this Figure demonstrates, small decreases in cellular Gag (top panel) were observed 
in the presence of AP-1 or -3 siRNAs. Once again, when used in combination, a larger 
effect was exerted. AP-2 also again had no visible effect on cellular Gag. When 3 
repeat experiments were analysed by densitometry (Figures 57A and B), it was 
revealed that AP-1 and -3 siRNAs caused a significant (p<0.005) decrease in processed 
Gag at both 24 and 40 hours post transfection, however, AP-1 had a larger 
(approximately 10%) effect in both instances. When AP-1 and -3 siRNAs were used 
together, a significant (p<0.05) decrease in both processed Gag fractions (p41 and p24) 
was observed at 24 hours, whereas at 40 hours, a significant decrease in all Gag 
fractions (p55, p41 and p24) was seen.  
The middle panel of Figure 56 shows MA2 viral supernatant samples. As can be seen, 
little effect was seen at 24 hours, except when AP-1 and -3 were used in combination. 
At 40 hours, however, AP-1 and -3 siRNAs caused a decrease in Gag release, and AP-1 
and -3 siRNAs together once again exerted a larger effect. AP-2 knockdown increased 
particle release, as for HIV-1. When 3 repeat experiments were analysed by 
densitometry (Figure 57C), it was found that AP-1 and -3 siRNAs had a similar effect, 
reducing particle release by approximately 60% (p<0.05), whereas AP-1 and -3 siRNAs 
in combination reduced particle release by 74% (p<0.05). AP-2 siRNA indeed was 
found to significantly increase particle release by 30% (p<0.05).  
These results were slightly surprising; although the AP binding sites have not been 
reported in HIV-2, it could be assumed that due to sharing 60% amino acid sequence 
identity in Gag (Dilley et al., 2011), they exist in a similar position to HIV-1. Since we 
know that the APs do indeed effect HIV-2 trafficking and assembly, it was assumed 
that MA2 would behave in a similar manner to HIV-2. These results, however, suggest 
something different. AP-2 was found to have an inhibitory effect on MA2 particle 
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Figure 57: The effect of the adaptor proteins on MA2 assembly and release. 
Densitometry was performed on bands from 3 western blots using ImageJ, to 
calculate Gag levels obtained from independent repeat experiments. A and B- 24 
and 40 hour cell samples, respectively. Supernatants (C) represent 40 hour p41 
values only. Results shown are percentages of Gag expression from no siRNA 
treatment. (Key: *=p<0.05, **=p<0.005, ***=p<0.001).  
0
50
100
150
R
el
ea
se
d
 G
a
g
 (
%
) 
** 
** 
** 
* 
* 
** 
*** 
* 
** 
A 
B 
C 
** 
** 
*** 
*** * 
** 
Chapter 6                                                                              Results       
 
138 
 
release, similar to that of HIV-1; however, this was not observed for HIV-2. 
Furthermore, AP-1 only had a modest effect on HIV-2 assembly and release, whereas 
the effect was found to be slightly larger than AP-3 on MA2. Together, these results 
suggest that the MA domain is likely not the only area containing AP binding sites, and 
that MA2 has a similar trafficking phenotype to that of HIV-1, as opposed to HIV-2.  
6.2.6 The Effect of the Adaptor Proteins on MA1 Assembly  
To investigate the effects of the APs on MA1, the same protocol for MA2 was 
repeated, except that an anti-SIV p27 antibody was used in Western blots. Viral 
supernatant samples were not collected, however, since data collected previously in this 
lab found that MA1 is unable to egress (Michela Marongiu, unpublished data). The 
results for MA1 cell samples are shown in Figures 58 and 59.  
The Western blot (Figure 58) presents a similar story to that of HIV-2; AP-1 siRNA 
caused a moderate effect on Gag, causing a decrease in Gag at both 24 and 40 hours. 
AP-3 siRNA, however, once again exerted a larger effect than AP-1; densitometry of 3 
repeat experiments revealed that p27 was reduced by 12% more in the presence of AP-
3 siRNA at 24 hours, and 19% more at 40 hours (see Figure 59A and B). Interestingly, 
however, p57 was significantly reduced by both AP-1 and AP-3 at 24 hours, but not at 
40 hours, whereas little effect was seen at 24 hours when HIV-2 was used. Currently, it 
is unclear as to why this is occurring. AP-2 was again found to have no significant 
effect. This data suggests that, despite containing the known AP binding sites of HIV-1, 
this provirus adopts a similar phenotype to that of HIV-2, again inferring that perhaps 
the MA domain is not the only region to contain AP binding sites.  
As mentioned, MA1 is incapable of releasing viral particles. It was not discovered, 
however, why this is. One possibility for this that seemed plausible was that the virus is 
incapable of antagonising tetherin. Tetherin is a restriction factor expressed on the 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: The effect of the adaptor proteins on MA1 Gag processing. Western 
blot of cell lysate samples taken from MA1 and AP or negative control siRNA co-
transfected HeLa cells, 24 or 40h post-transfection, using an anti-SIV p27 
antibody.   
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Figure 59: The effect of the adaptor proteins on MA1 Gag processing. 
Densitometry was performed on bands from western blots using ImageJ, to 
calculate Gag levels obtained from 3 independent repeat experiments. A- 24 hour 
cell samples, B- 40 hour cell samples. Results shown are percentages of Gag 
expression from no siRNA treatment. (Key: *=p<0.05, **=p<0.005).  
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surface of some cells, including HeLa cells, which prevents release of budding 
particles. HIV-2 Env is a tetherin antagonist, but is absent in the env-deleted HIV-2 
provirus SVRΔNB, which was also the backbone of MA1. It therefore seemed a 
possibility that tetherin restriction is the reason for the inability of MA1 to egress.  
To test this theory, a cell line which does not express tetherin was utilised; HEK 293T 
cells. HIV-2 and MA1 proviruses were transfected into these cells, and supernatant 
samples were harvested at 24 and 40 hours. The results are shown in Figure 60.  
As can be seen env deleted HIV-2 was able to egress in this tetherin-deficient cell line; 
MA1, however, was still unable to escape HEK 293T cells. This tells us that there are 
other factors at play resulting in the ability of MA1 to egress, other than the inability to 
antagonise tetherin.  
6.2.7 The Effect of the Adaptor Proteins on MA1 and MA2 
Localisation 
Previous studies (Ono et al., 2000) have demonstrated that the MA domain of Gag 
directs the trafficking and targeting of HIV-1 to assembly sites. Since it is apparent 
from Western blot analysis that these chimeras have different to expected phenotypes 
with regards to interactions with the APs, Gag localisation was analysed by confocal 
immunofluorescence microscopy, to see whether MA does indeed direct Gag 
localisation. HeLa cells were transfected with the chimeric proviruses, and compared 
with HIV-1 and -2 proviruses. The results are shown in Figure 61.  
Figures 61 A-D demonstrate the typical Gag distributions observed for HIV-1, MA2, 
HIV-2 and MA1, respectively. As can be seen, MA2 Gag clearly adopted a more 
punctate staining, which is reminiscent of HIV-2 Gag. MA1 Gag also remained more 
diffusely stained, similar to that of HIV-1 Gag. This is intriguing since with regards to 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 60: Viral egress from HEK 293T cells. This figure shows a western blot of 
viral supernatant samples from HIV-2 and MA1 transfected HEK 293T cells, 24 
and 40h post-transfection, using an anti-SIV p27 antibody.  
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Figure 61: The effect of HIV Matrix on Gag localisation. A-D- Confocal 
immunofluorescence images of HIV-1, MA2, HIV-2 and MA1 transfected HeLa 
cells, respectively. Anti-HIV-1 p24 (HIV-1, MA2) and anti-SIV p27 (HIV-2, MA1) 
antibodies were used (red). Gag localisation was quantified from 3 independent 
experiments, and the results are shown graphically in E. Blue stain= DAPI.   
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the interactions with the APs, MA2 typically behaved like HIV-1, and MA1 like HIV-
2. It was surprising therefore to find the Gag localisation phenotype was the opposite 
way around. When this data was quantified across repeat experiments (Figure 61E), a 
similar story was observed. MA2 was predominantly punctate and rarely diffuse, 
whereas MA1 was predominantly diffuse. PM Gag staining was rarely observed for 
MA1; this would support the observation that MA1 is inefficient at release, and perhaps 
suggests a trafficking/membrane localisation defect of this virus.  
Since MA1 and MA2 have differing phenotypes with regards to Gag localisation, it 
seems plausible that it is a function other than the APs which is directing Gag to 
assembly sites. One such possibility is that myristoylation plays an essential role in 
directing Gag to assembly sites. Myristoylation of Gag is a two-step process; first, a 
free myristate is activated to myristoyl-CoA, then this myristoyl residue is transferred 
to the N-terminal glycine of Gag (Morikawa et al., 1996). The myristate group on Gag 
exists in two conformations, exposed (which is required for membrane binding) and 
sequestered within the protein. The HIV-1 Gag myristate group is in a dynamic 
equilibrium between exposed and sequestered conformation whereas the HIV-2 Gag 
myristate is more tightly sequestered (Saad et al., 2008). Insertion of the HIV-1 
myristate into the PM is important in stabilising the association of Gag with the PM 
(Saad et al., 2006). If the HIV-2 Gag myristate is sequestered it may not be able to 
stabilise an association with the PM; it is possible that association with internal 
membranes occurs instead. 
To investigate the effects the APs exert on MA1/MA2 Gag localisation, HeLa cells 
were co-transfected with these proviruses and the AP siRNAs, and viewed under the 
confocal microscope after staining for Gag. The results from 3 repeat experiments are 
summarised in Figure 62.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62: The effect of the AP siRNAs on MA2 and MA1 Gag localisation. 
Percentages of Gag distributions from 3 independent experiments seen in AP or 
negative control siRNA and HIV provirus co-transfected HeLa cells 24h post-
transfection, viewed under a confocal microscope. A- Gag localisation in MA2 
transfected HeLa cells. B- MA1 Gag localisation under the same conditions. 
Significant differences from untreated cells are highlighted with an asterisk 
(p<0.05).  
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As shown in figure 62, the AP siRNAs actually had little effect on the localisation of 
Gag from these proviruses. The only result that was significant was a reduction in PM 
Gag localisation of MA2 when AP-3 siRNA was used (see Figure 62A). AP-1 
knockdown did slightly reduce MA2 PM Gag localisation, but this was not found to be 
statistically significant (p>0.05). Interestingly, no siRNA treatment significantly 
affected the localisation of MA1 Gag. Although AP-1 and -3 siRNAs did reduce PM 
localised MA1 Gag, since so few cells express Gag at this location, the reduction was 
not significant. Once again, AP-2 was found to have no effect. This also means that the 
very punctate staining observed for MA2 is likely not a result of the clathrin mediated 
endocytosis of budding viral particles. The fact that AP-3 had a larger effect than AP-1 
on reducing PM localised Gag in MA2 supports the notion that this virus presents a 
similar phenotype to HIV-2 in regards to the trafficking pathway adopted to reach 
assembly sites.  
A summary of the results gathered so far for HIV-1, HIV-2, MA1 and MA2 with 
regards to adaptor protein interactions is shown in Table 3. 
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 HIV-1 HIV-2 MA2 MA1 
Assembly 
AP-1 and AP-3 
KD exerted 
similar effects 
on decreasing 
Gag processing. 
AP-2 and AP-5 
KD no effect. 
AP-3 KD exerted 
greater effect on 
decreasing Gag 
processing than 
AP-1. AP-5 KD 
inhibited 
processing. AP-2 
KD no effect. 
AP-1 and AP-3 
KD exerted 
similar effects on 
decreasing Gag 
processing. AP-2 
KD no effect. 
AP-3 KD 
exerted greater 
effect on 
decreasing Gag 
processing than 
AP-1. AP-2 KD 
no effect. 
Gag Release 
AP-1 and AP-3 
KD exerted 
similar effects 
on inhibiting 
Gag release. 
AP-2 KD 
enhanced Gag 
release. AP-5 
KD had no 
effect. 
AP-3 KD 
inhibited Gag 
release to a 
greater extent 
than AP-1. AP-2 
did not inhibit 
release. AP-5 KD 
inhibited release. 
AP-1 and AP-3 
KD exerted 
similar effects on 
inhibiting Gag 
release. AP-2 KD 
enhanced Gag 
release. 
N/A- inefficient 
at particle 
release. 
Gag 
Localisation 
AP-1 and AP-3 
KD decreased 
PM localised 
Gag. AP-3 KD 
increased 
punctate Gag 
appearance. AP-
1 KD made Gag 
appear more 
diffuse. AP-5 
KD had no 
effect. 
AP-3 KD 
decreased PM 
localised Gag to a 
greater extent 
than AP-1. AP-2 
KD no effect. AP-
5 KD decreased 
PM Gag and 
slightly increased 
diffuse Gag.  
AP-3 only 
reduced PM Gag.  
No effect. 
Table 3: A summary of the effect of AP knockdown (KD) on Gag assembly, 
release and localisation of the 4 proviruses tested.  
6.2.8 The Effect of HIV Gag on AP-3 Localisation 
In chapter 3, it was found that HIV-1 Gag had no effect on the localisation of AP-3, and 
also only displayed minimal colocalisation with this protein, despite it being required 
for efficient particle release and assembly. Since Gag of HIV-2 and MA2 was localised 
predominantly to intracellular compartments, and both of these viruses require AP-3 as 
part of their life cycle, it was predicted that colocalisation with AP-3 would be higher 
than HIV-1. To investigate this, HeLa cells were transfected with HIV-2, MA2 and 
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MA1 proviruses for 24 hours, and co-stained for AP-3 and Gag, prior to viewing under 
the confocal microscope. The results are shown in Figure 63.  
Figure 63A shows that HIV-2 could be seen to not only strongly colocalise with AP-3 
(Pearson’s correlation coefficient Rr=0.736), but also relocalised it. When cells 
expressing Gag were compared with surrounding untransfected cells, the localisation of 
AP-3 was dramatically different; it was concentrated into areas where Gag was present. 
This provides further evidence for the hypothesis that HIV-2 utilises AP-3 to traffic to 
or from intracellular compartments, either for particle assembly, or for delivery to the 
PM via endosomal/PM fusion. It could be speculated that AP-3 works in concert with 
ESCRT proteins and clathrin to drive Gag into endosomal compartments. Since clathrin 
is known to form scaffolds around cargo containing membranes in order to form 
vesicles, it could be that these two proteins work together with, for example Tsg101 to 
direct HIV-2 to intracellular sites of assembly, and assist in the formation of viral 
particles through cargo concentration and membrane deformation. Presumably, an 
absence of AP-3 would affect clathrin recruitment, which is reported to stabilise Gag in 
SIV and HIV-1 (Zhang et al., 2011), which could explain why an absence of AP-3 
causes a decrease in Gag levels; if Gag is unable to assemble it seems likely that it 
would be degraded. However, the results gathered so far do not convincingly show that 
Gag is being degraded under the conditions tested.  
Surprisingly, when MA2 was investigated, the same pattern was not observed. AP-3 
was not relocalised to Gag containing areas, and only a small amount of colocalisation 
could be seen (see Figure 63B). Pearson’s correlation coefficient was calculated across 
repeat experiments, and deduced the colocalisation to be moderate (Rr=0.455). When 
MA1 was investigated (Figure 63C), a similar observation was made. A small amount 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63: The effect of HIV Gag on AP-3 localisation. Confocal 
immunofluorescence images of transfected HeLa cells co-stained for Gag (red) 
and AP-3δ (green), in the presence of HIV-2 (A), MA2 (B), and MA1 (C). Blue 
stain= DAPI. HIV-2 Gag and AP-3 colocalisation was calculated by Pearson’s 
correlation coefficient (average Rr=0.736), which was found to be high. MA2 
shows a small amount of colocalisation, as indicated by the white arrows, which 
was found to be moderate by Pearson’s correlation coefficient (average Rr=0.455). 
MA1 also displays colocalisation with AP-3, as demonstrated by white arrows, 
which was also found to be moderate (average Rr = 0.434).  
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of colocalisation was observed (Rr=0.434), but no relocalisation. This was similar to 
what was seen in HIV-1 transfected cells.  
It was predicted that since MA2 displayed a similar Gag localisation to HIV-2, that we 
would also see a strong colocalisation with AP-3. Why this was not observed is 
unclear. It remains a possibility that since there potentially exists ulterior AP binding 
sites other than in MA, that MA2 is efficient at using the APs interchangeably. 
Therefore, a reliance on one AP would not exist, and this virus may not solely be 
dependent on AP-3 to reach assembly sites. 
Interestingly, it was discovered that the cytoplasmic tail of HIV-2 Env contains a 
GYxxΦ (where Φ is a bulky hydrophobic residue) motif which binds AP-2; this was 
found to direct Env to a particular cellular location that is critical for the ability of Env 
to enhance viral release. Exchanging this tail with that of MLV (murine leukaemia 
virus), however, provided a functional substitute that did not require this GYxxΦ motif, 
or AP-2 (Noble et al., 2006). This could potentially suggest an ability of HIV 
constituents to alter usual trafficking pathways taken when, for example, the 
availability of or interactions between certain proteins are changed. Therefore, an 
absence of a particular AP could cause HIV to adopt a different trafficking route, in 
order to overcome something that could potentially inhibit efficient viral replication.  
6.2.9 The Effect of HIV Gag on AP-1 Localisation 
HIV-1 was found to slightly alter the localisation of AP-1 in transfected HeLa cells 
(Figure 28); when HIV-1 was present, AP-1 was present in a smaller, more 
concentrated juxtanuclear position (see chapter 3.2.4ii for more details). This 
experiment was repeated for HIV-2, MA2 and MA1 to see if the same pattern was 
observed. Since AP-1 siRNA was found to only have a moderate effect on HIV-2 Gag 
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as compared with HIV-1 Gag, it was predicted that HIV-2 would likely not exert the 
same effects. The results are shown in Figure 64 for HIV-2 and MA1. 
As can be seen, surprisingly, both HIV-2 and MA1 had a dramatic effect on the 
localisation of AP-1. In cells expressing Gag, AP-1 was present not only in the usual 
juxtanuclear area, but also appeared to be localised to long, tubular structures, which 
was not observed in cells that were not transfected. This was also different to the effect 
exerted by HIV-1, and suggested that it is not a MA mediated effect, but rather a result 
of another HIV-2 encoded protein. It is unclear as to what these structures are that HIV-
2/MA1 is relocalising AP-1 to, but possibilities include tubular endosomes or 
cytoskeletal elements.  
Next, to investigate whether MA2 exerted a similar effect to HIV-1 or HIV-2, the 
experiment was repeated using the MA2 provirus. The results are shown in Figure 65. 
As is indicated by the white arrows, AP-1 in MA2 Gag expressing cells appeared once 
again in a tighter juxtanuclear position, as compared with untransfected cells. This is a 
similar observation to AP-1 in HIV-1 transfected cells, as is shown in Figure 65B, 
although the relocalisation was slightly less obvious in MA2 transfected cells.  
It is clear from these results that HIV Gag expression can alter the cellular distribution 
of AP-1; however, it is also evident that HIV-1 and HIV-2 exert different effects on this 
protein, and that these are not mediated by the MA domain. This could be because 
these viruses utilise AP-1 at different cellular locations, and at slightly different stages 
of the virus life cycle. This also suggests that the relocalisation is not merely a result of 
interactions between MA and AP-1, whereby AP-1 is directing the intracellular 
trafficking of HIV, and therefore becomes localised to Gag containing areas. This is 
also unlikely since although redistribution is seen, we did not see colocalisation 
between these proteins.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: The effect of HIV-2 and MA1 on AP-1 localisation. Confocal 
immunofluorescence images of HeLa cells transfected with HIV proviruses co-
stained with anti-SIV Gag (p27, red) and anti-AP-1γ antibodies (green). A and B- 
HIV-2 at 2X and 4X zoom, respectively. C and D- Repeat conditions for MA1 
transfected cells. Scale bars are shown in the bottom right of overlay images.  
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Figure 65: The effect of MA2 on AP-1 localisation. Confocal immunofluorescence 
images of HIV provirus transfected HeLa cells co-stained with anti-HIV-1 Gag 
p24 (red) and anti-AP-1γ antibodies (green). A- MA2 transfected cells, B- HIV-1 
transfected cells. White arrows indicate changes in AP-1 localisation. Blue stain= 
DAPI.  
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6.2.10 The Interactions Between HIV Gag and Clathrin 
It was recently reported that clathrin facilitates the morphogenesis of retrovirus 
particles through interactions with GagPol (Zhang et al., 2011); although HIV-2 was 
not investigated, its simian homologue SIVsm was investigated, alongside HIV-1. Since 
results gathered in this chapter suggest a strong role for the APs, in particular AP-3 in 
the HIV-2 life cycle, it seemed plausible that clathrin may be recruited to intracellular 
budding areas via AP-3. To investigate the localisations of HIV-1 and HIV-2 Gag with 
respect to clathrin, HeLa cells were transfected with the HIV-1 and HIV-2 proviruses 
(HXB2 and SVRΔNB) and co-stained with anti-Gag p24/p27 and anti-clathrin heavy 
chain antibodies, and viewed under the confocal microscope. Results for HIV-1 and 
HIV-2 are demonstrated in Figure 66.  
Figure 66A shows the typical distribution of clathrin in untransfected HeLa cells. 
Although a diffuse cytoplasmic localisation was observed, more clathrin staining was 
seen in a juxtanuclear position. This likely represents the TGN area. When cells were 
transfected with HIV-1 (Figure 66B), we saw some colocalisation with clathrin, and 
also a slight redistribution of clathrin to Gag containing areas such as the PM. We 
would expect this as per the current literature (Zhang et al., 2011). Colocalisation was 
analysed using ImageJ across 2 independent repeat experiments, and Pearson’s 
correlation coefficient deduced the colocalisation with clathrin to be moderate 
(Rr=0.435). When cells were transfected with HIV-2 (Figure 66C), the colocalisation 
was observed to be much stronger (Rr=0.671). We also saw a more obvious 
redistribution of clathrin to Gag containing areas. This supports the current literature 
described for SIVsm (Zhang et al., 2011), and also supports the hypothesis that AP-3 
and clathrin function in concert to facilitate HIV-2  assembly; since clathrin is critical 
to Gag stabilisation and the morphogenesis of viral particles (Zhang et al., 2011), it 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: The effect of HIV-1 and HIV-2 on clathrin localisation. Confocal 
immunofluorescence images of HeLa cells with or without HIV-1/2 proviruses, 
stained with an anti-clathrin heavy chain antibody (green), and in transfected 
cells, anti-Gag antibodies were also used (red). A- Clathrin distribution in 
untransfected cells. B- HIV-1 transfected cells; colocalisation observed was 
deduced to be moderate across independent repeat experiments by Pearson’s 
correlation coefficient (Rr=0.435). C- HIV-2 transfected cells. Pearson’s 
correlation coefficient demonstrated this colocalisation to be high (Rr=0.671). Blue 
stain= DAPI. 
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Figure 67: The effect of MA2 and MA1 on clathrin localisation. Confocal 
immunofluorescence images of provirus transfected HeLa cells, co-stained for Gag 
(p24/p27, red) and clathrin heavy chain (green). A- MA2 transfected cells. White 
arrows indicate areas of colocalisation; colocalisation was deduced to be moderate 
by Pearson’s colocalisation coefficient (Rr=0.483) across independent 
experiments. B and C- MA1 transfected cells, at 2X and 4X zoom, respectively. 
Pearson’s correlation coefficient deduced this colocalisation to be high (Rr=0.709). 
Blue stain= DAPI.  
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seems plausible that AP-3 assists in this by recruiting clathrin to Gag assembly sites. 
Since HIV-2 Gag strongly colocalises with both of these proteins, this makes sense.  
When MA2 and MA1 were investigated (Figure 67), slightly different observations 
were made. MA2 demonstrated little colocalisation with clathrin, reminiscent of the 
lack of colocalisation observed with AP-3 (Figure 63B). This was deduced to be 
moderate from independent repeat experiments, by Pearson’s correlation coefficient 
(Rr=0.483). MA1, however, showed very strong colocalisation with clathrin 
(Rr=0.709), which was seen mostly around the PM. This may represent assembling 
particles which have become stuck intracellularly, unable to egress, concentrated in 
areas where clathrin is abundant (the PM).  
6.2.11 The Effect of Tetherin on HIV Gag 
As mentioned, tetherin is a restriction factor present on the surface of HeLa cells, 
capable of trapping released virions, preventing their efficient release. HIV-1 Vpu is a 
tetherin antagonist, as are HIV-2 Env and Nef. HIV-1 Vpu and HIV-2 Env are non-
functional in proviral strains utilised in previous experiments (HXB2, SVRΔNB). It 
was therefore hypothesised that the punctate appearance of both MA2 (lacking Vpu) 
and HIV-2 (lacking Env) could be due to re-internalisation of tethered particles, 
causing accumulation in endosomes. Therefore, HEK 293T cells which do not express 
tetherin, and full-length wild type (WT) HIV-2 (pSVR) which produces Env, were used 
to investigate the role of tetherin in Gag localisation in the proviruses through confocal 
immunofluorescence microscopy. The results for HIV-2 are shown in Figure 68.  
Figure 68A shows the typical Gag localisation observed in HIV-2 (SVRΔNB) 
transfected HeLa cells, demonstrating a very punctate appearance. Figure 68B shows 
Gag localisation from HeLa cells transfected with WT HIV-2 (pSVR). Once again, 
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Figure 68: HIV-2 localisation using different HIV-2 proviruses and cell lines. A-C-
Confocal immunofluorescence images of Gag in HIV-2 transfected cells using an 
anti-SIV p27 antibody (red). Gag distribution when HeLa cells are transfected 
with env deleted HIV-2 provirus (SVRΔNB, A) or wild-type HIV-2 (pSVR, B). C- 
Gag distribution when HEK 293T cells are transfected with SVRΔNB. Blue stain= 
DAPI. D- Percentages of Gag distribution quantified from 2 independent 
experiments.  
D 
C B A 
Chapter 6                                                                              Results       
 
148 
 
similar observations were made; a very punctate appearance of Gag. When HIV-2 was 
transfected into HEK 293T cells (Figure 68C), however, we see a slightly different 
image. Although we do still see some very large puncta, we also now see some 
diffusely staining cells, which were never seen in HeLa cells. When Gag localisation 
was quantified in these conditions across 2 independent repeat experiments (Figure 
68D), we see that HIV-2 and WT HIV-2 had similar Gag localisations, albeit WT HIV-
2 does display some diffusely stained cells unlike HIV-2. HIV-2 Gag in HEK 293T 
cells, however, had a different phenotype. Not only was there virtually no PM localised 
Gag, but we also saw similar levels of diffuse and punctate Gag; punctate Gag still 
remained the most abundant form, however. This suggests that although tetherin clearly 
plays a part in determining the localisation of Gag, it is not the sole reason for the 
punctate pattern observed.  
When MA2 was investigated, the cell type was significant. Figure 69A shows the 
typical Gag localisation observed in MA2 transfected HeLa cells; similar to HIV-2 it 
had a very punctate appearance. When MA2 was transfected into HEK 293T cells 
(Figure 69B), however, we saw a dramatically different localisation pattern. Although 
we still saw some puncta, it was more reminiscent of the staining observed in HIV-1 
transfected cells. When Gag localisation was quantified across independent repeat 
experiments (Figure 69C), we saw a complete reversion of the Gag localisation 
phenotype; from HIV-2 like to HIV-1 like. This suggested that the MA domain is not 
solely responsible for Gag localisation, and that tetherin is a factor in causing the 
punctate appearance of MA2 Gag through re-internalisation of tethered particles. 
When MA1 was investigated (Figure 69D), the localisation of Gag remained essentially 
unchanged, except for a slight reduction in punctate staining. Since MA1 is unable to 
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Figure 69: MA2 and MA1 Gag localisation in different cell types. A and B-
Confocal immunofluorescence images of MA2 using an anti-HIV-1 p24 antibody 
(red) in MA2 transfected HeLa and HEK 293T cells, respectively. Blue stain= 
DAPI. C and D- Quantification of Gag localisation in HeLa and HEK 293T cells 
transfected with MA2 or MA1, respectively, from 2 independent repeat 
experiments.  
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egress, we would not expect the absence of tetherin to have much of an effect on this 
virus. HIV-1 Gag also remained unchanged in HEK 293T cells (data not shown).  
To see if tetherin could also explain the strong colocalisation observed with both 
clathrin and AP-3 in HIV-2 transfected cells, WT HIV-2 (pSVR) was transfected into 
HeLa cells, and these were co-stained for both proteins under scrutiny. Figure 70 shows 
results from confocal immunofluorescence microscopy.  
Figure 70A shows that WT HIV-2 still colocalised with clathrin, and was capable of re-
distributing clathrin to areas concentrated with Gag. Figure 70B, however, 
demonstrates that although WT HIV-2 still strongly colocalised with AP-3, the re-
distribution of this protein was not observed as before. In the presence of HIV-2, AP-3 
still remained evenly distributed throughout the cytoplasm, albeit it seemed to be 
slightly more concentrated in the areas containing Gag. This suggests that tetherin plays 
a role in the strong colocalisation of AP-3 with Gag, and the redistribution of AP-3 
observed previously (Figure 63A).  
When HIV-2 (SVRΔNB) was transfected into HEK 293T cells (Figure 71), we saw a 
similar story with regards to AP-3 and clathrin. Once again, we saw colocalisation with 
AP-3 (Figure 71A) but without an obvious re-distribution. Clathrin (Figure 71B), 
however, was once again relocalised to Gag containing areas, and strong colocalisation 
within these areas was seen. Interestingly, however, when MA1 was transfected into 
HEK 293T cells, we no longer saw the extreme clathrin-Gag colocalisation. This was 
suggestive of tetherin restriction possibly causing an entanglement of assembling MA1 
particles with clathrin, which was absent therefore when tetherin was not expressed. As 
previously deduced in this chapter, however, tetherin is not the sole factor in preventing 
MA1 egress.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70: Wild-type HIV-2 strongly colocalises with and redistributes clathrin. 
Confocal immunofluorescence images of WT HIV-2 transfected HeLa cells. A- 
HeLa cells stained with anti-SIV p27 (red) and anti-clathrin heavy chain (green) 
antibodies. Colocalisation between Gag and clathrin was deduced to be strong by 
Pearson’s correlation coefficient (average Rr= 0.681). B- HeLa cells co-stained for 
AP-3δ (green) and Gag p27 (red). Pearson’s correlation coefficient deduced the 
colocalisation to be moderate (average Rr=0.43), however, Mander’s overlap 
coefficient deduced the colocalisation to be strong (average R=0.645). Blue stain= 
DAPI.  
 
 
 
A 
B 
p27 
p27 
Clathrin 
AP-3 
Overlay 
Overlay 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 71: HIV-2 Gag colocalises with AP-3 and clathrin in HEK 293T cells. 
Confocal immunofluorescence images of HEK 293T cells transfected with HIV-2 
or MA1. A- HIV-2 transfected cells co-stained with anti-SIV p27 (red) and anti-
AP-3δ (green) antibodies. Strong colocalisation is seen (average Rr= 0.541). B- 
HIV-2 transfected cells co-stained with anti-SIV p27 (red) and anti-clathrin heavy 
chain (green) antibodies. White arrow indicates areas of colocalisation with 
clathrin (average Rr= 0.675). C- MA1 transfected cells co-stained with anti-SIV 
p27 and clathrin. The white arrow indicates small areas displaying colocalisation.  
Blue stain= DAPI.  
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To determine the intracellular compartment to which HIV-2 Gag is localising, 
endosomal markers were used. CD81 is a member of the tetraspanin family, and is 
enriched in LE/MVBs (Escola et al., 1998); if HIV Gag is localising to this 
compartment, we would expect to see colocalisation between these two proteins. 
Therefore, the HIV-2 provirus (SVRΔNB), and HIV-1 HXB2 for comparative 
measures, were transfected into both HeLa and HEK 293T cells for 24 hours, followed 
by preparation of samples for confocal immunofluorescence using anti-Gag and anti-
CD81 antibodies. The results are shown in Figure 72. 
As can be seen, HIV-1 displayed no/little colocalisation with CD81 in both HEK 293T 
(Figure 72A) and HeLa cells (Figure 72B). The average Pearson’s correlation 
coefficient, calculated from multiple cells across 2 repeat experiments, confirmed low 
colocalisation (Rr=0.21 and 0.18, respectively). HIV-2, however, displayed 
colocalisation in both HEK 293T and HeLa cells (average Rr= 0.62 and 0.491, 
respectively). This demonstrates that HIV-2 Gag, but not HIV-1, is localised to CD81 
positive compartments. 
Previous results also gathered in this lab demonstrated that HIV-2 Gag, but not HIV-1, 
was localised to CD63 positive compartments (M. Marongiu and E.C. Anderson, 
unpublished results); CD63 is another member of the tetraspanin family and is also 
enriched in the LE/MVB (Escola et al., 1998). Therefore, HIV-2 Gag is localised to 
CD81 and CD63 positive compartments; this therefore indicates that HIV-2 uses the 
LE/MVB in Gag trafficking to a greater extent than HIV-1. This suggests that although 
results gathered in chapter 5 indicate that at least some HIV-1 Gag is directed to 
endosomal compartments in the normal trafficking pathway, this likely represents a 
small population of total Gag. HIV-2 Gag, however, is likely either beginning to 
assemble in these compartments, or uses an endosomal trafficking route to reach the 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72: HIV-2, but not HIV-1, colocalises with CD81 in HeLa and HEK 293T 
cells. Confocal immunofluorescence images of HEK 293T cells transfected with a 
HIV-1 provirus (A) or HIV-2 provirus (C), co-stained with anti-p24 (HIV-1, red) 
or anti-p27 (HIV-2, red) and anti-CD81 (green). Pearson’s correlation coefficient 
calculated across 2 repeat experiments deduced colocalisation to be low for HIV-1 
(average Rr=0.21) but high for HIV-2 (0.62). B and D show HIV-1 and HIV-2 
proviruses transfected into HeLa cells, staining for the same proteins. Pearson’s 
correlation coefficient deduced colocalisation to be low for HIV-1 (average 
Rr=0.18) but borderline moderate/high for HIV-2 (average Rr=0.491). Blue 
stain=DAPI. 
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PM assembly site; direct trafficking of newly synthesised Gag to the PM is not 
supported by these results.  
In order to ascertain whether HIV-2 Gag is indeed capable of assembling in 
intracellular compartments, electron microscopy studies were carried out. Results 
gathered previously in this lab found, through cryo-electron microscopy (EM), both 
immature and mature HIV-2 particles within intracellular compartments of HeLa cells 
(M. Marongiu, I. Portman and E.C. Anderson, unpublished results). HIV-1, in contrast, 
was found predominantly at the PM. Since these particles may have been a result of 
tetherin restriction, EM was carried out on HIV-2 transfected HEK 293T cells. Results 
are shown in Figure 73.  
Although mature particles could not be seen intracellularly, immature particles were 
observed within a clear intracellular compartment distant from the PM. This indicates 
the possibility that HIV-2 is capable of assembling within intracellular compartments, 
destined for extracellular release by PM fusion. Particles were also seen, however, 
budding from the PM (data not shown). Therefore, it is possible that HIV-2 may adopt 
two intracellular assembly sites in both HeLa and HEK 293T cells; intracellular 
compartments or the PM.  
6.2.12 Inhibition of Endocytosis Does Not Affect HIV-2 Gag 
Localisation 
Although knockdown of AP-2, which would impair clathrin mediated endocytosis, did 
not alter the punctate phenotype of HIV-2 Gag, and HIV-2 Gag is still predominantly 
punctate in tetherin deficient (HEK 293T) cell lines, it was necessary to investigate the 
possibility of clathrin-independent endocytosis playing a role in the phenotype of HIV-
2 Gag. Rab5 is localised to early endosomes (EE), and has been demonstrated to 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 73: Localisation of HIV-2 particles in HEK 293T cells. HEK 293T cells 
were transfected with HIV-2 pSVRΔNB proviral plasmid for 40 hours prior to 
formaldehyde fixation and viewing with a cryo-transmission electron microscope. 
Assembled HIV-2 particles can be observed within an intracellular compartment. 
White arrows indicate immature viral particles approximately 100nm in diameter, 
red arrow indicates intracellular compartment membrane.  
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Figure 74: Dominant negative Rab5 does not alter the localisation of HIV-2 Gag. 
A and B show confocal immunofluorescence images of HeLa and HEK 293T cells, 
respectively, co-transfected with a HIV-2 provirus and a Rab5dn (green) 
construct. Anti-p27 was used to stain Gag (red). Blue stain=DAPI. C and D show 
average percentages of Gag localisations taken from counts of cells expressing 
Gag, with and without Rab5dn, across 2 repeat experiments in HeLa and HEK 
293T cells, respectively.  
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regulate endosome biogenesis (Zeigerer et al., 2012) and regulates the fusion of 
incoming endocytic vesicles from the PM to the EE (Barbieri et al., 1996). A dominant 
negative Rab5 construct has been developed, which blocks both clathrin-dependent and 
clathrin-independent endocytosis events (Dinneen and Ceresa, 2004; Zeigerer et al., 
2012). This is because the Rab5dn is unable to facilitate fusion of the endocytic vesicle 
with the EE, and cannot promote the recycling of factors necessary to internalisation 
(Li et al., 1995). To investigate the localisation of HIV-2 Gag in the presence of this 
construct, HeLa and HEK 293T cells were co-transfected with the HIV-2 SVRΔNB 
provirus and Rab5dn for 24 hours. Samples were prepared for confocal 
immunofluorescence microscopy, and stained for anti-p27 Gag. The results are 
demonstrated in Figure 74. 
As can be seen, visually the presence of Rab5dn did not reduce the punctate appearance 
of HIV-2 Gag. In order to quantify the localisation of HIV-2 Gag in these two cell 
lines, with and without the Rab5dn, cells expressing Gag were counted across 2 repeat 
experiments, and Gag localisation was recorded. The results are shown graphically in 
Figures 74C and D. As can be seen, Rab5dn did not significantly alter the HIV-2 Gag 
localisation in either cell line. This again indicates that the presence of HIV-2 in 
punctae is not a result of internalisation of particles from the PM, further supporting a 
role for endosomal compartments in the trafficking of HIV-2 Gag.  
6.3 Discussion 
HIV-2 is certainly less prevalent worldwide in comparison to HIV-1, however it is still 
an important feature of the AIDS epidemic. Although the epidemic of HIV-2 has been 
limited in comparison to HIV-1, with the majority of HIV-2 infections reported in West 
Africa and countries with colonial links to this region, HIV-2 infections have been 
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documented globally, for example in Europe, America and India (Remy, 1998; 
McCutchan, 2006; de Silva and Weiss, 2010). Fewer HIV-2 patients progress to AIDS 
than HIV-1; however, in HIV-2 patients that have reached this stage, the clinical 
manifestations are very similar (Nyamweya et al., 2013). The interactions between 
HIV-1 and the adaptor proteins have been described, however, no such studies existed 
for HIV-2. HIV-1 and HIV-2 Gag share 60% amino acid similarity in their Gag 
proteins (Dilley et al., 2011), it was assumed that they likely follow similar pathways. 
This chapter aimed to shed light on the trafficking pathways of newly synthesised HIV-
2 Gag proteins, and how HIV-2 interacts with the clathrin adaptor proteins.  
Initial experiments indicated that HIV-1 and HIV-2 were not identical with regards to 
interactions with the APs; the effects on HIV-1 viral assembly and egress when AP-1/-
3 were knocked down were similar (Figure 39), whereas AP-3 siRNA had a markedly 
larger effect than AP-1 siRNA on HIV-2 (Figure 47). AP-2 knockdown had no effect 
on HIV-2 release, whereas AP-2 is known to inhibit HIV-1 particle release. HIV-2 also 
colocalised extensively with AP-3, redirecting it to Gag concentrated intracellular 
areas. The late endosome adaptor AP-5 also played a prominent role in HIV-2 
assembly and release (Figures 52 and 53), unlike HIV-1 (Figure 45). This, taken 
together with the very punctate intracellular appearance of HIV-2 Gag, seemed to draw 
an obvious conclusion that HIV-2 trafficking is heavily dependent on internal 
compartments, most probably endosomes.  
Two possible non-exclusive hypotheses emerged; HIV-2 Gag traffics to the PM via 
endosomes and assembles at the PM, or HIV-2 particles predominantly assemble 
within intracellular compartments, in a similar manner to that of HIV-1 within 
macrophages. Both of these could explain the heavy co-staining with AP-3; if AP-3 is 
facilitating the delivery of Gag to or from intracellular compartments, we would expect 
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to see these proteins together in discrete colocalised areas. Since AP-3 is involved in 
endosomal trafficking, this would also explain the prominent effects of AP-3 
knockdown on Gag. A severe depletion in total Gag levels was observed upon AP 
siRNA treatment, particularly when AP-3 was knocked down. A plausible explanation 
for this is that in the absence of AP-3, Gag filled or coated endosomes are unable to 
efficiently traffic to the PM for assembly and release of particles. Therefore, we could 
envisage that they instead become fused with lysosomes or are targeted to the 
proteasome, and Gag is ultimately degraded. Experiments involving 
lysosome/proteasome inhibitors (Figure 49) would however suggest that this is not the 
case. A more likely explanation therefore is that AP-3 indeed facilitates the entry of 
HIV-2 Gag into endosomal compartments, working in concert with clathrin to deform 
endosomal membranes and concentrate Gag into virus-like particles. In the absence of 
AP-3, therefore, we might expect unbound cytoplasmic Gag to be readily degraded by 
cellular systems.  
This theory would support the evidence gathered by Zhang et al. (2011), who found 
that clathrin stabilised SIV Gag proteolysis products. Since the adaptors are crucial to 
clathrin function, we could assume that in their absence, clathrin would be unable to be 
recruited efficiently, therefore explaining the disappearance of HIV-2 Gag when AP-1/-
3 are knocked down. AP-5, however, was discovered not to interact with clathrin, and 
when AP-5 was knocked down, we saw a decrease in HIV-2 Gag levels only. This 
suggested that clathrin stabilisation, although playing a role in preventing Gag 
degradation is not the sole reason for the disappearance of Gag when AP-1/-3 were 
knocked down.  
Where does AP-1 come in? Clearly AP-1 is involved in HIV-2 trafficking, since in its 
absence we see a slight decrease in both cellular and released Gag (Figure 47), however 
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its role is certainly superseded by AP-3, given that AP-3 knockdown caused 
significantly larger effects. Although these proteins function in different cellular 
pathways, there is some overlap. Indeed, AP-1 is involved in facilitating cargo delivery 
to endosomes. Therefore we cannot exclude the possibility that AP-1 is actually 
involved in the direction of Gag to endosomes, and that the role of AP-3 is instead in 
ensuring maturation/delivery of endosomes; perhaps HIV-2 is unable to bud into early 
endosomes, and therefore the requirement of AP-3 is to facilitate the trafficking to 
mature, late intracellular compartments for budding. What seems a more likely 
explanation, however, is there is some redundancy in AP-1 and AP-3 function, but that 
in the case of HIV-2, AP-3 plays the greater role; thus when AP-1 is knocked down, 
AP-3 compensates for this loss, but when AP-3 is knocked down, AP-1 is unable to 
fully compensate.  
This model of HIV-2 trafficking was, however, complicated by confocal 
immunofluorescence results gathered in HEK 293T cells. Although Gag expressed in 
HEK 293T cells was still predominantly punctate, we saw a large increase in the 
amount of diffusely stained cells. This suggested that tetherin played a role in the 
punctate appearance of HIV-2 Gag. There may also be other differences between these 
cell types. Although a tetherin antagonist, Env was evidently unable to antagonise 
tetherin entirely since WT HIV-2 and env deleted HIV-2 exhibited almost identical Gag 
appearances. We also know that AP-2/clathrin mediated endocytosis of newly released 
particles is not the reason for the punctate Gag pattern, since AP-2 knockdown exerted 
no effect on Gag localisation. The use of a dominant negative Rab5 construct, in both 
HeLa and HEK 293T cells, demonstrated that the Gag phenotype we observed was not 
due to endocytosis of released particles (Figure 74). Tetherin was also, however, found 
to be responsible for the relocalisation of AP-3 to Gag concentrated areas; this is likely 
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because re-internalised particles would aggregate into endosomal-like compartments, 
around which AP-3 would be relatively abundant. Electron microscopy, however, 
found immature particles within clear intracellular compartments in HEK 293T cells; 
this supports the theory that HIV-2 may indeed begin assembling within these 
compartments. Confocal immunofluorescence microscopy found that the compartments 
HIV-2 Gag localises to are enriched in CD81, a late endosome marker (Figure 72), and 
CD63, another late endosome marker (M. Marongiu and E. C. Anderson, unpublished 
data), further supporting the role of late endosomes in HIV-2 assembly. 
It therefore remains a possibility that HIV-2 Gag is capable of adopting two 
independent trafficking pathways for viral egress; HIV-2 traffics directly/via an 
endosomal intermediate to the PM where assembly begins, or HIV-2 traffics to the PM 
after assembling within intracellular compartments. Why HIV-2 adopts a different 
pathway to HIV-1 is so far unclear. The presence of Vpx, which allows HIV-2 to evade 
restriction by SAMHD1 in myeloid cells may have given rise to evolutionary pressures 
to adopt different cellular pathways to HIV-1(Laguette et al., 2011).  
The MA domain of HIV-1 Gag was discovered to not only contain AP binding sites, 
but may also contribute to the intracellular trafficking and localisation of newly 
synthesised Gag. MA chimeras were used to investigate whether the possession of an 
alternate MA domain may confer a Gag phenotype similar to that of the donor virus. 
Initial results suggested the contrary; MA2 in fact behaved more like HIV-1 with 
regards to interactions with the APs, particularly since AP-2 was found to affect 
particle release (Figure 56). MA1 also had assembly characteristics reminiscent of 
HIV-2 (Figure 58). Intriguingly, however, when these viruses were investigated by 
confocal microscopy, MA2 Gag behaved more like HIV-2, and MA1 Gag like HIV-1 
(Figure 61). Taken together, these do indeed support a role for MA in the Gag 
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targeting, but also suggest that AP binding sites may exist outside of MA. Although 
HIV-1 Nef binds AP-1, -2 and -3, Nef and Gag traffic independently, therefore this 
cannot be the explanation for the effects seen on Gag.  
Initial results suggested that possession of HIV-2 MA was solely able to confer the 
localisation of Gag, and the ability of HIV-1 to assemble within intracellular 
compartments, since a very punctate Gag appearance was observed, reminiscent of 
HIV-2 Gag (Figure 61). The same could be said for MA1; cells transfected with this 
provirus displayed a Gag localisation phenotype more similar to HIV-1 than HIV-2 
(Figure 61). MA2 was also observed in immature and mature forms within intracellular 
compartments through the use of EM, suggesting an ability of this virus to also 
assemble within such compartments (M. Marongiu, I. Portman and E.C. Anderson, 
unpublished results). Since we know MA is responsible for Gag targeting, this made 
sense. The story was complicated, however, by the reversal of the Gag phenotype when 
MA2 was transfected into HEK 293T cells, where Gag localisation became reminiscent 
of observations typically found in HIV-1 transfected cells. It could therefore be 
concluded that the punctate appearance of MA2 was not due to assembly within 
intracellular compartments, but by re-internalisation of tetherin-restricted virus 
particles. This also means that although MA targets Gag to assembly sites, it is unable 
to solely confer Gag localisation and assembly within the context of the virus.  
The story emerging for MA1 is also complex. MA1 is unable to egress, but this was not 
solely due to tetherin restriction as released particles could not be observed when MA1 
was transfected into HEK 293T cells (Figure 60). However, the strong colocalisation 
seen between MA1 Gag and clathrin in HeLa cells was not observed in HEK 293T cells 
(Figure 71). It may be that MA1 only colocalises with clathrin after it has been re-
internalised into vesicles from the PM (Figure 67). Therefore, tetherin may be 
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responsible in part for MA1’s inability to egress, but another feature of the virus makes 
it unable to release even in the absence of tetherin. The lack of PM Gag staining seen 
by confocal microscopy using this virus may hint that it is unable to engage efficiently 
with the PM; very few particles could be observed at the PM via EM (M. Marongiu, I. 
Portman and E.C. Anderson, unpublished results).  
MA1 and HIV-2 also exerted interesting effects on AP-1 localisation, which were not 
observed in MA2 or HIV-1 transfected cells. The localisation of AP-1 appeared 
dramatically different in transfected HeLa cells, yet colocalisation was not seen with 
MA1 or HIV-2 Gag. AP-1 appeared less diffuse, and in some cells could be observed in 
long filamentous structures, which was never observed in un-transfected cells. Three 
potential explanations for this surfaced.  
The first was from previous observations that HIV-1 Gag, in particular the NC domain, 
interacts directly with the cytoskeletal element actin. Although some controversy exists 
as to the exact role actin plays within the retroviral life cycle, it was proposed to be 
involved in assembly and budding (Rey et al., 1996; Liu et al., 1999; Gladnikoff et al., 
2009). Although Gag may reach the PM via cytosolic diffusion, it remains a possibility 
that cytoskeletal elements may indeed actively transport Gag to the PM (Stolp and 
Fackler, 2011). Although the same interactions have not been elucidated for HIV-2, it 
is possible that actin plays a role in facilitating Gag trafficking to either the PM or 
intracellular compartments, and that this is AP-1 driven. AP-1 may recruit Gag to 
cytoskeletal elements for active trafficking through the cytosol, which would explain 
the filamentous appearance of AP-1 in HIV-2 transfected cells. Since the interacting 
domain was deduced to be NC within HIV-1 Gag, it may be that this is the same for 
HIV-2, explaining why we see the same AP-1 distribution in HIV-2 and MA1 
transfected cells. HIV-1 may rely on actin in later stages only, for example assembly 
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and budding, explaining why we do not see the same AP-1 distribution in HIV-1 
transfected cells.  
The second possibility comes from a similar observation in HIV-1 transfected cells. 
KIF4, a microtubule motor and member of the kinesin family, was found to play a role 
in increasing the efficiency of HIV-1 Gag trafficking and assembly (Martinez et al., 
2008). Once again, although this has not been studied in HIV-2, it remains a possibility 
that similar mechanisms exist to promote HIV-2 trafficking through the cytoplasm. It 
seems plausible that AP-1 may either direct KIF4 towards Gag molecules for 
microtubule associated trafficking, or vice versa. This would not only explain the 
tubular appearance of AP-1, but also support the comments made in results chapter 2 
with regards to kinesin assisting lipoplex trafficking, possibly mediated by AP-1. The 
same group also found that an absence of KIF4 resulted in Gag instability and 
subsequent degradation, which could explain the decrease in Gag observed in AP-1 
siRNA treated cells. This hypothesis is, however, complicated by the fact that we 
would expect similar AP-1 observations in HIV-1 transfected cells, which we do not.  
The third possibility is that AP-1 is recruited to tubular endosomes by Gag, from which 
HIV-2 may pass through as an intermediate step to late endosomes or the PM. Since we 
know that HIV-1 does not require AP-5 for assembly and release but HIV-2 does, this 
also seemed a plausible explanation for the alteration in AP-1 localisation.  
6.4 Future Work 
Although the work in this chapter has characterised the phenotypes of MA1 and MA2 
with regards likely trafficking pathways utilised and AP interactions, little is still 
known about why these viruses have striking differences in their ability to be able to 
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egress. Therefore, more work is needed to elucidate the reasons behind these 
characteristics.  
More work needs to be continued on HIV-2 to also further characterise the trafficking 
pathway adopted by this virus. It would be interesting to see if an absence of AP-3, or 
indeed AP-1 also, decreased expression/functionality of viral protease, thus explaining 
the decrease in processed Gag observed when these proteins are absent. It would also 
be interesting to see if the same is seen when clathrin is knocked down. Yeast two-
hybrid screening on HIV-2 MA mutants would also be a good assay to ascertain where 
the AP binding sites lie within Gag. Since results in this chapter also suggest that there 
may be further AP interacting domains outside of MA, further research is critical to 
determine whether this is indeed true, and where these potential interactions occur.  
Future work on this project would also benefit from the construction of a GFP-tagged 
HIV-2 provirus could be used to directly visualise Gag trafficking in live cells. 
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CHAPTER 7: CAN HIV DISTURB WELL 
CHARACTERISED TRAFFICKING PATHWAYS? 
7.1 Introduction 
Diphtheria toxin (DTx), produced by toxigenic strains of the bacterium 
Corynebacterium diphtheriae, is one of the most extensively studied bacterial toxins 
and is widely utilised in scientific research. This is because of its many properties 
which include its cytotoxicity, the ability to cause a cessation in protein synthesis 
through the ADP-ribosylation of elongation factor 2 (EF-2) and capability of crossing 
membranes (Collier, 2001, Murphy, 2011). DTx is a single-chain member of the A-B 
toxin family, where the A and B chains are linked by a disulphide bridge (Watson and 
Spooner, 2006). The DTx mode of action and its trafficking pathway is well known, 
making it an ideal candidate for investigating trafficking.  
Ricin, from the seeds of the castor oil plant Ricinus communis (Sandvig and van Deurs, 
1999), is a heterodimeric ribosome inactivating protein composed of a catalytic A and 
galactose binding B chain, both of which are around 30 kDa and are also linked by a 
disulphide bridge (Sandvig et al., 2010). Enzymatically active ricin is able to 
specifically cleave 28S rRNA, and one active ricin molecule is capable of inactivating 
around 2000 ribosomes per minute, making it an extremely potent toxin (Schep et al., 
2009). Ricin is also widely used today as a valuable marker for the study of endocytosis 
and intracellular transport steps (Sandvig and van Deurs, 1999). 
Diphtheria toxin is synthesised in a single-chain precursor form that is processed by 
cellular furin upon uptake into 2 fragments; the catalytic A fragment, and fragment B 
which is composed of the translocation and receptor binding domains (Drazin et al., 
1971; Choe et al., 1992; Lemichez et al., 1997; Murphy 2011). DTx enters the cell via 
clathrin-mediated receptor endocytosis of the bound toxin to the heparin-binding 
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epidermal growth factor (HB-EGF) precursor receptor, which is mediated by the 
receptor binding domain of the toxin (Naglich et al., 1992). This results in clathrin-
coated vesicles containing the toxin which is enzymatically inactive. From an 
endosomal compartment, the B fragment of the toxin must assist in the translocation 
across the endosomal membrane to facilitate the transport of the catalytic domain into 
the cytosol, which is a pH sensitive step (Lemichez et al., 1997). The clathrin coat on 
these vesicles becomes replaced by Arf1 and COPI, and the proton pump vacuolar 
(v)ATPase lowers the pH of these endosomal vesicles (Murphy, 2011). This 
acidification triggers the transmembrane domain to unfold and consequently become 
inserted in the endosomal membrane, forming a transmembrane channel, or pore, 
which results in the translocation of the catalytic domain into the cytosol (Boquet et al., 
1976; Donovan et al., 1981). There has been some controversy over the endosomal 
compartment from which DTx translocates into the cytosol; some suggested this may 
occur in compartments as late as lysosomes (Donovan et al., 1981), whereas others 
report that it occurs in a compartment upstream of late endosomes, which is the general 
consensus (Papini et al., 1993; Lemichez et al., 1997).  
Once in the cytosol, the catalytic domain catalyses the NAD
+
-dependent ADP- 
ribosylation of elongation factor 2 (EF-2) (Spooner et al., 2006; Murphy, 2011). EF-2 
facilitates the movement of the peptidyl tRNA-mRNA complex from the A site of the 
ribosome to the P site during protein synthesis, and its ADP-ribosylation inhibits its 
translocation activity, and therefore prevents protein synthesis, resulting in cell death 
(Mateyak and Kinsy, 2013).  
Ricin enters cells via galactose containing receptors (Sandvig and van Deurs, 1999; Li 
et al., 2010), and can utilise both clathrin-dependent and clathrin-independent endocytic 
pathways (Sandvig et al., 2010; Sandvig et al., 2013). From here, a large portion of 
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endocytosed ricin is actually recycled back to the cell surface (Sandvig and van Deurs, 
1996), but the rest traffics to the Golgi directly from early endosomes in a clathrin-
independent manner (Iversen et al., 2001; Sandvig et al., 2013). From here, ricin travels 
to the endoplasmic reticulum (ER) in a COPI independent manner (Llorente et al., 
2003). In the ER, ricin is reduced to its RTA (ricin A chain) and RTB subunits (ricin B 
chain) before RTA is dislocated and enters the cytoplasm by exploiting the ERAD (ER-
associated protein degradation) pathway (Watson and Spooner, 2006; Spooner et al., 
2008; Li et al., 2010). From here, ricin acts in a different to way to DTx by directly 
modifying the EF-2 binding site within the large subunit of eukaryotic ribosomes. RTA 
is an RNA N-glycosidase that removes an adenine residue from 28s rRNA which forms 
part of a motif that interacts with EF-2 (Endo and Tsurugi, 1988).   
Since HIV-1 Gag and Nef are known to bind to and interact with the adaptor proteins, 
we hypothesised that HIV-1 might cause disruption of cellular trafficking pathways; to 
test this hypothesis, we carried out DTx cytotoxicity assays and tested whether HIV-1 
could interfere with this pathway via (reducing the cytotoxic effect of DTx). Ricin 
(RTx) was chosen as the control in these experiments since it is capable of trafficking 
in a clathrin-independent manner.  
ts045-VSV-G-EGFP (VSV-G) is a temperature-sensitive mutant  of the vesicular 
stomatitis virus glycoprotein, fused with EGFP (enhanced GFP) for visualisation. This 
glycoprotein has a well characterised secretory trafficking pathway and due to its strict 
temperature sensitivity it is a useful tool in determining interference with protein 
trafficking. At the restrictive temperature (39.5
o
C) the protein is co-translationally 
synthesised and imported into the endoplasmic reticulum where it becomes 
glycosylated. However, it cannot traffic further than the ER (Schnitzer et al., 1979). 
Upon transition to the permissive temperature (32
o
C) the glycoprotein follows a 
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particular route to its final destination; the plasma membrane, via the Golgi. This 
trafficking takes approximately 2 hours after the temperature shift; therefore it is 
possible to fix cells at predetermined points and visualise the localisation of the GFP-
tagged glycoprotein. At t0 (39.5
o
C) VSV-G appears at the ER, at t30 (30 minutes post 
temperature shift) VSV-G is present in the Golgi, at t60 the construct begins to shift 
towards the PM, presenting a diffuse localisation with some presence at the PM, and at 
t120 the construct is almost entirely present at the PM with some remaining 
Golgi/diffuse localisation.  
It was reported that VSV-G requires the delta subunit of AP-3 in order to traffic 
efficiently from the ER to the PM (Nishimura et al., 2002). This is the same subunit 
which HIV-1 Gag has been reported to interact with, directly or indirectly, and is 
required for efficient viral egress. It was therefore hypothesised that HIV-1 may 
interfere with VSV-G trafficking to the PM through competition for the AP-3δ subunit.  
7.2 Results 
7.2.1 HIV-1 Protects against Diphtheria Toxin 
Diphtheria toxin (DTx) traffics down the endosomal pathway, requiring clathrin for cell 
entry and therefore most likely AP-2 also. Although a role for AP-3 in DTx trafficking 
has never been formally defined, we propose to investigate a possible role for AP-3 in 
DTx trafficking. Since HIV-1 Gag may traffic at least some of the time via endosomal 
compartments in an AP-3 dependent manner, we speculated whether HIV-1 
transfection could therefore interfere with the trafficking of DTx. Although ricin (RTx) 
may involve clathrin in its trafficking, it can also traffic in a clathrin-independent 
manner. Since inhibition of protein synthesis by DTx and RTx can be quantified by 
measuring the effect of the toxins on incorporation of 35S-methionine, we used these 
assays to test whether HIV-1 perturbs cellular trafficking of DTx and RTx.  
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HeLa cells, which express the DTx receptor on their surface, were transfected with one 
of a number of different proviral plasmids. 40 hours post-transfection the cells were 
challenged with increasing concentrations of DTx or RTx. 4 hours after toxin 
challenge, cellular 
35
S-methionine incorporation was measured to determine 
cytotoxicity by IC50 values (the amount of a substance required to inhibit a biological 
process by 50%). All assays were carried out in quadruplicate on at least 3 independent 
occasions. Cytotoxicity curves from one representative experiment, used to calculate 
IC50 values, are shown in Figures 75 A-G. A change in IC50 values in the presence of 
provirus was used to calculate the protective effect of the provirus on DTx or RTx 
toxicity, shown in Figure 75H.  
HXB2N
+
 (see chapter 3) was the first provirus tested; this is the envelope-deleted 
HXB2 HIV-1 provirus, with full length Nef. Figure 73A shows a large difference 
between the DTx cytotoxicity curves of the mock (no DNA, Lipofectamine only) 
transfected cells, and the proviral transfected cells, and consequently a large difference 
between the IC50s. As can be seen, a higher concentration of toxin was required to 
cause a 50% cessation in protein synthesis. The calculated protective effect of HIV-1 
HXB2N
+
 against DTx across repeat experiments was 3.5 fold (Figure 75H). Although 
the effect on RTx was minor (Figure 75Ai), as seen by little change in the IC50 values 
and cytotoxicity curves, the opposite effect could be seen; a slight sensitisation, as a 
lower concentration of toxin was required to cause a cessation in protein synthesis. This 
was calculated to be 1.6 fold (Figure 75H). These results demonstrate the ability of 
HIV-1 to interfere with a stage of the DTx trafficking pathway, but also a surprising 
slight effect on the RTx pathway.  
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Since both Gag and Nef are able to interact with the APs, it was next investigated 
whether the presence of Nef is necessary for this protective effect against DTx. To 
ascertain this, the HXB2 provirus was used, has a truncated Nef protein. The results are 
shown in Figures 75B, Bi and H. The average protective effect against DTx was 
calculated to be 3.2 fold, and a 1.7 fold sensitisation to RTx. To determine whether this 
slight difference in protection was significant, p values were calculated. This test 
deduced that the results are not significantly different (p>0.05). This would indicate 
that Nef is not required for the protective effect observed against DTx cytotoxicity.  
To ascertain whether the protective effect observed was specific to the presence of 
HIV-1 proteins, and not transfecting cells with any provirus, HVPΔEC was used 
(Richardson et al., 1993). Although this provirus has the backbone of HIV-1, it does 
not produce Env, most of Gag, or the accessory genes (including Nef). The results are 
shown in Figures 75C, Ci and H. As can be seen, this provirus has little effect on both 
DTx and RTx cytotoxicity. The observed effects against DTx and RTx were found to 
be a 1.9 fold protection, and a 1.3 fold sensitisation, respectively. Student’s t-test 
deduced the protective effect to DTx to be very significantly different from the results 
obtained from HXB2N
+
 (p<0.01), whereas once again the sensitisation to RTx was not 
significantly different (p>0.05). This indicated that the presence of HIV-1 are required 
to increase protection against DTx. It is possible that this slight effect observed is due 
to an interruption of plasma membrane function caused by transfection, which could 
possibly interfere with DTx internalisation. 
Next, to investigate whether Gag was necessary to produce the protective effect against 
DTx, the two Gag mutant proviruses were used; HXB2N
+ΔGag and HXB2ΔGag. The 
use of these two proviruses would also demonstrate whether the presence of Nef can 
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compensate for the absence of Gag. The results are shown in Figures 75D, E and H. 
Small protective effects against DTx were observed for these proviruses; 1.9 fold for 
HXB2N
+ΔGag and 2.3 fold for HXB2ΔGag. These were deduced not to be 
significantly different from HVPΔEC (p>0.05), but very significantly different from 
HXB2N
+
 (p<0.01). Together, these results indicate that Gag is likely necessary for the 
protective effect. Once again, slight sensitisations to RTx were observed (Figures 75Di, 
Ei and H); 1.6 fold for HXB2N
+ΔGag, and 1.5 fold for HXB2ΔGag, which were also 
not significantly different from HXB2N
+
.  
Since it was clear that Gag is required to protect against the cytotoxic effects of DTx, 
the next logical step was to ascertain whether Gag alone could produce the same effect 
as the provirus. A Gag-GFP pcDNA construct was used, alongside a GFP only control. 
The results are shown in Figures 75F, G and H. Although Gag-GFP produced a larger 
2.4 fold protection against DTx, compared with only 1.75 fold for GFP, t-test deduced 
these results to be not significantly different from each other (p>0.05). Both of these 
results, however, were once again very significantly different from HXB2N
+ 
(p<0.01). 
Both of these plasmids also produced a slight sensitisation to RTx (Figures 75Fi, Gi 
and H); 1.1 fold for Gag-GFP and 1.6 fold for GFP, which were not significantly 
different from HXB2N
+
. Together, these results indicate that Gag is necessary, but not 
sufficient, to protect against DTx. The fact that GFP also produces a slight sensitisation 
to RTx also indicates that this is a non-specific effect of transfecting in DNA or 
overexpressing exogenous protein, rather than a HIV mediated effect. The compiled 
protective effects observed are summarised in Figure 75H, which also highlights 
significant differences in values by asterisks, as compared with HXB2N
+
.  
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Figure 75: The effect of HIV-1 on DTx/RTx cytotoxicity. A-G- Left panels show 
DTx cytotoxicity curves, Ai-Gi- Right panels show RTx, from 4 hour toxin 
challenges of transfected HeLa cells, showing one representative result from 3 
repeat experiments. IC50 (concentration in ng/ml at which protein synthesis is 
inhibited by 50%) is shown to the right of each graph. Proviruses used in 
experiments are as follows; A-HXB2N
+
, B- HXB2, C-HVPΔEC, D-HXB2N+ΔGag, 
E-HXB2ΔGag, F- Gag-GFP, G- GFP pcDNA. H shows a compilation of average 
protections/sensitisations to toxins from 3 repeat experiments. Statistically 
significant results, as compared to HXB2N
+
, are highlighted by an asterisk 
(p<0.01) 
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7.2.2 HIV-2 has a Greater Effect on DTx Trafficking than HIV-1 
Results gathered in the previous chapter suggest that HIV-2 Gag trafficking and 
assembly requires intracellular compartments, which are likely to be multivesicular 
bodies (MVBs)/late endosomes. Similar to HIV-1 Gag, it is also probable that HIV-2 
Gag reaches these late endosomal compartments via early endosomal compartments, 
since in both cases when AP-3 was knocked down, Gag became stuck within 
intracellular compartments and could not traffic to the PM. Since early endosomal 
compartments are used in DTx trafficking (Papini et al., 1993; Lemichez et al., 1997), 
and late endosomes may also play some role, it was predicted that HIV-2 would also 
interfere with DTx cytotoxicity, but perhaps to a greater extent than HIV-1, since HIV-
1 predominantly assembles and buds at the PM. Results gathered from transfecting 
HeLa cells with the env deleted HIV-2 provirus SVRΔNB are shown in Figures 76A, 
Ai and D, where A and Ai are one representative from repeat experiments. As can be 
seen, HIV-2 had a large effect on DTx cytotoxicity, and the protective effect was 
revealed to be 4.6 fold, which was higher than HIV-1 HXB2. T-tests revealed this 
difference to be significant, indicating that HIV-2 SVRΔNB transfected provirus had a 
significantly greater protective effect against DTx cytotoxicity than HIV-1 HXB2. The 
effect for RTx was also a slight sensitisation as with HIV-1; an average of 1.7 fold, 
similar to that of HIV-1.  
Next, to investigate whether the MA domain contributes to this effect, the MA2 
provirus was tested. Since this virus is more efficient at particle release than HIV-1, it 
was predicted that this may have a greater effect on DTx cytotoxicity. The results are 
shown in Figures 76B, Bi and D. Surprisingly, the protective effect against DTx was 
revealed to be 3.5 fold; a similar value to that obtained for HIV-1 HXB2. HXB2 was 
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Figure 76: The effect of HIV-2 and chimeric proviruses on DTx/RTx cytotoxicity. 
A-C- left panels show DTx cytotoxicity curves, Ai-Ci- right panels show RTx, from 
one representative of 3 repeat experiments.  Proviruses used in experiments are as 
follows; A-HIV-2 (SVRΔNB), B- MA2 (HXB2 MA2), C-MA1 (SVRΔNB MA1). D- 
Compilation of average protections/sensitisations to toxins. Statistically significant 
results, as compared to HIV-1 HXB2, are highlighted by an asterisk (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
Figure 77: The effect of AP knockdown on DTx/RTx cytotoxicity in siRNA treated 
HeLa cells. Compiled average protections/sensitisations to DTx and RTx are 
shown from 3 independent repeat experiments.  
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used for comparative measures as this was the provirus used to generate both MA1 and 
MA2. This again indicated that this virus has a similar phenotype to HIV-1 with 
regards to interactions with the APs, despite containing the MA domain of HIV-2. 
Another surprising result was that there was no sensitisation to RTx; this is the first 
transfected construct to have no effect on RTx trafficking. This was not expected, 
considering one could expect the increase in viral egress seen with this virus to have 
some effect on general receptor recycling/entry from the PM.  
Finally, the MA1 provirus was used to determine whether this behaved in a similar 
manner to HIV-1 or HIV-2. The results are shown in Figures 76C, Ci and D. The 
average protective effect against DTx observed for this provirus was found to be 3.7 
fold, which although was not as high as with HIV-2, it was still significantly higher 
than HIV-1 HXB2 (p<0.05). This was again indicative that this virus has a similar 
phenotype to HIV-2, despite containing the MA of HIV-1.  
7.2.3 Knocking Down the APs does not Affect DTx Trafficking 
To investigate whether the interference of HIV with DTx trafficking is mediated by the 
APs, the next logical stage was to test whether siRNA induced knockdown of the APs 
also affected DTx trafficking. This would then infer which AP may be involved in DTx 
trafficking, and therefore also imply which AP HIV is likely interfering with to cause 
an interruption in toxin trafficking. The siRNAs directed against AP-1, -2 and -3 were 
first used to transfect HeLa cells individually. The summarised results are shown in 
Figure 77. As can be seen, surprisingly no protective effect against DTx was found. A 
slight sensitisation to RTx, representative of the non-specific effect of transfection seen 
before, was once again observed. This indicates that RTx remains a suitable control.  
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Since it is possible that DTx could use several APs to work in a redundant manner 
efficient trafficking, it was postulated that reducing one AP at a time is not sufficient to 
produce a significant effect. Therefore, AP-1 and -3, then all 3 siRNAs together were 
utilised. The results are also summarised in Figure 77. Once again, surprisingly, very 
little effect/ no effect was seen. When AP-1 and -3 siRNAs were used together, this 
produced the largest effect against both DTx and RTx. The protection against DTx was 
still only 1.5 fold, however. This is similar to the result obtained from HVPΔEC, which 
we would most likely regard as a non-specific effect, especially since when all 3 AP 
siRNAs were used together, no effect was seen. These results indicate that reducing the 
APs is not sufficient to interrupt DTx trafficking. However, since in this particular 
experiment efficient knockdown was not proven, we cannot exclude the possibility that 
the small protective effects seen were due to inefficient knockdown. 
7.2.4 HIV-1 Interferes with Early and Late Stages of DTx Trafficking 
Although it has so far been demonstrated that HIV interferes with DTx, but not RTx, it 
is necessary to gather data which can infer the stage of toxin trafficking that is 
interrupted. Therefore, in order to gauge an idea as to how HIV is exerting this 
observed effect on DTx cytotoxicity, toxin time course assays were carried out. In these 
assays, fixed (high) concentration of toxin was added to a different well of cells every 
15 minutes over a period of 3 hours prior to measuring 
35
S-methionine incorporation. 
This determines approximately when the first ribosomes start to be inhibited, and the 
subsequent rate of inhibition. This ascertains whether a delay in toxin trafficking (lag 
time) is occurring, or a delay in the later stages (intoxication) of the toxin pathway, 
which would be indicated by an alteration in the gradient of protein synthesis 
  
 
Figure 78: HIV-1 interferes with DTx trafficking. A- Remaining protein synthesis 
after toxin challenge for different amounts of time. White and grey arrows 
indicate transition from the lag phase to the intoxication phase (mock and HXB2, 
respectively). Black double arrow highlights a change in intoxication rate, as 
shown by a change in slope gradient. B- Table of calculated changes in toxin 
trafficking times (lag) and intoxication (T1/2).  
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inhibition. HXB2 provirus was transfected as before and compared to mock-transfected 
cells. Results are shown in Figure 78.  
This Figure shows that a significant increase in lag time occurred in the presence of 
HIV-1, as compared to mock transfected cells. This was calculated to be approximately 
40 minutes (see Figure 78B). This is indicative of a delay in toxin trafficking, likely 
explains the protective effect observed before. Slightly surprisingly, however, a slight 
delay (approximately 17 minutes) in the intoxication phase was also observed, as 
demonstrated by a slight change in the gradient of the slope on the graph, and the 
change in T1/2 times calculated. It may therefore be that the interruption of DTx 
cytotoxicity is not simply a result of interrupting the normal trafficking pathway of this 
toxin as presumed, but possibly a combination of effects during early and late stages of 
this pathway.  
This Figure also shows a very slight decrease in the lag time of RTx, which was 
expected since a slight sensitisation was observed after plasmid transfection. The 
change in lag time was, however, very modest (4 minutes). This was lower than the 
expected value from this experiment. Selection of appropriate times of toxin addition 
is, however, crucial to this experiment, so it remains possible that modest changes were 
missed, masking real effects.  
7.2.5 HIV does not Interfere with VSV-G Trafficking 
As mentioned above, trafficking of ts045-VSV-G-EGFP (VSV-G)has been reported to 
be dependent on AP-3 (Nishimura et al., 2002); in particular, it was found to interact 
with the δ subunit of AP-3. This is the same subunit which HIV-1 has been proposed to 
interact with (Dong et al., 2005), although others have disputed this from in vitro 
peptide expression experiments (Kyere et al., 2012). Since direct visualisation of the 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79: HIV-1 and -2 do not interfere with ts045-VSV-G-EGFP trafficking. 
Confocal immunofluorescence images of VSV-G-EGFP (green) and HIV Gag 
(red) in HeLa cells at 0 (t0), 30 (t30), 60 (t60) and 120 (t120) minutes after shift to 
32
o
C. Panel A- VSV-G trafficking in the absence of HIV provirus. Panel B- VSV-
G trafficking in the presence of HIV-1 HXB2. Panel C- VSV-G trafficking in the 
presence of HIV-2 SVRΔNB.  
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trafficking of VSV-G is possible, it was thought to be a particularly useful tool for 
investigating potential interference with an AP-3-dependent trafficking pathway.  
The trafficking of the temperature sensitive VSV-G-EGFP protein was followed at 0, 
30, 60 and 120 minutes after release from the ER in HeLa cells transfected with HIV-2 
HXB2 or HIV-2, by confocal immunofluorescence microscopy. The results are shown 
in Figure 79.  
Panel A shows VSV-G-EGFP fluorescence (green) in the absence of HIV. At t0, VSV-
G could be observed in a perinuclear position, which is likely the ER. At t30, the protein 
could be observed in a tight juxtanuclear location, which is likely the Golgi/ TGN. AT 
t60, less was present in the TGN, and some diffuse cytoplasmic staining could be 
observed. Some had also reached the PM, as shown by some projections around the 
edge of the cell. By t120, most of the construct was present at the PM, as shown by 
strong fluorescence around the edge of the cell. Panel B shows VSV-G trafficking in 
the presence of HIV-1, and panel C shows trafficking in the presence of HIV-2 (Gag 
immunofluorescence shown in red). As can be seen, VSV-G displayed localisations 
similar to when the provirus was absent. This suggests that HIV did not interfere with 
the trafficking of VSV-G. This would support the evidence gathered by Kyere et al. 
(2012), suggesting that HIV-1 does not interact directly with the AP-3δ subunit, but 
also infers that HIV-2 may not either. However, Kyere et al. (2012) used a purified AP-
3δ fragment in vitro, whereas Dong et al. (2005), carried out multiple approaches with 
intact AP-3 in vivo. This was particularly surprising since data gathered in the previous 
chapter show a strong dependence of HIV-2 trafficking on AP-3. However, this 
experiment cannot rule out the possibility of AP-3 interactions since it is an indirect 
assay, and it may simply be that HIV Gag and VSV-G are able to both traffic in an AP-
3 mediated manner without competitively interfering with each other.  
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7.3 Discussion 
HIV-1 has evolved the ability to interrupt the trafficking of numerous proteins in order 
to benefit the virus life cycle. For example, HIV-1 Nef is able to interfere with the 
trafficking of MHC-I to aid immune evasion (Blagoveshchenskaya et al., 2002) by 
sequestering it to the TGN. Since data collected in previous chapters demonstrates that 
both HIV-1 and HIV-2 are able to disrupt the localisation of the adaptor proteins, and 
require them for trafficking and assembly, the ability of these viruses to interfere with 
AP dependent trafficking pathways was investigated.  
The first trafficking pathway to be investigated was that of Diphtheria toxin (DTx). 
This toxin is a useful tool since it is known to enter the cell via clathrin-mediated 
receptor endocytosis, pass into early endosomes, and then enter the cytoplasm after 
endosomal acidification. Since we know both HIV-1 and -2 interact with AP-3, which 
is involved in endosomal trafficking, this seemed an appropriate assay.  
Results obtained from these experiments clearly demonstrate the ability of HIV-1 to 
interfere with the DTx trafficking pathway, as demonstrated by a protective effect. 
Protection against DTx meant that there is an interference with toxin action at some 
stage, i.e. it was not able to as efficiently cause a cessation in protein synthesis in the 
presence of HIV. Sensitisation to RTx were observed throughout, meaning that there 
was an increase in toxin action, i.e. a more efficient cessation in protein synthesis.  
It was also discovered through the use of mutant viruses that Gag was necessary, but 
not sufficient for the interruption in DTx cytotoxicity. Since Gag deleted proviruses 
caused a small protective effect, this means that the presence of other viral components 
exert some effect, but that the majority of the effect is Gag driven. A possible 
explanation for the fact that Gag-GFP could not substantially protect against DTx is 
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that Gag, in the absence of other viral proteins, behave differently. This could subvert 
the need to pass through endosomes, and therefore reduces the disruption of DTx 
trafficking. Viral Nef was also found to be dispensable for the protective effects 
observed, which was surprising since Nef too interacts with the APs.  
A possible explanation for the observed protective effect against DTx is sequestration 
of the APs by Gag. DTx may require AP-3 to travel along the endosomal pathway 
before it enters the cytoplasm if this occurs from late endosomes. A requirement for 
AP-1 may be involved in DTx receptor recycling if it transits through the Golgi, 
although it may cycle directly from endosomes without the APs/clathrin, and AP-2 
would also be required for receptor mediated endocytosis. It is possible that HIV could 
sequester the APs as a consequence of Gag interactions, therefore making them 
unavailable for utilisation by DTx. However, the siRNA cytotoxicity assays 
demonstrate that it is possibly more complex than merely sequestering the APs, as a 
reduction in the APs does not appear to interfere with DTx trafficking. This was 
surprising especially since AP-2 knockdown should disrupt clathrin-mediated 
endocytosis; however, it may be that the siRNAs are not capable of removing all AP 
molecules present in the cell, and that only a few molecules are required to assist DTx 
trafficking, since a very small amount of toxin is capable of exerting a cytotoxic effect. 
Another explanation could be that the presence of Gag on endosomal membranes 
prevents the translocation of DTx into the cytosol.  
Not surprisingly, it was found that HIV-2 had a significantly larger effect on DTx 
trafficking than HIV-1. Since previous results indicate that HIV-2 alters the localisation 
of AP-3, requires this protein for trafficking and assembly, and also likely involves the 
endosomal pathway for Gag trafficking, this was logical. The most likely explanation is 
that the presence of HIV-2 Gag in endosomal compartments (M. Marongiu, I. Portman 
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and E. C. Anderson, unpublished results) either prevents the entry of DTx into these 
compartments, or causes a failure in endosomal acidification required for cytoplasmic 
entry. MA1 was also found to have a significantly larger effect on DTx as compared 
with HIV-1. This makes sense since MA1 is not capable of releasing viral particles; this 
would cause an intracellular accumulation, which will be more likely to interfere with 
intracellular pathways. Confocal immunofluorescence microscopy in HeLa cells also 
demonstrated that this virus gets stuck around the edge of the cell in clathrin 
concentrated areas, which could have detrimental effects on clathrin-mediated 
endocytosis. MA2, however, exerted a similar effect to HIV-1, further indicating that 
this virus adopts a similar trafficking phenotype to HIV-1. Since this virus has a higher 
release efficiency than HIV-1, it is also likely that this results in a decrease in 
intracellular Gag, and therefore a lower burden on cellular trafficking pathways.  
With regards to time course assays, the results gained from DTx assays were as 
expected; there was a significant (~40 minute) decrease in trafficking of the toxin, but a 
small effect on intoxication was also observed. There are several possible explanations 
for the results observed. Firstly, it may be that HIV present at the PM interferes with 
AP-2- dependent receptor mediated endocytosis of DTx. Secondly, it is possible that 
HIV Gag localised to endosomal membranes may prevent DTx from trafficking down 
the endosomal pathway or translocating into the cytosol. Finally, if AP-1 facilitates 
DTx receptor recycling back to the surface, it is possible that Gag may interfere with 
this since we saw a change in the localisation of AP-1 in HIV-1 transfected cells (see 
chapter 3.2.4ii). The small decrease in intoxication rate seen could be due to the 
perturbation of the delivery of a facilitating enzyme necessary for DTx activation, such 
as furin. Or it may be that there is a defect in endosomal maturation, also caused by an 
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interference with AP-3. Repeat experiments would be necessary to determine whether 
this effect is indeed significant, however.  
The ts045-VSV-G-EGFP results showed that HIV did not alter its trafficking. This was 
puzzling and unexpected, since it has been demonstrated that both Gag and VSV-G 
interact with the AP-3δ subunit. It was therefore assumed that, through competition, 
HIV may inhibit VSV-G trafficking from the ER to the PM. This was not the case as 
can be seen from the results. It is possible that Gag is not present in high enough 
quantities to inhibit the trafficking of VSV-G to the PM, as some AP-3 subunits are still 
available for utilisation. It is possible, however, that subtle changes in trafficking times 
do occur, but are missed by the time points selected for this experiment. Alternatively, 
since HIV is able to use VSV-G as an envelope in the absence of Env, it may be that 
these molecules are capable of co-trafficking; therefore no disruption would be seen.  
7.4 Future Work 
The most obvious limitation of this study is the absence of repeat time course assays. 
This was due to a limited availability of toxin, and could not be avoided. Unfortunately, 
therefore, repeat experiments utilising different time intervals was not possible. This 
means that the sensitisation to RTx was not well characterised, and it was not possible 
to confirm the possible delays in the intoxication phase of DTx.  
An obvious gap in the results presented in this chapter is the absence of HIV-2 Gag 
deleted proviruses. Although it would be assumed that these follow the same pattern as 
HIV-1, it would be interesting to see whether an absence of HIV-2 Gag also removes 
the interference with DTx.  
Future experiments involving siRNAs should also ensure that knockdown is efficient 
via Western blot, which was lacking in this chapter. Since AP-2 knockdown in 
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particular did not produce the expected effect of reducing DTx cytotoxicity by 
inhibiting entry, it is likely that knockdown was not sufficient.  
Although confocal microscopy failed to reveal an interruption in VSV-G trafficking, 
this study was somewhat limited. Despite the observation that the construct was 
localised to the previously described areas at each designated time point, this 
experiment failed to show what happens to the construct between time points. It is 
therefore possible that, in the presence of HIV, VSV-G trafficked at a different speed to 
when it was absent. For example, it is possible that VSV-G reaches the PM fully by 
100 minutes, but not until 110/120 minutes in the presence of HIV. Real-time confocal 
microscopy would have been a useful tool to investigate this.  
 
Chapter 8                                                                              Results       
 
178 
 
CHAPTER 8: DOES HIV-1 AFFECT VESICLE 
RECYCLING WITHIN ASTROCYTES? 
 8.1 Introduction 
Individuals infected with HIV not only suffer a severely impaired immune system, but 
many will experience neurological complications later on in the disease process. These 
neurocognitive complications have been collectively categorised as HIV-associated 
neurocognitive disorders (HAND), which defines three categories of dysfunction; 
asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-
associated dementia (HAD), with the latter being the most severe manifestation (Kaul, 
2009). Approximately 60% of HIV infected individuals experience some neurological 
impairment and prior to the widespread use of HAART, up to 30% of patients would 
suffer HAD. Symptoms include a range of motor and cognitive impairments, ranging 
from diminished short term memory, leg weakness and behavioural and personality 
changes (Gonzalez-Scarano and Martin-Garcia, 2005; Ghafouri et al., 2006).  
HIV enters the CNS during early stages of infection, shortly after systemic viral 
dissemination. The favourite hypothesis for viral invasion is the “Trojan horse” 
hypothesis, whereby HIV enters host cells that are destined for the brain. These cells 
are predominantly monocyte-derived macrophages, which are highly efficient at 
crossing the blood brain barrier (BBB). There is some evidence that free viral particles 
may also enter the brain through the BBB via a similar mechanism to adsorptive 
endocytosis, mediated by the Env glycoprotein (Kramer-Hӓmmerle et al., 2005; Aquaro 
et al., 2008; Banks et al., 2011).  
Within the CNS, HIV preferentially infects perivascular macrophages and microglia; 
these cells permit productive infection. Some lines of evidence have suggested that 
neurons may be infected by HIV; however, this remains controversial and the damage 
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that occurs within these cells is likely mediated by the inflammatory molecules secreted 
by infected cells (Sharma and Bhattacharya, 2009). Another cell line which has been 
the focus of much interest is astrocytes. Astrocytes are latently rather than productively 
infected, and thus do not produce new virions after an initial burst of viral protein 
production when first infected; they do represent a viral reservoir, however. Initial PCR 
investigation of astrocytic populations in HAD patients revealed infection in only 1-3% 
of the population, whereas the development of highly sensitive methods detected gene 
expression in 19% of GFAP
+
 (glial fabrillary acidic protein; a marker for astrocytes) 
cells (Churchill et al., 2009).  
Astrocytes represent an important aspect of HAD for numerous reasons. Firstly, they 
are the most abundant cell type present within the brain, constituting 40% of the total 
nervous system cell population, outnumbering neurons 10-50:1 (Brack-Werner, 1999). 
Secondly, astrocytes play a pivotal role in brain functioning, forming an essential part 
of the tripartite synapse, releasing a number of neurotransmitters and neurotrophins 
essential for regulating neuronal synaptogenesis and synaptic activity. Astrocytes are 
also essential for brain homeostasis, mopping up excess glutamate and converting it 
into glutamine, preventing excessive neuronal excitation (Wang et al., 2004). Finally, 
latent infection of astrocytes, or exposure of astrocytes to either progeny virions or 
extracellular gp120 also alters global astrocyte gene expression, causing glutamate 
catabolism to become compromised, the induction of apoptotic protein synthesis, 
excitotoxic neuronal death and impaired glutamate uptake and release (Wang et al., 
2004; Dou et al., 2006; Churchill et al., 2009). 
Within these cells, HIV expression is restricted to early gene products, such as Nef and 
Rev (Aquaro et al., 2008); Gag expression was found to be dramatically less than that 
in HeLa cells (Gorry et al., 1999). Replication within astrocytes is down-regulated at 
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several different stages of the life cycle, including virus entry, reverse transcription, 
nucleocytoplasmic HIV-1 RNA transport, translation of viral RNA, and maturation of 
progeny virions (Gorry et al., 2003). One such example, proposed to account for low 
Gag expression, is that it is mainly the multiply spliced, smaller (2kb) transcripts are 
able to enter the cytoplasm from the nucleus due to a cell determined block in the 
nucleus-cytoplasmic Rev shuttling, causing nuclear retention of Rev-dependent 
mRNAs and their subsequent degradation (Gorry et al., 1998; Aquaro et al., 2008). It 
was also found that translation of gag and env transcripts was inefficient; only Tat and 
Rev were efficiently translated from their native mRNAs (Gorry et al., 1999).  
Many of the hypotheses which have been so far proposed with regards to how 
astrocytic infection impairs CNS function are speculative, due to a lack of suitable 
experimental systems. One such hypothesis is that infected astrocytes may become 
impaired in their role in neuronal support. Astrocytes, unlike previously believed, play 
an active role in brain signalling, behaving as both secretory and receptive elements to 
numerous transmitters (Volkandt, 2002). They can release a variety of transmitters 
including ATP and glutamate in response to increased intracellular Ca
2+ 
levels 
(Montana et al., 2006).  
As mentioned in the introduction (chapter 1.5.3) AP-1, -2 and -3 are extensively 
involved in neurotransmitter recycling. Although adaptor protein mediated vesicle 
recycling has not been studied within astrocytes, it was revealed that astrocytes do 
indeed express at least AP-2 (Miñana et al., 2001).  
A summation of this evidence led to the following hypothesis; if vesicle recycling in 
astrocytes occurs in an AP dependent manner, can HIV infection in astrocytes perturb 
this process via interference with the APs? If so, perhaps this may contribute to the loss 
of neuronal function observed in HAD, and therefore the motor/cognitive symptoms 
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observed. This chapter aimed at developing techniques to investigate the potential 
effects of HIV on vesicle recycling pathways within a human astrocytoma cell line.  
8.2 Results 
8.2.1 U373 MG Cells Express Gag from a Gag-GFP Construct 
Due to the Rev associated block of protein expression, proteins from larger splice 
products have not been reported to be synthesised to high levels in astrocytes. 
Transfection of astrocytes with a Rev-independent Gag-GFP plasmid (Hermida-
Matsumoto and Resh, 2000) should bypass this block and allow synthesis of Gag 
proteins. To test this theory, both Gag-GFP and GFP plasmids were used to transfect 
human astrocytoma (U373 MG) cells, which were viewed under the confocal 
microscope. The results are shown in Figure 80.  
As can be seen, both GFP and Gag-GFP were expressed well in this cell line 24 hours 
post-transfection. GFP expressing cells increased at 48 hours as compared with samples 
taken at 24 hours; the same could not be said for Gag-GFP, however. As can be seen in 
Figure 80D, both untransfected U373 MG cells and Gag-GFP expressing cells were 
sparse and some had very altered morphologies. The nucleus also appeared to have 
disintegrated in some cells, as shown by the loss of defined round nuclei, replaced with 
a diffuse DAPI staining.   
Although this is an artificial system as Gag is not predicted to be expressed at high 
levels in astrocytes, and therefore this is not representative of an in vivo situation, this 
does suggest that Gag expression in astrocytes has a detrimental effect on astrocyte 
morphology and viability.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80: GFP and Gag-GFP expression in U373 MG cells. Confocal 
immunofluorescence images of U373 MG cells 24 (A, B) and 48 hours (C, D) post-
transfection with GFP (A and C) or Gag-GFP (B and D) expression plasmids. Blue 
stain= DAPI.   
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8.2.2 HIV-1 Gag and Nef are Expressed in Provirus-Transfected U373 
MG Cells 
The ability of astrocytes to produce Nef in high quantities when infected with HIV-1 
has been previously described (Ranki et al., 1995). Although Gag expression has been 
detected in transfected astrocyte cell lines, inefficient translation of gag transcripts, 
amongst other things, leads to a decrease in Gag protein expression when compared 
with non-neuronal cell lines (Gorry et al., 1999). Transfection of astrocytes with 
proviral DNA will bypass viral entry and reverse transcription, but not 
nucleocytoplasmic RNA transport or mRNA translation. To determine whether 
transfected U373 MG cells do indeed express Nef in high quantities, and to establish 
whether Gag expression can be detected despite blocks in translation, U373 MG cells 
were transfected with the HXB2N
+
 HIV-1 provirus and analysed by both Western blot 
and by confocal immunofluorescence microscopy, using anti-HIV-1 p24 and anti-HIV-
1 Nef antibodies for viral protein detection. The results are shown in Figure 81.  
Figure 81A shows a Western blot of cellular Gag collected at 24 and 48 hours after 
transfection of both HeLa and U373 MG cells. As can be seen, although Gag could be 
detected, it was present at much lower levels than in HeLa cells. These levels were 
comparable since equal amounts of protein were loaded into each lane of the gel. No 
Gag was detected in supernatant samples, supporting the non-productive nature of these 
cells (data not shown). Figure 81B shows Nef 24 hours after HIV-1 transfection of 
U373 MG cells only. As can be seen, even at 24 hours, a significant amount of Nef was 
detectable.  
Figures 81C and D show confocal immunofluorescence images of Gag and Nef 
staining, respectively, within transfected U373 MG cells. Nef had a diffuse staining 
pattern, similar to that of HeLa cells. Gag was a mixture of punctate and diffuse, again 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 81: HIV-1 Gag and Nef are expressed in U373 MG cells. A- Western blot of 
HeLa and U373 MG cell lysates, 24 and 48 hours post transfection with the HIV-1 
provirus, using an anti-HIV p24 antibody. B- Western blot U373 MG cell lysates, 
24 hours post-transfection with the HIV-1 provirus, using an anti-HIV-1 Nef 
antibody. C and D- Confocal immunofluorescence images of U373 MG cells 
transfected with the HIV-1 provirus for 24 hours, stained with anti-HIV-1 p24 and 
anti-HIV-1 Nef, respectively (red). Blue=DAPI.   
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reminiscent of staining within HeLa cells. Confocal immunofluorescence microscopy 
revealed Gag expression in between 10-30% of U373 MG cells, compared to 50-70% 
of HeLa cells (data not shown).  
8.2.3 HIV-2 Gag is Expressed in Significantly Lower Levels than HIV-
1 Gag in U373 MG Cells 
Evidence for the neuropathology of HIV-2 infections is limited. This is mainly due to 
the fact that HIV-2 predominantly exists in Western Africa, where diagnostic tests and 
medical surveillance are limited. Nonetheless, there has been evidence gathered from a 
number of patients which would support the notion that HIV-2 has a similar impact on 
the CNS as HIV-1, with patients developing HAD and other neurological conditions 
such as giant cell encephalitis (Rolfe, 1994).  
To investigate whether astrocytes are permissive to HIV-2 through transfection, U373 
MG cells were transfected with the HIV-2 provirus and investigated by confocal 
microscopy, using an anti-SIV p27 antibody as a marker for Gag expression. The 
results are shown in Figure 82. As can be seen, HIV-2 Gag was clearly expressed in 
this cell line (82B). The distribution of Gag was slightly different as compared with 
HIV-1 (Figure 82A); once again we observed a very punctate staining, similar to that in 
HeLa cells, whereas with HIV-1 we saw a mixture of punctate and diffusely stained 
cells, again reminiscent of the pattern seen in HeLa cells.  
Transfected U373 MG cells were also analysed by Western blot using an anti-SIV p27 
antibody on harvested cell samples and compared with transfected HeLa cells. The 
results are shown in Figure 82C. 
As can be seen, very little HIV-2 Gag was present in transfected U373 MG cells. The 
same amount of protein was loaded between HeLa and U373 MG samples, which 
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demonstrate that HeLa cells produced significantly more than the astrocytes. In 
addition, the relative expression of HIV-2 in U373 MG compared to HeLa cells 
appeared to be less than the relative expression of HIV-1 in these cell types (Figure 
81A vs. Figure 82C).  
In agreement with the Western blot results, when cells expressing Gag were counted 
using confocal microscopy (Figure 82D), HIV-1 transfection produced significantly 
more Gag expressing cells than HIV-2 (p<0.05) at 24 hours. At 48 hours, however, 
there was no significant difference despite there being >10% more Gag expressing cells 
in the HIV-1 transfection (p>0.05). This could perhaps be due to the toxicity of HIV on 
these cell lines, destroying many apoptosed Gag expressing cells, which would then be 
washed away during the fixing and staining procedure. It must be mentioned, however, 
that even in HeLa cells, HIV-1 transfection gives significantly more Gag expressing 
cells than HIV-2 (data not shown).Therefore this decrease in HIV-2 expression is not 
an astrocyte-specific mechanism.    
8.2.4 U373 MG Cells Express Adaptor Proteins -1, -2 and -3 
As mentioned in the introduction, AP-2 has been detected in astrocytes (Miñana et al., 
2001). To investigate whether they express AP-1 and -3 also, confocal 
immunofluorescence microscopy was carried out on U373 MG cells, using anti-AP-1 
and -3 antibodies. As Figures 83A and B demonstrate, these proteins are clearly 
abundantly expressed within astrocytes. For further confirmation, Western blot analysis 
was carried out on both U373 MG and HeLa cell lysates, using antibodies against all 3 
adaptor proteins. As Figure 83C shows, all 3 adaptor proteins are expressed within this 
cell line. Abundances of these proteins in comparison to HeLa cells cannot be 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82: HIV-2 Gag is expressed in transfected U373 MG cells at significantly 
lower levels than HIV-1. A and B- Confocal immunofluorescence images of U373 
MG cells transfected for 24 hours with HIV-1 and HIV-2 proviruses, respectively. 
Anti-HIV-1 p24 and anti-SIV p27 antibodies were used for Gag detection (red). 
Blue=DAPI. C- Western blot of HeLa and U373 MG cell lysates, 24 and 48 hours 
post-transfection with the HIV-2 provirus, using anti-SIV p27 antibody. D- 
Quantification of HIV-1 and HIV-2 Gag expressing U373 MG cells, 24 and 48 
hours post proviral transfection, gathered from 3 independent repeat experiments. 
Statistically significant differences between HIV-1 and HIV-2 are highlighted by 
an asterisk (p<0.05).  
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Figure 83: U373 MG cells express adaptor proteins -1, -2 and -3. A and B- 
Confocal immunofluorescence images of U373 MG cells stained with anti AP-1γ 
and AP-3δ, respectively (green). Blue stain= DAPI. C- Western blot of harvested 
HeLa and U373 MG cell lysates. Membranes were probed with anti AP-1γ, AP-2µ 
or AP-3δ antibodies.  
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extrapolated since samples were collected directly by using SDS-protein sample buffer 
to increase concentration, therefore total protein concentrations could not be measured.  
Since it has been discovered that HIV-1 infection of astrocytes leads to impaired 
glutamate uptake and release (Wang et al., 2003), it was postulated whether this could 
be due to HIV interfering with glutamate receptor recycling, since it is likely that this 
process will be at least AP-2 mediated. AMPA receptors are ionotropic glutamate 
receptors that are found in both neurons and astrocytes. They are tetrameric heteromers 
composed of 4 subunits of GluR1, GluR2, GluR3 and GluR4, which form ligand gated 
ion channels (Chang et al., 2012). Extensive investigation of the U373 MG cell line by 
Western blot analysis revealed that this cell line does not express GluR1 or GluR2 in 
detectable amounts (data not shown). It remains to be elucidated, however, whether 
they may express GluR3 or GluR4; however, since GluR2 is usually the common 
subunit of this receptor, coupled with different combinations of the other subunits, it 
seems unlikely.  
8.2.5 HIV-1 Interferes with Astrocytic Vesicle Recycling 
Mechanisms of investigating synaptic vesicle recycling and vesicle 
endocytosis/exocytosis events has been revolutionised since the advent of styryl dyes. 
Previously, no such experimental system existed whereby examinations of single 
vesicle events taking place within a cellular process could be studied.  
Styryl dyes possess a hydrophilic head attached to a lipophilic tail; this allows the 
unique property of reversible insertion into the outer leaflet of lipid surface membranes 
without permeating the vesicle, which is due to two cationic charges located in the head 
group (Betz et al., 1996; Cousin and Robinson, 1999; Amaral et al., 2011).  These dyes 
are not fluorescent when in aqueous solution, however, they increase in fluorescence 
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100-fold when partitioned into membranes; this means that fluorescent labelling is 
limited to outer leaflets of plasma membranes the inner leaflet and recycling vesicles 
(Cousin and Robinson, 1999; Khvotchev and Kavalati, 2008).  
Many styryl dyes have been developed; FM1-43 is one of the more popular dyes since 
it possesses a short half-time in membrane, which allows dye that has not been 
internalised to be quickly washed off. This dye can be used to investigate vesicle 
recycling; after incubation of a cell line with this dye, it inserts into the outer leaflet of 
the PM, and after stimulation of exocytosis it becomes internalised during vesicle 
retrieval. Leftover dye is washed off, and what remains reflects fluorescently labelled 
vesicles. By recording uptake of the dye, insight is given into vesicle endocytosis. 
Stimulation of exocytosis allows release of the vesicles upon a second round of 
stimulation, which can be measured by loss of fluorescence (Cousin and Robinson, 
1999).  
This technique therefore seemed an appropriate and direct way to investigate whether 
HIV-1 is able to vesicle recycling within astrocytes; does HIV prevent dye uptake, 
therefore interfering with endocytosis, which is likely through interactions with AP-
2/AP-1 (Kim and Ryan, 2009)? Or does HIV-1 prevent destaining (loss of 
fluorescence), thereby interfering with vesicle exocytosis, which AP-3 has been 
implicated in (Nakatsu et al., 2004; Scheuber et al., 2006)? 
To test this, four conditions were investigated; mock-transfected cells, the Gag-GFP 
expression construct, a GFP only control, and HIV-GFP (pNL4-3-EGFP). This proviral 
construct expresses all of the structural, regulatory and accessory proteins of HIV-1 
except Env, because a form of enhanced GFP (EGFP) has been inserted into the env 
open reading frame. Vesicle recycling was investigated using the styryl dye FM1-43 
and two receptor agonists; UTP and TFLLR-NH2. UTP is a P2Y receptor agonist; P2Y 
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receptors are a family of G protein-coupled receptors, and TFLLR-NH2 is a PAR1 
(Protease-activated receptor) agonist (Huang, 2007; Jacobson et al., 2009).  
Mock-transfected and Gag-GFP transfected cells were investigated first. Cells were 
pre-loaded with FM1-43 for 1 hour to stain vesicles. Cells were selected for recordings 
using a 2-photon microscope, and vesicle exocytosis (destaining) was stimulated by the 
addition of TFLLR-NH2 for five minutes. ImageJ was then utilised to measure changes 
in fluorescence over time from multiple regions of interest per cell, which were 
expressed as percentages of peak fluorescence. A recording taken from a mock 
transfected cell is shown in Figure 84.  
As can be seen, the addition of TFLLR-NH2 successfully stimulated vesicle exocytosis, 
as demonstrated by a loss of fluorescence. This experiment was repeated and the same 
pattern was seen; however, due to differences in numbers of frames recorded from 
these repeat experiments, the results could not be compiled into one graph. UTP alone 
was also found to stimulate a loss of fluorescence (data not shown).  
Next, Gag-GFP transfected cells were investigated using the same protocol. The results 
are shown in Figure 85. As can be seen, in multiple experiments, the presence of Gag-
GFP severely compromised vesicle exocytosis upon stimulation by TFLLR-NH2. 
Although a decrease in fluorescence was observed over time, this was found to be only 
a 20% loss of total fluorescence, as compared with 50% in mock transfected cells. This 
demonstrates that the presence of HIV-1 Gag disrupted the normal vesicle recycling 
process within astrocytes. The response of FM1-43 stained Gag-GFP transfected cells 
to other agonists, UTP and anandamide (AEA, a cannabinoid neurotransmitter), was 
also investigated, and once again only very modest losses of fluorescence could be 
observed (data not shown).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 84: TFLLR-NH2 stimulates vesicle exocytosis in U373 MG cells. U373 cells 
were grown on glass coverslips and mock-transfected for 24 hours, followed by 
pre-loading with FM1-43 for 1 hour to allow dye uptake. Cells were viewed using 
a 2-photon microscope, and coverslips were perfused with a hypotonic solution 
containing TFLLR-NH2 from 2 minutes into the experiment for 5 minutes, 
followed by a wash. A- Confocal fluorescence images of vesicles containing FM1-
43 at 0, 10 and 14 minutes. Changes in fluorescence intensity over time were then 
calculated for individually selected regions of interest (ROIs) (see circles in panel 
A) using ImageJ. Background fluorescence was subtracted from each value. This 
was then plotted, and the result from 1 cell is demonstrated in B, with values 
expressed as percentages of peak of fluorescence.  
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Figure 85: Gag-GFP compromises vesicle exocytosis in U373 MG cells. U373 cells 
were grown on glass coverslips and transfected with Gag-GFP for 24 hours, 
followed by pre-loading with FM1-43 for 1 hour to allow dye uptake. Cells were 
viewed using a 2-photon microscope, and cells expressing GFP were selected for 
recordings. Coverslips were perfused with a hypotonic solution containing 
TFLLR-NH2 from 2 minutes into the experiment for 5 minutes, followed by a 
wash. A- Confocal fluorescence images of vesicles containing FM1-43 at 0, 8 and 
10 minutes. Changes in fluorescence intensity over time were then calculated for 
individually selected ROIs (see circles in panel A) using ImageJ. Background 
fluorescence was subtracted from each value. This was then plotted, and the 
results from 3 independent experiments are demonstrated in B, with values 
expressed as percentages of peak of fluorescence.  
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To take this further, the HIV-GFP provirus was used, with GFP pcDNA used as a 
control for these experiments. Dye uptake, as well as destaining, was also investigated 
in these experiments to look at both vesicle endocytosis and exocytosis. Cells were 
transfected for 24 hours, and cells expressing GFP were selected for recordings using a 
2-photon confocal microscope. FM1-43 plus UTP was added cells to stimulate dye 
uptake (vesicle staining), followed by the addition of the two agonists together 
(TFLLR-NH2 and UTP) to stimulate vesicle exocytosis. ImageJ was then used as 
before to measure changes in fluorescence over time for defined regions of interest. 
The results for GFP transfected cells are shown in Figure 86. 
A relatively slow increase in fluorescence was observed in these cells; it took 25-30 
minutes to reach peak fluorescence (Figure 86B). Dye uptake was found to be initially 
slow, with a rapid increase approximately 8 minutes prior to reaching peak 
fluorescence. This was followed by a rapid decrease in fluorescence when UTP and 
TFLLR-NH2 were added together; meaning vesicle exocytosis was efficient and 
occurring to compensate for the increase in endocytosis. A total loss of fluorescence 
was not observed; fluorescence decreased by 40% after stimulation of vesicle 
exocytosis, which was 30% higher than the initial fluorescence values. The error bars at 
the initial stages of the experiment were also large, as one cell fluoresced much more 
rapidly than others. The second stage of the experiment, however, displayed very small 
error bars and was therefore more reliable.  
The HIV-GFP provirus was next investigated, and the results are shown in Figure 87. 
As can be seen, the pattern of staining and destaining was strikingly different from that 
of GFP only transfected cells. An initial burst of fluorescence upon dye and agonist 
addition was observed, followed by a long period of slow increase. Since dye uptake 
was evidently very rapid, FM1-43 was only added for 10 minutes, as oppose to 20 
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Figure 86: Vesicle recycling in GFP only transfected cells. U373 cells were grown 
on glass coverslips and transfected with GFP DNA for 24 hours. Cells were viewed 
using a 2-photon microscope, and cells expressing GFP were selected for 
recordings. Coverslips were perfused with a hypotonic solution containing FM1-
43 and UTP for 20 minutes to allow uptake of dye (A-left and middle, 0 and 27 
minutes, respectively). Cells were then washed for 10 minutes, and then perfused 
with TFLLR-NH2 and UTP for 10 minutes to allow vesicle de-staining (A-right, 35 
minutes). Changes in fluorescence intensity over time were then calculated for 
individually selected ROIs (see circles in panel A) using ImageJ. Background 
fluorescence was subtracted from each value. This was then plotted, and the 
results from 3 cell recordings are demonstrated in B, expressed as percentages of 
the peak of fluorescence.  
FM1-43 + UTP TFLLR + UTP 
A 
B 
FM1-43 + UTP TFLLR + UTP - 
Time (min) 0  35 27 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 87: Vesicle recycling in HIV-GFP transfected cells. U373 cells were grown 
on glass coverslips and transfected with pNL4-3-EGFP for 24 hours. Cells were 
viewed using a 2-photon microscope, and cells expressing GFP were selected for 
recordings. Coverslips were perfused with a hypotonic solution containing FM1-
43 and UTP for 10 minutes to allow uptake of dye (A-left and middle, 0 and 23 
minutes, respectively). Cells were then washed for 10 minutes, and then perfused 
with TFLLR-NH2 and UTP for 10 minutes to allow vesicle de-staining (A-right, 35 
minutes). Changes in fluorescence intensity over time were then calculated for 
individually selected ROIs (see circles in panel A) using ImageJ. Background 
fluorescence was subtracted from each value. This was then plotted, and the 
results from 4 cell recordings are demonstrated in B, expressed as percentages of 
the peak of fluorescence.  
B 
A FM1-43 + UTP TFLLR + UTP - 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40
M
ea
n
 F
lu
o
re
sc
en
ce
 (
%
) 
Time (m) 
FM1-43 + UTP TFLLR + UTP 
B 
Time (min) 0  23 35 
Chapter 8                                                                              Results       
 
189 
 
minutes (used in GFP experiments), to prevent over staining. Peak fluorescence was 
reached by approximately 22 minutes; around 2-3 minutes faster than GFP only. 
Following this, a very gradual decrease in fluorescence during stimulation with UTP 
and TFLLR was observed, unlike the rapid more drop we saw in GFP only cells. 
Fluorescence only dropped by approximately 15% of the peak of fluorescence by the 
end of the experiment; 25% less than GFP only transfected cells. The recording did not 
continue for an extended period after the agonist was added because the maximum 
amount of recording time for the software was reached.  
These results support the results gathered in Gag-GFP transfected cells, and indicate 
that the presence of HIV-1 proteins does indeed have an effect on vesicle recycling. It 
is difficult to deduce whether the effect on dye uptake is reliable since the error bars 
were large in GFP-only cells, but certainly the patterns of vesicle staining and 
destaining were markedly different between these two treatments. The second half of 
the experiment (destaining) was perhaps more accurate since error bars for both 
conditions were small.  
8.2.6 HIV-1 does not Affect Calcium Waves 
Astrocytes are capable of a type of intercellular communication based on the 
propagation of calcium (Ca
2+
) waves. Calcium waves are defined as a localised increase 
in cytosolic Ca2+, followed by a succession of similar events in a wave-like fashion. These 
may be restricted to individual cells (intracellular), or alternatively may spread to 
neighbouring cells (intercellular) by one of two proposed mechanisms. These are direct 
communication through adjacent cytosols via diffusion through gap junctions, or 
receptor mediated activation via gliotransmitter release, presumably ATP. Intracellular 
calcium waves involve a cascade of events following G protein coupled receptor 
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activation, which ultimately leads to release of Ca
2+
 from the ER (Scemes and Giaume, 
2008) 
Mechanisms have been developed that allow direct visualisation of calcium waves, 
through the use of fluorescently labelled calcium probes. One such probe is the 
genetically encoded probe known as GCaMP, which was forged by connecting DNA 
encoding EGFP to a fragment of myosin light chain kinase sequence and the calcium 
binding calmodulin (CaM) DNA. When Ca
2+
 binds to the expressed CaM, it induces 
conformational changes which subsequently trigger a change in EGFP that in turn leads 
to a change in fluorescence intensity (Nakai et al., 2001).   
In order to visualise calcium waves within the U373 MG cell line, a modified GCaMP 
construct was used; Sy-GCaMP-mCh. This construct is mCherry tagged, as oppose to 
GFP, to complement the GFP tagged constructs already used in this chapter.  
It is possible that HIV-1 could interfere with the propagation of Ca
2+
 waves through 
two different mechanisms. HIV-1 could interfere with G protein coupled receptor 
expression, possibly through interference with receptor recycling and targeting it for 
degradation, such as with MHC-I. We would not expect HIV-1 to be able to affect the 
release of Ca
2+ 
stores from the ER since results gathered do not suggest that HIV 
interferes with ER trafficking. Alternatively, HIV-1 could interfere with gliotransmitter 
signalling between astrocytes, thus preventing calcium wave propagation.  
To investigate the possibility of HIV interfering with calcium waves, U373 MG cells 
were grown on glass coverslips and co-transfected with Sy-GCaMP-mCh and either 
GFP and HIV-GFP for 24 hours. A Sy-GCaMP only control was also used. Cells were 
visualised using a 2 photon confocal microscope, and were stimulated using different 
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agonists for defined time periods; these were as anandamide (AEA), UTP and TFLLR-
NH2.  
The results for Sy-GCaMP only are shown in Figure 88. As can be seen, the addition of 
various stimulants did trigger visible Ca
2+
 waves in this cell line; increases and 
decreases in fluorescence could be seen over time (Figure 88A). To quantify this, 
recordings were taken from several individual cells using ImageJ, selecting multiple 
regions of interest (ROIs), as shown by the circles in Figure 88A. ImageJ was used to 
calculate changes in fluorescence (pixels) over time, correcting for background 
fluorescence; this was converted into a percentage of peak fluorescence. The average 
change in fluorescence over time is shown in Figure 88B. The error bars were fairly 
large as some cells appeared more responsive than others, possibly because some cells 
were connected via hemichannels and were therefore able to spread waves between 
each other. The initial large loss of fluorescence was likely attributable to release of 
readily available calcium pools, whereas the subsequent increases and decreases were 
likely from using reserve pools and were therefore smaller, although some calcium (as 
CaCl2) was added in the wash solution.  
Next, GFP only transfected cells were used as a control (see Figure 89), since the HIV 
provirus used also expresses GFP.  Once again, calcium waves could be propagated 
within this cell line. Although the oscillations in fluorescence appeared moderate in 
comparison to GCaMP only expressing cells, it is worth mentioning that only two 
agonists were used in this experiment, as opposed to three, and that the most dramatic 
changes in fluorescence observed in the previous experiment were when the agonist 
AEA was added. This agonist was not used in these experiments, and therefore 
provides a likely explanation for the results observed.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 88: Calcium waves can be propagated in U373 MG cells. Sy-GCaMP-
mCherry only transfected U373 MG cells were visualised on a 2 photon 
microscope. Cells expressing mCherry were selected for analysis. Slides were 
perfused with AEA for five minutes, followed by TFLLR-NH2 for five minutes, 
and finally UTP. A- Confocal images of Sy-GCaMP-mCherry fluorescence at 0, 6, 
15 and 20 minutes. Washes with a hypotonic solution were included in between 
stimulations. Recordings from multiple cells were analysed by ImageJ using 
multiple ROIs (circles in A), including a background area. Changes in 
fluorescence over time were calculated and expressed as percentages of the peak 
of fluorescence (B).   
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Figure 89: GFP does not affect calcium waves. Sy-GCaMP and GFP transfected 
U373 MG cells were visualised on a 2 photon microscope. Cells expressing both 
GFP and mCherry were selected for analysis. Slides were perfused with TFLLR-
NH2 for ten minutes, and finally UTP. Washes with a hypotonic solution were 
included in between stimulations. A- Confocal images of Sy-GCaMP-mCherry 
fluorescence at 0, 11, 21 and 39 minutes. Recordings from multiple cells were 
analysed by ImageJ using multiple ROI’s (circles in A), including a background 
area. Changes in fluorescence over time were calculated and expressed as 
percentages of the peak of fluorescence (B).  
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Figure 90: HIV does not affect calcium waves. Sy-GCaMP and HIV-GFP 
transfected U373 MG cells were visualised on a 2 photon microscope. Cells 
expressing both GFP and mCherry were selected for analysis. Slides were 
perfused with TFLLR-NH2 for ten minutes, and finally UTP. Washes with a 
hypotonic solution were included in between stimulations. A- Confocal images of 
Sy-GCaMP-mCherry fluorescence at 0, 10, 20 and 45 minutes. Recordings from 
multiple cells were analysed by ImageJ using multiple ROIs (circles in A), 
including a background area. Changes in fluorescence over time were calculated 
and expressed as percentages of the peak of fluorescence (B). 
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When HIV-GFP was transfected into cells (see Figure 90), a similar pattern to that of 
GFP only transfected cells was observed. Again the oscillations were smaller than that 
of cells only expressing GCaMP, but calcium waves were indeed propagated. The error 
bars for these two conditions were also much smaller than that of GCaMP only cells, 
and therefore may represent a more reliable data set. Since the results were similar to 
that of GFP transfected cells, this suggests that HIV does not interfere with calcium 
waves within astrocytes.  
8.3 Discussion 
Various hypotheses have been suggested for the development of neurological 
symptoms in HIV infected individuals. The CNS is a complex, multi-faceted system, 
and it seems most likely that the conditions observed are due to a variety of HIV 
induced effects, as opposed to one. This chapter aimed to shed light on the role of 
astrocyte infection in the development of HIV associated dementia; particularly, 
drawing links between the trafficking perturbations of AP dependent pathways 
observed in other cell lines utilised within this thesis. Since we know that both AP-1, -2 
and -3 are critical to vesicle recycling within neurons, it seemed an appropriate 
extrapolation that similar mechanisms exist within astrocytes.  
Having first established that the cell line chosen for experimentation (U373 MG) did 
indeed express these 3 APs (Figure 83), and was capable of expressing Gag (and Nef) 
from both transfected Gag-GFP (Figure 80) and a HIV-1 proviral plasmid (Figure 81), 
methods were chosen to investigate vesicle recycling. Direct visualisation of vesicle 
endocytosis and exocytosis through the use of fluorescent dyes was used to investigate 
the potential of HIV-1 to interfere with these specific trafficking pathways, having 
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already established the ability of HIV to interfere with DTx trafficking within HeLa 
cells (as described in chapter 7).  
Difficulties arose in the fine tuning of early experiments; establishing optimum 
concentrations of FM1-43 and length of agonist addition proved arduous. Having 
attempted various protocols, the addition of the agonist TFLLR-NH22 after dye pre-
loading was selected for examination of mock transfected and Gag-GFP transfected 
cells. There was a striking difference in the response to this agonist between these two 
experimental conditions (Figure 84 vs Figure 85); Gag-GFP transfected cells exhibited 
only a very modest and slow loss of fluorescence in comparison to mock transfected 
cells, which displayed a relatively rapid loss of fluorescence.  
These results would suggest that the presence of HIV-1 Gag can indeed interfere with 
the recycling of gliotransmitter vesicles within astrocytes. This is, however, not 
necessarily representative of an in vivo situation since Gag will be expressed in much 
lower levels during HIV-1 infection, since transfection of this construct bypasses 
numerous blocks of HIV-1 replication. These results do, however, raise the possibility 
of a similar situation arising in HIV infected individuals, and demonstrate the capability 
of a Gag-mediated effect. Interestingly, as shown in chapter 7, the Gag-GFP construct 
displayed little interference with the trafficking of DTx in HeLa cells, suggesting 
different mechanisms operating within these two cell lines. Since HeLa cells are 
undoubtedly a more robust cell line, it is possible that they are inherently hardier, and 
therefore transfection of the astrocytoma cell line is more likely to produce toxic 
effects. Gag-GFP transfected U373 MG cells often had altered morphologies, as shown 
by confocal microscopy (Figure 80), which would support the notion that 
overexpression of Gag is toxic to these cells, which would of course affect normal cell 
functioning.  
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To investigate this apparent effect further, a HIV-GFP provirus was used (Figure 87), 
alongside a GFP only control (Figure 86). This provirus expresses all the viral proteins 
(except Env), including Nef, which is also known to interact with the APs and can 
disturb trafficking pathways, for example of the transferrin receptor (Craig et al., 2000; 
Madrid et al., 2005). Both dye uptake and dye release were investigated in these 
experiments. When just release events (loss of fluorescence) are taken into account, a 
similar pattern to that in Gag-GFP transfected cells could be observed; severely 
compromised vesicle destaining when compared to the control. When dye uptake is 
also taken into account, we also saw a difference between HIV-GFP and GFP only 
transfected cells; interestingly, HIV-GFP transfected cells displayed more rapid dye 
uptake, reminiscent of the slight sensitisation to RTx described in chapter 7. Since these 
two processes will be governed by different adaptor proteins; possibly AP-2 (and/or 
AP-1) and AP-3, respectively, it is suggestive of interference in more than one 
trafficking pathway within astrocytes.  
As mentioned, vesicle release (exocytosis) events involve AP-3 in neuronal cells 
(Nakatsu et al., 2004; Scheuber et al., 2006); and therefore this likely occurs in 
astrocytes also. DTx trafficking may be dependent on AP-3 (see chapter 7), and both 
HIV-1 and HIV-2 significantly interrupted this pathway in HeLa cells, in a Gag 
dependent manner. This is suggestive of a universal effect of HIV on AP-3-dependent 
trafficking pathways. Despite HIV not being able to productively infect astrocytes, it 
does not necessarily mean that newly synthesised Gag and Nef proteins do not traffic in 
the same manner to assembly sites, or at least engage with the adaptor proteins, 
rendering them unavailable for cellular processes such as synaptic vesicle biogenesis. 
However, since astrocytes transfected with HIV proviruses, or indeed infected 
astrocytes in vivo, express very limited amounts of viral Gag proteins, it does beg the 
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question whether the effects observed are indeed Gag mediated. However, Nef is 
expressed in high levels in astrocytes in vivo and in vitro, which may be suggestive of 
Nef mediated interference. Nef was found to be dispensable for the interruption of DTx 
trafficking, but certainly what happens in one cell may not mirror what happens in 
another. At this stage, it remains unknown how HIV-1 interrupts with vesicle 
exocytosis events, therefore more research is required.  
Vesicle uptake (endocytosis), as mentioned, is governed by AP-2 in neuronal cells, and 
in its absence, AP-1 may act to replace it (Kim and Ryan, 2009). AP-2 has an inhibitory 
effect on HIV-1 particle release in productively infected cells such as HeLa; this may 
also occur in astrocytes, however it is unlikely that this is the sole reason for the 
inability of HIV to egress since it evidently does not abolish particle release in other 
cell lines. It was therefore surprising to see that the presence of HIV appeared to 
increase dye uptake in U373 cell lines, in comparison to GFP transfected cells. It seems 
plausible that the presence of actively trafficking HIV particles may cause an increase 
of AP-1 at the plasma membrane, which therefore may make this protein more readily 
available to mediate vesicle endocytosis. That being said, since the error bars for this 
part of the experiment were very large for GFP transfected cells, it still remains a 
possibility that HIV does not significantly increase vesicle uptake. More experiments 
are therefore required to investigate whether this is a real effect.  
What do these results mean with regards to HIV associated neurocognitive disorders? 
The idea that astrocytes merely provide a neuronal support network is outdated, and 
they have been discovered to play many crucial and active roles in brain functioning. 
Astrocytes release numerous transmitters, including glutamate, ATP and D-serine, 
which regulate neuronal excitability and synaptic transmission (Hamilton and Attwell, 
2010). Both D-serine and glutamate release by astrocytes are essential for neuronal 
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NMDA receptor function, which in turn is essential for the induction of long-term 
synaptic plasticity (the ability of synapses to strengthen or weaken over time), which is 
crucial for learning and memory (Halassa et al., 2007). More specifically, it was found 
that the release of D-serine from astrocytes upon neuronal stimulation was critical for 
long-term potentiation (the long lasting enhancement of signal transmission between 
neurons), which underlies synaptic plasticity, to occur in the hippocampus; a major 
component of the brain responsible for consolidation of short-term memory into long-
term memory and spatial navigation (Yang et al., 2003). We could therefore envisage 
that if HIV perturbs the release of these transmitters, synaptic plasticity would be 
compromised, therefore affecting short-term memory; one of the symptoms commonly 
associated with HAD patients.  
Interestingly, recent evidence has started to suggest a role for astrocytes in motor 
function, and it is anticipated that much future research will begin to answer questions 
in this area. Rhythmic motor behaviours, such as locomotion, are controlled by 
neuronal cells named central pattern generators (CPGs). Within the spinal cord, 
numerous transmitters are responsible for modulating the CPGs involved in 
locomotion. These include ATP, adenosine and endocannabinoids (Christensen et al., 
2013). We know that astrocytes are capable of releasing ATP (Montana et al., 2006), 
but recent evidence gathered suggests that astrocytes can also release the 
endocannabinoids AEA alongside homo-γ-linolentlethanolamide and 
docosatetraenylethanolamide (Walter et al., 2002). It therefore also seems plausible that 
an interference with the release of these transmitters by astrocytes may also affect 
locomotion, which we could postulate may contribute to the loss of motor function 
observed in some HAD patients. I should hasten to add, however, that conclusions 
drawn are speculative, and it remains a difficulty in neuroscience to definitively draw 
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links between what happens at the cell level and physiological manifestations. 
However, this research certainly has the potential to shed light on some grey areas with 
respect to the neurological manifestations of HIV infection. Since the brain is a 
complex system, it seems likely that symptoms result from not one, but an 
amalgamation of numerous different virological consequences on cell function.  
Astrocytes are also capable of communication through calcium signalling. The synaptic 
release of particular neurotransmitters from neighbouring neurons, such as glutamate, 
can lead to an increase in intracellular Ca
2+ 
in astrocytes, which triggers the release of 
glutamate from these cells, which in turn causes glutamate receptor mediated Ca
2+
 
increases in nearby neurons (Fellin and Carmignoto, 2004). It was found that exposure 
of astrocytes to either HIV-1 particles, or gp120 alone, impaired glutamate uptake and 
release, which was attributed to the concomitant decrease in expression of the 
glutamate transporter EEAT2 (Wang et al., 2003). Since results in this chapter suggest 
that Ca
2+
 signalling is not impaired in HIV transfected astrocytes compared to GFP 
transfected astrocytes (Figure 90 vs Figure 89), it would suggest that this is not an 
additional factor contributing to the loss of glutamate signalling by astrocytes during 
HIV infection. It would also support data collected from RTx cytotoxicity assays and 
VSV-G trafficking assays, in which HIV did not interfere with ER trafficking, since 
propagation of Ca
2+
 waves involves release of Ca
2+
 pools from the ER. 
8.4 Future Work 
This chapter has provided novel insights into possible mechanisms behind the 
development of neurological complications in HIV infected individuals. In particular, 
results have demonstrated that HIV-1 causes perturbation of vesicle recycling within 
astrocytes, which may be a possible contribution to short-term memory loss in 
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individuals suffering with HAND. The research carried out in this chapter is, however, 
very much in its infancy, and requires more rigorous investigation. However, work 
carried out certainly provides a firm backbone for the continuation of research in this 
novel field. 
Fine tuning of protocols in this chapter meant that, despite using 3 agonists, not enough 
data was gathered to draw conclusions for UTP and AEA in mock transfected and Gag-
GFP transfected cells, therefore repeat experiments are required following the same 
protocol that was used for TFLLR-NH2. More experiments are also required to 
investigate the effects of HIV on dye uptake; these experiments were not performed in 
mock transfected or Gag-GFP transfected cells, and the error bars for GFP transfected 
cells were large, possibly indicating unreliability in the current data set.  
An obvious gap in research is the lack of studies using HIV-2. Since these studies were 
novel and HIV-1 expressed Gag better than HIV-2, and success was not guaranteed, it 
was decided to conduct experiments utilising only HIV-1. An HIV-2-GFP construct 
could be made and utilised for future experiments as a useful tool for comparative 
means; with data gathered so far, it would suggest that these viruses likely would not 
produce identical effects.  
An interesting direction to take this chapter forward would be to investigate individual 
vesicle trajectories within these different conditions. It would be interesting to see 
whether the presence of HIV specifically slowed down individual vesicle movement, as 
compared with control cells. This would be a relatively simple analysis using software 
on ImageJ; vesicle labelling is more problematic. A sister construct to the SyGCaMP-
mCherry used in this chapter, SyPhy-mCherry, which labels individual vesicles could 
be used to carry on research.  
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Another interesting set of experiments would be to investigate receptor recycling on 
astrocytes. This could be carried out using biotinylation, whereby receptors on the cell 
surface are labelled, and then compared with the total pool of receptors after 
stimulation. It had been our intention to test receptor recycling of the glutamate 
receptor; unfortunately, since it was discovered that U373 MG down-regulate 
glutamate receptor expression, it was not possible to conduct these experiments on this 
cell line. Therefore, a suggestion would be to attempt this experiment in a cell line 
which does express glutamate receptors. Alternatively, it would be interesting to see if, 
in a co-culture of astrocytes and neurons, the presence of HIV inhibited the uptake of 
receptors on neuronal surfaces, which would also likely affect synaptic plasticity.  
This leads to a further limitation of this work; the use of an astrocytoma cell line, rather 
than primary astrocytes or astrocyte/neuron co-culture. HIV does not infect rodent 
cells, which rules out the use of rodent-derived primary cells, and would necessitate the 
use of human tissue. In the future, stem cell technology may aid these experiments.  
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CHAPTER 9: CONCLUSIONS  
9.1 Conclusions and Future Work 
This thesis aimed at shedding light on the interactions between HIV-1 and not only the 
clathrin adaptor proteins, but adaptor protein dependent trafficking pathways. The 
trafficking pathways adopted by newly synthesised HIV-2 Gag proteins were also 
scrutinised. This chapter will summarise the conclusions drawn from results gathered 
and how these have contributed to research in this field.  
Firstly, results gathered through confocal immunofluorescence microscopy and 
Western blot of AP siRNA treated cells supported the hypothesis that HIV-1 traffics to 
the PM via an endosomal intermediate, and that AP-1 and AP-3 likely function in 
different stages of the HIV-1 trafficking process. AP-1 most likely facilitates the 
direction of newly synthesised Gag molecules to endosomes, since Gag in cells where 
AP-1 was knocked down appeared more diffuse; whereas AP-3 may facilitate the 
delivery of these compartments to the PM, since Gag in cells where AP-3 was knocked 
down appeared more punctate. In both cases, PM Gag staining was virtually abolished.  
Next, novel research investigating HIV-2 trafficking found that this virus traffics, and 
interacts with the APs, in a different manner to HIV-1. Confocal immunofluorescence 
microscopy studies demonstrated that HIV-1 and HIV-2 Gag display different cellular 
localisations. The punctate pattern observed in HIV-2 transfected HeLa cells, in 
comparison to the diffuse staining seen with HIV-1, was suggestive of the potential of 
this virus to assemble within intracellular compartments, which has been observed with 
HIV-1 but only in macrophage cell lines. Further investigation of viral protein levels 
after siRNA mediated knockdown of the adaptor proteins found that HIV-2 was more 
dependent on AP-3, which is involved in endosomal cargo trafficking, than AP-1 for 
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efficient particle assembly and release, whereas HIV-1 presented similar dependencies 
on the two proteins. The novel adaptor protein AP-5, which associates with late 
endosomes, also facilitated HIV-2 particle assembly and release, but did not affect 
HIV-1.  
Interestingly, however, HIV-1 and HIV-2 both affected the localisation of AP-1, but 
produced strikingly different effects; HIV-1 appeared to condense AP-1 into a tight 
juxtanuclear position, possibly the Golgi/TGN, although this was not formally 
identified. HIV-2, however, caused AP-1 to adopt a somewhat tubular appearance. 
Although this remains uncertain, it may indicate a role for AP-1 in transporting newly 
synthesised HIV-2 Gag molecules to cytoskeletal elements such as actin or 
microtubules for efficient trafficking, which would support the novel role also found 
for AP-1 (and AP-3) in the transport of lipoplexes, which may involve delivery of 
cytoskeletal motor molecules, such as kinesin KIF4, to cargo.  The identity of the 
compartments to which AP-1 was relocalised to was not discovered, however, because 
colocalisation studies with cellular markers were not performed. 
The depletion of cellular Gag observed in the absence of AP-1 or -3, in both HIV-1 and 
HIV-2 transfected cells, indicated that when newly synthesised Gag molecules are 
unable to efficiently traffic and assemble into particles, total Gag levels fall. This 
suggests degradation by cellular mechanisms. Results indicated that this was not due to 
lysosomal or proteasomal degradation, or the formation of aggregates which were not 
recovered by the method of lysis adopted, or inhibition of translation; therefore the fate 
of Gag in AP-1/-3 deficient cells remains to be elucidated.  
Further evidence to support a role of intracellular compartments in the trafficking of 
HIV-2 Gag was gathered through the use of Diphtheria toxin, which enters the cell via 
clathrin mediated endocytosis, which is therefore likely AP-2 mediated. From here, it 
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traffics to the early endosome, and possibly uses AP-3 in trafficking to the late 
endosome, prior to escape to the cytosol. Although HIV-1 Gag perturbed the toxicity of 
DTx, HIV-2 Gag was found to have a significantly larger protective effect. Earlier 
investigation of adaptor protein levels during HIV-1 transfection indicated that the 
disruption of DTx trafficking was not due to altered AP expression. It was therefore 
speculated that the observed protective effects of HIV Gag on cells to DTx challenge 
could be due to AP sequestration by HIV Gag molecules, possibly preventing the 
availability of the APs to facilitate efficient DTx trafficking, especially if some DTx is 
using a late endosomal compartment to enter the cytosol. Alternatively, the presence of 
Gag on internal membranes, such as early endosomes, might interfere with endosomal 
acidification or the emergence of DT A fragment across the endosomal membrane. 
These possibilities were not explored.  
Further analysis by confocal immunofluorescence microscopy revealed a strong 
colocalisation and re-distribution of AP-3 by HIV-2 in HeLa cells, which was not 
observed in HIV-1 transfected cells. While the speculation that increased AP-3 
sequestration in the presence of Gag may explain the interference with DTx entry and 
toxicity, there may be other explanations. These data also, however, suggested that the 
pronounced intracellular distribution of HIV-2 Gag could be due to the re-
internalisation budding particles at the plasma membrane following restriction by 
tetherin, rather than a preference for assembly within intracellular compartments. 
Utilisation of a tetherin-deficient cell line (HEK 293T) revealed that although HIV-2 
Gag became more diffuse, punctate staining was still the dominant phenotype. 
Therefore tetherin restriction is not solely responsible for the increased intracellular 
localisation of HIV-2 Gag in non-macrophage cell lines. Inhibition of endocytosis by 
AP-2 knockdown and expression of a Rab5 dominant negative construct further 
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demonstrated that the presence of HIV-2 Gag within intracellular compartments was 
not due to internalisation of released virions. Electron microscopy studies revealed the 
presence of HIV-2 immature particles within intracellular compartments in HEK 293T 
cells, further verifying the ability of this virus to assemble within intracellular 
compartments in non-macrophage cells. Confocal immunofluorescence demonstrated 
these to be CD81 (and CD63) positive compartments, which HIV-1 Gag did not 
localise to. 
So HIV-1 and HIV-2 Gag differ in their trafficking pathways, but what could this mean 
in terms of the disease caused by these two viruses? As discussed in chapter 6.1, HIV-2 
is overall less pathogenic than HIV-1, and a considerably higher proportion of infected 
individuals are classed as long term non-progressors. This has been linked to lower 
plasma viraemia levels in the majority of HIV-2 patients in comparison to HIV-1. 
There have been several theories proposed to account for this, such as a less efficient 
ability to evade immune responses. Since results gathered in this thesis propose that 
HIV-2 can begin to assemble within LEs/MVBs in non-macrophage cell lines, and a 
higher proportion of Gag is present within these compartments than HIV-1, it may be 
that this could also contribute to the decrease in pathogenicity of HIV-2. This is 
because it is possible that some of these compartments enter a degradative pathway, for 
example by fusing with lysosomes, as oppose to being recycled to the PM for release. 
This could result in a lower efficiency of viral particle release in comparison to HIV-1, 
which we speculate could also contribute to a decrease in plasma viraemia levels.  
Although current literature suggests that the AP binding sites of HIV-1 Gag lie within 
the MA domain, the use of chimeric viruses suggested that other AP binding sites may 
exist. For example, depletion of AP-2 in MA2 transfected cells greatly enhanced 
particle release, as was the case with HIV-1, indicating that AP-2 has a negative effect 
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on MA2 release. This is in contrast to HIV-2, where release was not found to be 
inhibited by AP-2. The MA domain was previously described to drive Gag localisation 
and membrane binding, however, results gathered here through the use of chimeric 
viruses would suggest that other factors are also required for Gag localisation since 
MA2 Gag displayed a similar appearance to HIV-1 in HEK 293T cells.  
The final stage of this project aimed at investigating the ability of HIV to cause a global 
disruption in trafficking pathways, through the use of an astrocytoma cell line. This was 
based on the following observations: AP-1, -2 and -3 are involved in neuronal vesicle 
recycling (Nakatsu et al., 2004; Scheuber et al., 2006; Kim and Ryan, 2009); AP 
deficiencies in mice lead to defects in learning and memory (Glyvuk et al., 2010); 
astrocytes, but not neurons, are infected in HIV patients (Churchill et al., 2009; Sharma 
and Bhattacharya, 2009); similar vesicle recycling mechanisms are presumed to exist in 
astrocytes; HIV infected patients suffering neurological complications often experience 
memory loss (Gonzalez-Scarano and Martin-Garcia, 2005; Ghafouri et al., 2006). 
Through the use of fluorescent dyes, it was possible to ascertain that HIV was indeed 
capable of disrupting vesicle recycling in astrocytes; in particular, vesicle exocytosis 
events. Since vesicle biogenesis and exocytosis has been shown to be regulated by AP-
3 in neuronal cells, (Nakatsu et al., 2004; Scheuber et al., 2006), this may suggest that 
HIV globally interferes with AP-3 dependent trafficking pathways, since DTx may also 
traffic in an AP-3 dependent manner.  
In summary, this research has demonstrated that although there are common aspects 
between the trafficking pathways adopted by HIV-1 and HIV-2, these two viruses may 
indeed differ not only in their interactions with the clathrin adaptor proteins, but also in 
their mechanisms of transport to, and preferred location of assembly sites, and thus in 
their ability to interfere with AP dependent trafficking pathways.  
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Future work to continue research is necessary in several areas. Firstly, it would be 
interesting to understand why HIV-1 and HIV-2 adopt different cellular trafficking 
pathways, since they share 60% amino acid sequence similarity in their Gag proteins 
(Dilley et al., 2011). Mutational analysis may provide some insights here. It is also 
particularly important to provide more robust evidence of the involvement of 
endosomes in the trafficking of HIV-2, for example by direct visualisation of a 
fluorescently labelled virus. 
Second, confirmation of the suggested existence of AP binding sites other than those 
described in MA and Nef is needed to verify findings about the behaviour of the MA 
chimeric viruses.  
Finally, this project has provided some foundations for research into insights behind the 
contributions to neurological manifestations during HIV infection. As mentioned, 
research is very much in its infancy, but now that protocols have been established, 
continuation of work should not be problematic.  
9.2 Contributions to the Field 
This research has contributed to the field in several ways. Firstly, it has highlighted 
differences in the trafficking of HIV-1 and HIV-2, which was previously unknown, and 
in doing so has also suggested that current literature on the AP binding sites within Gag 
may be outdated. Particularly, results herein have posited the possible presence of 
ulterior AP binding sites besides those currently described in MA. Results from the use 
of chimeric viruses may also indicate that the current theory of MA being solely 
responsible for Gag localisation to be oversimplified. Results gathered also stand to 
support, rather than dispute, the current hypothesis for HIV-1 Gag trafficking; that Gag 
travels to the PM via an endosomal intermediate, but also highlight the different roles 
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the adaptor proteins AP-1 and -3 play. AP-1 likely facilitates Gag delivery to 
endosomes, whereas AP-3 likely assists in the trafficking of Gag from early to late 
endosomal compartments, therefore indirectly assisting the PM delivery of Gag.  
Secondly, a novel role for the clathrin adaptor proteins in the trafficking of lipoplexes 
has been unravelled. This is particularly interesting since these proteins have not been 
implicated in this role previously, and due to the nature of the cargo usually transported 
by the APs, this was particularly surprising.  
Finally, this research has demonstrated a global ability of HIV to interfere with AP 
dependent pathways, even in cells that are not productively infected. This shows us that 
the APs are not solely involved in assisting particle assembly, but that a complex 
interplay of different APs likely exists in order to direct both the trafficking, 
localisation and formation of new virus particles. Although studies carried out using an 
astrocytoma cell line are preliminary and require further work, it was intriguing to 
discover that HIV-1 is able to perturb vesicle recycling within this cell line. 
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